Mechanisms of Methylglyoxal-elicited Leukocyte Recruitment by Su, Yang
  
Mechanisms of Methylglyoxal-elicited Leukocyte Recruitment 
 
 
A Thesis 
Submitted to the College of 
Graduate Studies and Research 
In Partial Fulfillment of the Requirements 
For the Degree of Doctor of Philosophy 
In the Department of Pharmacology 
University of Saskatchewan 
Canada 
 
 
By 
Yang Su 
© Copyright Yang Su, July 2014. All rights reserved
i 
 
PERMISSION TO USE  
 
In presenting this thesis in partial fulfillment of the requirements for a Postgraduate degree from 
the University of Saskatchewan, I agree that the libraries of this University may make it freely 
available for inspection. I further agree that permission for copying of this thesis in any manner, 
in whole or in part, for scholarly purposes may be granted by the professor or professors who 
supervised my thesis work or, in their absence, by the Head of the Department or the Dean of the 
College in which my thesis work was done. It is understood that any copying or publication or use 
of this thesis or parts thereof for financial gain shall not be allowed without my written permission. 
It is also understood that due recognition shall be given to me and to the University of 
Saskatchewan in any scholarly use which may be made of any material in my thesis.  
 
Requests for permission to copy or to make other use of material in this thesis in whole or part 
should be addressed to:  
 
Head of the Department of Pharmacology  
University of Saskatchewan  
Saskatoon, Saskatchewan S7N 5E5  
Canada  
ii 
 
ABSTRACT 
Methylglyoxal (MG) is a reactive dicarbonyl metabolite formed during glucose, protein and fatty 
acid metabolism. In hyperglycemic conditions, an increased MG level has been linked to the 
development of diabetes and the accompanying vascular inflammation encountered at both macro- 
and microvascular levels. The present study explores the mechanisms of MG-induced leukocyte 
recruitment in mouse cremasteric microvasculature. Biochemical and intravital microscopy studies 
performed suggest that administration of MG (25 and 50 mg/kg) to mouse cremaster muscle tissue 
induces dose-dependent leukocyte recruitment in cremasteric vasculature with 84-92% recruited 
cells being neutrophils. MG treatment up-regulated the expression of endothelial cell (EC) 
adhesion molecules P-selectin, E-selectin and intercellular adhesion molecule-1 (ICAM-1) via the 
activation of nuclear factor-κB (NF-κB) signalling pathway and contributed to the increased 
leukocyte rolling flux, reduced leukocyte rolling velocity, and increased leukocyte adhesion, 
respectively. The inhibition of NF-κB blunted MG-induced endothelial adhesion molecule 
expression and thus attenuated leukocyte recruitment.  
 
Further study of signalling pathways revealed that MG induced Akt-regulated transient glycogen 
synthase kinase 3 (GSK3) activation in ECs, which was responsible for NF-κB activation at early 
time-points (< 1 h). After MG activation for 1 h, the endothelial GSK3 activity was decreased due 
to the up-regulation of serum- and glucocorticoid-regulated kinase 1 (SGK1), which was 
responsible for maintaining NF-κB activity at later time-points. Silencing GSK3 or SGK1 
attenuated P-selectin, E-selectin and ICAM-1 expression in ECs, and abated MG-induced 
leukocyte recruitment. SGK1 also promoted cyclic adenosine monophosphate (cAMP) response 
element-binding protein (CREB) activity which was partially involved in ICAM-1 expression. 
Silencing CREB blunted ICAM-1 expression while P-selectin and E-selectin levels remained 
unaffected. MG also induced GSK3 activation in isolated neutrophils after 30 min treatment, an 
effect that was not responsible for MG-elicited Mac-1 expression. These data suggest the 
sequential activation of GSK3 and SGK1 in ECs as the pivotal signalling mechanism in MG-
elicited leukocyte recruitment. 
 
Additionally, MG-treatment led to uncoupling of endothelial nitric oxide synthase (eNOS) 
following MG-induced superoxide generation in ECs. MG triggered eNOS uncoupling and 
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hypophosphorylation associated with superoxide generation and biopterin depletion in EA.hy926 
ECs. In cremaster muscle, as well as in cultured murine and human primary ECs, MG increased 
eNOS monomerization and decreased 5,6,7,8-tetrahydroboipterin (BH4)/total biopterin ratio, 
effects that were significantly mitigated by supplementation of BH4 or its precursor sepiapterin 
but not by NG-nitro-L-arginine methyl ester (L-NAME) or 5,6,7,8-tetrahydroneopterin (NH4). 
These observations confirm that MG administration triggers eNOS uncoupling. In murine 
cremaster muscle, MG triggered the reduction of leukocyte rolling velocity and the increases in 
rolling flux, adhesion, emigration and microvascular permeability. MG-induced leukocyte 
recruitment was significantly attenuated by supplementation of BH4 or sepiapterin or suppression 
of superoxide by L-NAME confirming the role of eNOS uncoupling in MG-elicited leukocyte 
recruitment. MG treatment further decreased the expression of guanosine triphosphate 
cyclohydrolase I in murine primary ECs, suggesting the impaired BH4 biosynthesis caused by MG. 
 
Taken together, these data suggest that vascular inflammation and endothelial dysfunction 
occurring in diabetes may be linked to GSK3/SGK1 regulated adhesion molecule expression, as 
well as the uncoupling of eNOS evoked by elevated levels of MG. These findings not only provide 
a better understanding of the role of MG in the development of diabetic vascular inflammation, 
but also suggest the potential therapeutic targets for MG-sensitive endothelial dysfunction in 
diabetes. 
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INTRODUCTION AND LITERATURE REVIEW 
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1.1 Diabetes 
Diabetes mellitus (DM), or simply diabetes, is “a group of common metabolic disorders that share 
the phenotype of hyperglycemia” [1]. It is a group of chronic conditions that take place when the 
body is not able to sufficiently produce insulin or properly respond to insulin. As a hormone 
secreted by β cells in the pancreas, insulin enables the cells in the body to uptake sugar from 
bloodstream and use it to produce energy. Thus, diabetes is usually characterized by 
hyperglycemia. With the progression of the condition, hyperglycemia damages blood vessels and 
organs, for example the kidneys, eyes, heart, and nerves. These pathological changes can lead to 
serious complications and ultimately death [2, 3]. Hyperglycemia, hypertension and 
hyperlipidemia, which are associatively seen in diabetes patients, accelerate blood vessel damage, 
thus they need to be carefully controlled [4]. According to the most recent statistics on the burden 
of diabetes in Canada, in 2008/09, nearly 2.4 million Canadians (about 6.8%) were living with 
diabetes. Further estimates suggest that this number will reach 3.7 million by 2018/19 if the 
incidence and mortality rates remain the same [2, 5, 6]. Diabetes brings economic, physical and 
psychological burdens to the patient and their family. However, it is expected that this burden will 
only increase in the future. 
 
1.1.1 Type 1 diabetes mellitus 
Type 1 diabetes mellitus (T1DM) is considered an autoimmune disease. In T1DM, the body's 
immune system specifically destroys the insulin-secreting β cells in the pancreas [7]. Therefore 
the patients have to rely on an exogenous source of insulin for life. Type 1 diabetes usually occurs 
at a young age. It is partially genetically inherited, but the details are not fully known. Among all 
the diabetes patients, the prevalence of T1DM is about 10% [5]. 
 
1.1.2 Type 2 diabetes mellitus 
Type 2 diabetes mellitus (T2DM) is a metabolic disorder caused by either insufficient production 
of insulin in the pancreas or an inappropriate response to insulin in the body (insulin resistance) 
[8]. In the early stage of T2DM, insulin resistance causes a compensatory increase in pancreatic 
insulin production which results in elevated plasma insulin levels. Because of the compensatory 
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effect, there may be no symptoms at this stage. However, with the development of the disease, the 
release of insulin is finally reduced due to apoptosis of β cells, causing decreased plasma insulin 
levels and hyperglycemia [9, 10]. It is shown that T2DM has a strong genetic predisposition. 
However, other risk factors such as poor eating habits, overweight, and physical inactivity also 
make people more vulnerable to T2DM. The onset of type 2 diabetes usually occurs in adults at 
the age of 40 or above. Among all the diabetes patients, the prevalence of T2DM is about 90% [2, 
5]. 
 
1.1.3 Gestational diabetes 
Gestational diabetes refers to the condition in which the females without previously diagnosed 
diabetes show hyperglycemia during pregnancy [11]. Although the elevated glycemic levels 
usually disappear after delivery, females who experienced gestational diabetes have a higher risk 
of developing T2DM in the following five to ten years [12]. 
 
1.2 Diabetic vascular complications 
Vascular dysfunction is the main feature of diabetic complications and involves both micro- and 
macro-angiopathy [13]. The development of diabetic vascular complications leads to 
cardiovascular diseases (including coronary artery disease, peripheral arterial disease, and stroke), 
retinal damage, chronic renal failure, poor wound healing and neuropathy [2, 14]. The most recent 
diabetes statistics in Canada showed that diabetes patients increase their chances to develop heart 
disease by 3.8 times. They also increase the chance to have end-stage renal disease and non-
traumatic lower limb amputations by 12 times and 20 times, respectively [2, 5, 6]. Despite the 
serious burden and threats that diabetic vascular complications bring to our life, the mechanism 
underlying hyperglycemia-induced micro- and macro-angiopathy is not fully understood.  
 
1.2.1 Diabetic microvascular complications  
Diabetic microvascular complications includes diabetic retinopathy, diabetic nephropathy and 
diabetic neuropathy [15]. With the extended duration and poor control of hyperglycemia, the 
patients will have higher risk of developing diabetic microvascular complications [2]. Diabetic 
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retinopathy, the leading cause of blindness in diabetes patients, harms small blood vessels in the 
retina of the eye and might show no symptoms at all until it causes bleeding or retinal detachment-
induced acute vision loss [16]. Diabetic nephropathy which damages the blood vessels in the 
kidneys is the primary cause of renal failure in diabetes patients. The early stage of diabetic 
nephropathy shows leakage of blood proteins into the urine. As damage progresses, with 
compromised kidney function, eventually the patient will depend on dialysis or kidney transplant 
for survival [17]. Diabetic neuropathy is a result of damaged small blood vessels which provide 
oxygen to and remove toxins from nerves. It compromises both the structure and function of the 
nerves. Typically, patients experience numbness, tingling, burning, or pain. Patients with diabetic 
neuropathy are at high risk to develop foot ulceration [18].  
 
Several proposed mechanisms explain how hyperglycemia leads to the development of 
microvascular complications. The overflow of the polyol pathway under hyperglycemia is 
considered to be important in this process. Aldose reductase, which converts glucose into sorbitol, 
is the initial enzyme in the polyol pathway. Under the physiological conditions, glucose is 
metabolized via the glycolytic pathway since aldose reductase has less affinity for glucose than 
hexokinase. However, hyperglycemia forces the metabolism of glucose via polyol pathway and 
causes the accumulation of sorbitol, which results in osmotic stress in cells [19-21]. There is 
evidence showing that sorbitol accumulation is related to thickening of the vascular basement 
membrane, microaneurysm formation, and loss of pericytes [22, 23]. More importantly, sorbitol 
can be oxidized into fructose by sorbitol dehydrogenase, and the latter can be converted into 
dihydroxyacetone phosphate (DHAP) which is known to be a primary source of endogenous 
methylglyoxal (MG) generation [24, 25]. The formation of MG and other by-products under 
hyperglycemia further promotes nonenzymatic formation of advanced glycation end products 
(AGE), which is identified as another important mechanism underlying the development of 
microvascular complications [26]. AGE are formed when MG, 3-deoxy glucosone or glyoxal 
reacts with certain proteins, resulting in the alteration of protein structures and functions [27]. AGE 
formation in collagens causes cross-linking of extracellular matrix (ECM) molecules, which 
impairs matrix-matrix interactions and promotes vascular stiffness [28, 29]. Another mechanism 
involved in this process is oxidative stress. High glucose levels foster reactive oxygen species 
(ROS) and free radical formation [30]. Despite their nonspecific attack on the cell membrane and 
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proteins, increased ROS also promotes the reaction of nitric oxide (NO) with superoxide anion to 
produce peroxynitrite [31]. This reaction further reduces the bioavailability of NO and leads to 
endothelial dysfunction [31, 32]. Beside the mechanisms mentioned above, some growth factors, 
including transforming growth factor-β, growth hormone, and vascular endothelial growth factor 
(VEGF), are also involved in the progression of diabetic microvascular complications, especially 
in diabetic retinopathy [33-35]. The growth factors foster angiogenesis in retinal capillaries, which 
causes functional and anatomical damage to the capillary network [36]. Consistently, suppressing 
VEGF formation results in lower progression of retinopathy in animal models [35].  
 
1.2.2 Diabetic macrovascular complications  
Diabetic macrovascular complications increase the risk of cardiovascular diseases such as stroke, 
peripheral arterial disease, and coronary artery disease [2]. Diabetes fosters the progression of 
atherosclerosis, leading to the narrowing of arterial blood vessels in the body. The damage in the 
coronary blood vessels causes unstable angina and acute myocardial infarction, whereas the 
narrowing of the vessels in brain can result in stroke [37, 38]. In general, people with diabetes have 
a two to four times greater risk to have cardiovascular disease than those without diabetes [3].  
 
The most identified pathological mechanism of diabetic macrovascular disease is the progression 
of atherosclerosis. Atherosclerosis is induced by chronic inflammation and arterial endothelium 
injury in the coronary or peripheral vascular system. It is initiated with endothelial cell (EC) injury 
and increased plasma LDL levels, which foster the accumulation of LDL and oxidized LDL 
particles in the arterial wall. In the next step, monocytes migrate into the arterial wall where they 
further differentiate into macrophages. Macrophages ingest oxidized LDL and become foam cells, 
which then stimulate macrophage proliferation and attract more monocytes/macrophages to the 
injury site. During this process, the presence of angiotensin II further promotes the uptake of 
oxidized LDL by macrophages, thus accelerating the progression of the disease [39]. The injury 
in the local arterial walls also induces smooth muscle proliferation and promotes collagen 
accumulation. Finally, the result of this process is to form a lipid-rich atherosclerotic lesion 
covered with a fibrous cap, and the rupture of the atherosclerotic lesion is the leading cause of 
acute infarction [40-42]. In addition to atheroma formation, reduced NO production, elevated ROS 
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formation, and impaired calcium regulation in platelets were also found in diabetic patients. These 
changes promote platelet hyperaggregation, which increases the possibility of vascular occlusions 
[43, 44]. Besides, evidence showed that diabetes patients may have impaired fibrinolysis because 
of increased plasminogen activator inhibitor type 1 levels [45, 46]. The combination of impaired 
fibrinolysis and increased coagulability is an important mechanism involved in diabetic 
macrovascular complications as well.  
 
1.3 Inflammation and diabetes 
In the last decade, the perspective of diabetes has gradually evolved. It is now widely accepted that 
chronic inflammation and the activated immune system are essentially involved in the 
development of diabetes [47]. Inflammation can be induced by stress, aging, overnutrition, obesity 
and infection [48]. It is a protective response to remove the harmful stimuli and to start the healing 
process. However, long-term innate immune system activation, which results in chronic 
inflammation, causes disease instead of repair. Chronic inflammation is shown to be involved 
closely in the pathogenesis of diabetes. In addition, the findings that anti-inflammatory agents may 
decrease the risk of type 2 diabetes are of great interest [49]. 
 
1.3.1 Inflammation and type 1 diabetes 
Type 1 diabetes is due to the over-reactive immune response. As a result, the insulin-producing β 
cells in pancreas are selectively destroyed by the immune system [7]. This disease is characterized 
by the infiltration of CD8+ and CD4+ T-cells and macrophages to islets in the pancreas. A series 
of mechanisms have been suggested to participate in β-cell killing. For instance, CD8+ T-cells 
which produce lytic granules may kill β-cells by direct cytotoxicity. T effector cells, which express 
Fas ligand (FASL), bind with the Fas domain expressed on β-cells and induce apoptosis through 
FAS-FASL death domain signalling. Macrophages that release cytokines and ROS directly trigger 
apoptosis of β-cells [7]. Excessive cytokine signalling in β-cells also lead to endoplasmic reticulum 
(ER) stress. In addition, cytokines also indirectly activate and recruit immune cells to attack β-
cells [7].  
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1.3.2 Inflammation and type 2 diabetes 
In the last a few years, the link between cytokine production, insulin resistance and type 2 diabetes 
has been intensively established. Studies using non-diabetic subjects, people with impaired glucose 
tolerance (IGT) and lately diagnosed type 2 diabetes patients, showed that the levels of 
proinflammatory mediators and cytokines, such as C-reactive protein (CRP), tumor necrosis 
factor-α (TNF-α), and interleukin-6 (IL-6), are positively correlated with insulin resistance and the 
development of type 2 diabetes [47, 50].  
 
TNF-α is produced by macrophages, T cells, natural killer cells, etc. [51]. It promotes endothelial 
activation as well as vascular hyperpermeability [52]. Recent experimental studies have shown 
that chronic elevation of TNF- α and IL-6 levels directly impairs insulin-induced glucose uptake 
[53, 54]. Over production of TNF-α and IL-6 activates intracellular signalling pathways, such as 
Jun N-terminal kinase (JNK) and protein kinase C (PKC), which produce serine phosphorylation 
of insulin receptor (IR) and insulin receptor substrate 1 (IRS-1) [55, 56]. This phosphorylation 
impairs insulin-induced tyrosine phosphorylation on IRS via the activation of phosphoinositide 3-
kinase (PI3K) and Akt, and thus blocks the signalling transduction in insulin pathway [57]. Besides, 
in vitro studies have shown that TNF-α depresses glucose transporter type 4 (GLUT4) gene 
transcription and decreases GLUT4 mRNA stability [58]. Additionally, IL-6 and TNF-α also 
stimulate CRP production from the liver. The expression of CRP then promotes the expression of 
monocyte chemotactic protein-1 (MCP-1) and intercellular adhesion molecule-1 (ICAM-1) by 
ECs, which accelerates the progression of diabetic vascular complications [59, 60].  
 
On the other hand, the elevation of cellular free fatty acids (FFAs), commonly observed in pre-
diabetic and diabetes patients, also contributes to insulin resistance via the activation of toll-like 
receptors (TLRs) [61, 62]. The binding of FFA to TLRs stimulates proinflammatory cytokines 
expression in macrophages [61]. In addition, FFAs also directly activate JNK pathway, which 
leads to the phosporylation of IRS-1 on serine residues and results in insulin resistance [63, 64]. 
Under pathological conditions, the increases of FFAs combined with excessive glucose lead to 
oxidative stress. Such an oxidative stress in turn activates redox-sensitive transcription factors such 
as NF-ᴋB, which further promotes the transcription of TNF-α and IL-6 [65].  
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1.3.3 Inflammation and diabetic vascular complications  
Besides its critical role in diabetes pathogenesis, inflammation also plays a critical role in the 
development of diabetic vascular complications [66, 67]. The mechanism of diabetes-induced 
vascular inflammation involves pathological changes in vascular ECs, smooth muscle cells, and 
the migration and transformation of macrophages. Hyperglycemia, hyperlipidemia, increased 
serum and cellular FFAs and AGE all contribute to vascular inflammation, and finally result in 
micro- and macrovascular damage [68, 69]. 
 
1.3.3.1 The impact on endothelial cells 
Pro-inflammatory signals are involved in the mechanism of hyperglycemia-induced endothelial 
dysfunction. It has been shown that high glucose or glucose metabolites, such as MG, reduce nitric 
oxide (NO) production in ECs [70]. As an important anti-inflammatory molecule in ECs, NO 
reduction causes pro-inflammatory gene expression via the activation of pro-inflammatory 
signalling pathways [71]. On the other hand, the reactive glucose metabolite production under 
hyperglycemic conditions also promotes the formation of AGE, which exert multiple effects on 
cells via binding and activating RAGE (receptor for AGE). The activation of AGE-RAGE pathway 
results in excessive production of ROS through nicotinamide adenine dinucleotide phosphate 
(NADPH) oxidase and the activation of pro-inflammatory signalling events [72, 73]. A key target 
among these activated signals is NF-κB, which is responsible for the expression of EC adhesion 
molecules and cytokines [74]. Increased EC adhesion molecules, such as ICAM-1 and VCAM-1, 
together with the decreased NO and increased cytokines foster leukocyte adhesion and 
transmigration from the blood stream into the local tissue [75]. The movement of macrophages 
into the lipid-rich lesions on the vessel wall is the key step in the progression of atherosclerosis 
[76, 77]. Such a process in arterioles, especially renal arterioles, leads to hypertension and diabetic 
nephropathy over time [78]. Thus, it is clear that vascular inflammation, which is initiated by 
endothelial dysfunction, is deeply involved in the development of diabetic vascular complications.  
 
1.3.3.2 The impact on vascular smooth muscle cells 
Endothelial dysfunction directly affects the microenvironment of vascular smooth muscle cells 
(VSMCs) and causes pathological changes. The expression of pro-inflammatory molecules is 
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highly involved in this process. It was shown that high glucose induces adhesion molecule and 
cytokine expression in VSMCs [79, 80]. The expression of cytokines such as IL-1, MCP-1, IFN, 
IL-6 results in VSMCs proliferation, migration and over-expression of ECM proteins [79]. In the 
progression of diabetic macrovascular complications, for example atherosclerosis, the 
proliferation and migration of VSMCs towards the lipid-rich atherosclerotic lesion contributes to 
the formation of the fibrous cap which strengthens the atheromatous plaque [81]. In the progression 
of diabetic microvascular complications, such as arteriolosclerosis, VSMC-mediated excessive 
ECM production results in the thickening of arteriole walls and the deposition of homogeneous 
pink hyaline material, which is known as hyaline arteriolosclerosis [82, 83]. These changes narrow 
the lumen of the arteries in both macro- and microvasculature. In large vessels, the rupture of 
atheromatous plaque is the leading cause of coronary artery disease in diabetes patients [84]. In 
small vessels, reduced lumen size in renal arterioles decreases renal blood flow, and therefore 
reduces glomerular filtration rate. This could in turn cause increased renin secretion, which further 
increases the blood pressure, and finally the decreased kidney function [85]. All these changes can 
not be achieved without the presence of pro-inflammatory signals. 
 
1.3.3.3 The impact on monocytes/macrophages 
The role of monocytes/macrophages in diabetic vascular inflammation is widely studied in 
macrovasculature [65, 86]. As we know, the most identified pathological mechanism of diabetic 
macrovascular disease is the progression of atherosclerosis. In this process, increased FFA and 
lipoproteins firstly activate monocytes/macrophages via TLR signalling [61, 87, 88]. The activated 
cells are then attracted to the lesion site in the arterial wall by cytokines that are expressed locally 
by activated ECs or VSMCs. The pro-inflammatory cytokines IL-8 and MCP-1 are involved in 
this process [89-91]. In addition, the activated monocytes/macrophages also secret cytokines, 
which are important for recruiting more monocytes to the lesion site [81]. It is clear that the 
migration of monocytes/macrophages plays a major role in the pathogenesis of diabetic 
macrovascular diseases. However, the behavior of leukocytes in diabetic microvascular diseases 
is still poorly studied. In those small vessels, it remains unclear as to how leukocyte recruitment is 
involved in diabetic vascular complications.  
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1.4 Leukocyte recruitment  
Our immune system is a complex network of organs, tissues, and cells that work together to defend 
the body against infections and foreign materials. Being the key components in the immune system, 
leukocytes are tightly associated with the immune functions in our body. In most cases, leukocytes 
are produced and derived from hematopoietic stem cells in the bone marrow. As the hematopoietic 
stem cells mature, they differentiate into diverse subtypes of leukocytes, including neutrophils, 
eosinophils, basophils, lymphocytes and monocytes. Each of them have unique functions in 
immune defence [92].  
 
Neutrophils are usually the first responders to infections or tissue damage. They are commonly 
seen in the early stages of acute inflammation. These cells are not able to renew their lysosomes 
which are used to digest microbes, thus will die after phagocytosing a few pathogens [93]. 
Lymphocytes are much more common in the lymphatic system than in the blood. They include 3 
types of cells: T cells, which function in cell-mediated cytotoxicity in adaptive immunity; B cells, 
which function in antibody-mediated humoral immunity in adaptive immunity; and natural killer 
cells (NK cells), which function in cell-mediated cytotoxicity in innate immunity [93]. Monocytes 
can move to the infection sites and differentiate into macrophages or dendritic cells. Monocytes 
also have phagocyte function as do neutrophils, but are capable of replacing their lysosomal 
contents and thus have a much longer active life. They also act as antigen presenting cells which 
present pieces of processed pathogens to T cells so that the pathogens can be recognized and killed 
by the adaptive immune system. Eosinophils are primarily involved in parasitic infections and 
allergic reactions, whereas basophils are mainly responsible for allergic and antigen responses by 
releasing histamine [94].  
 
1.4.1 Mechanisms of leukocyte recruitment  
Leukocyte recruitment refers to the movement of leukocytes from the blood stream to the 
extravascular space. However, it is known that leukocyte recruitment, although essential to 
survival, can also be harmful to the host [95-97]. Figure 1-1 illustrates the leukocyte recruitment 
paradigm that is commonly seen in immunology textbooks. This process occurs at postcapillary 
venules and requires the presence of selectins to support rolling, and integrins to support adhesion. 
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The activation of integrins requires the presents of chemokines and other proinflammatory 
molecules on the surface of endothelium. Rolling and adhesion are essential for the migration of 
leukocytes. In most cases, the blockade of rolling by anti-selectin antibodies prevents firm 
adhesion of leukocytes, and thus inhibits leukocyte diapedesis [98-100]. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-1. Sequential phases of leukocyte recruitment from the blood stream to the inflamed 
tissue. Tethering and rolling are mostly selectin-dependent, while adhesion and intraluminal 
crawling are integrin-mediated. Endothelium-expressed chemokines activate the surface-
expressed integrins on the rolling leukocytes, resulting in conformational changes of the integrins. 
The transmigration of leukocytes requires the interaction of junctional adhesion molecules that are 
expressed on both leukocytes and ECs [100]. 
 
1.4.1.1 Tethering and rolling 
The initial contact between leukocytes and endothelium is termed tethering. Under physiological 
conditions, leukocytes move along with red blood cells at a high speed in the blood stream. 
Therefore, to initiate tethering, a greatly reduced velocity must take place. During inflammation, 
vascular hyperpermeability and vasodilation change the velocity and shear force of the blood. It 
was shown that during low shear, smaller cells, such as red blood cells, tend to move near the 
center of the bloodstream, while the larger cells, such as leukocytes, are pushed outward to the 
vessel wall. This physical property provides the chances for leukocyte-endothelium interaction, 
however it is not sufficient to slow down the high speed leukocytes [96, 97, 101]. The following 
Figure 1-1 Sequential steps of leukocyte recruitment from the vasculature to the tissue. 
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rotational movement of leukocytes along the vessel wall, which is named rolling, is dependent on 
the expression of selectins. It is well accepted that selectins are critical for initiating leukocytes 
tethering and rolling on endothelium [97, 102]. 
 
The selectins are calcium-dependent type I transmembrane glycoproteins. E-selectin and P-selectin 
are expressed on activated endothelium, while L-selectin is found on leukocytes. P-selectin 
(CD62P) is not constitutively expressed. In platelets it is stored in alpha-granules, while in ECs it 
is stored in Weibel-Palade bodies. In ECs, upon the stimulation of inflammatory mediators (such 
as cysteinyl leukotrienes, histamine, thrombin, and oxidants, etc.), the Weibel-Palade bodies fuse 
with the plasma membrane within minutes and increase the level of P-selectin on the surface of 
ECs. Thus, it is anticipated that P-selectin participates in the early stage of leukocyte recruitment 
[101]. Upon activation by cytokines, the transcriptional upregulation of P-selectin is also observed 
in endothelium. TNF-α, IL-1, and LPS are shown to increase P-selectin expression in murine, 
while IL-4 and IL-13 are functioning in human ECs [97, 100]. The blockade of P-selectin prevents 
leukocytes rolling and the subsequent adhesion in postcapillary venules. E-selectin (CD62E) is de 
novo synthesized in ECs upon the stimulation of proinflammatory cytokines such as TNF-α or IL-
1β. On the endothelium of non-inflamed tissue, minimal or no E-selectin is expressed. The 
expression of E-selectin takes place within 4 h and generally decreases within 24 h. Thus, it 
mediates leukocyte rolling at a delayed time point. E-selectin expression leads to a dramatic 
decline of rolling velocity (slow rolling), which facilitates the subsequent adhesion. The blockade 
of E-selectin results in higher rolling velocity and lower chance to adhere [95, 102]. On leukocytes, 
the binding to endothelial P-selectin and E-selectin is mediated by P-selectin glycoprotein ligand-
1 (PSGL-1), while other ligands such as E-selectin ligand 1 (ESL1), CD43, CD44 and L-selectin 
(in human neutrophils) are also responsible for E-selectin binding. L-selectin (CD62L) is 
constitutively expressed on most leukocytes. It is a homing molecule that is involved in 
lymphocyte recirculation. The binding between L-selectin and endothelial PSGL-1 is reported in 
postcapillary venules. L-selectin is involved in leukocyte rolling, however, its role may be limited. 
In the absence of L-selectin, leukocytes still rolled and adhered but failed to emigrate out of the 
vasculature, suggesting it is involved not just in the rolling process [97, 99]. Despite the differences, 
the three selectins functionally overlap with each other, and play a significant role in leukocyte 
recruitment during inflammation. 
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1.4.1.2 Activation of leukocytes 
The tethering and the rolling of leukocytes along the inflamed endothelium allow the leukocytes 
to contact chemokines on the surface of endothelium. Chemokines are critical for integrin 
activation. The binding between chemokine and its G protein-coupled receptor (GPCR) triggers 
the conformational change of the integrins which provides higher affinity to adhesion molecules. 
Both chemokines and activated integrins are required for the subsequent firm adhesion of the 
leukocyte.  
 
The activation of leukocyte integrins requires an “inside-out signalling”: the activation of 
intracellular signalling finally results in the conformational change of surface-expressed integrins, 
thus affects intercellular action. The binding of the chemokine to its receptor activates GPCR 
signalling, thus the Gβγ subunit is released from the receptor complex then activates phospholipase 
Cβ (PLCβ) which cleaves phosphatidylinositol 4,5-bisphosphate (PIP2) into diacylglycerol (DAG) 
and inositol triphosphate (IP3). Increased IP3 causes Ca2+ release from the endoplasmic reticulum, 
which leads to the activation of Ca2+ and DAG sensitive protein Ca2+ and diacylglycerol-regulated 
guanine nucleotide exchange factor 1 (CalDAG-GEF-1). This activation results in the binding of 
several proteins including Ras-related protein 1 (Rap-1), Rap1-GTP-interacting adapter molecule 
(RIAM), talin-1 and kindling-3 to form a complex. Finally, the contact between talin-1, kindling-
3 and the tail of β chain causes the conformational change of bended ligand-binding headpiece 
into an upright position, which allows the integrins to have higher affinity [103, 104]. It must be 
noted that the integrin activation occurs within seconds or subsecond time frames. Thus the 
“activation” is usually not considered as a specific stage in leukocyte recruitment paradigm. 
 
1.4.1.3 Firm adhesion 
With the presence of chemokines, lipid mediators or other proinflammatory molecules on the 
surface of the endothelium, the selectin-dependent rolling is followed by integrin-dependent firm 
adhesion. Integrins are heterodimers containing two distinct chains, named α and β subunits. In 
mammals, 18 α subunits couples with 8 β subunits to yield 24 different integrin molecules. It was 
shown that the expression of β2-integrins (CD18), such as LFA-1 (lymphocyte function-associated 
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antigen 1, αLβ2), Mac-1 (also known as macrophage-1 antigen, integrin αMβ2), p150, 95 (αXβ2) 
and αDβ2 on neutrophils, are important for their adhesion. Administration of anti-CD18 antibody 
blocks ischemia/reperfusion-induced leukocyte recruitment. Similar effects are observed in 
mesentery and other tissues. However, lack of β2-integrin gene could result in impaired wound 
healing and severe infectious complications. Besides β2-integrin, α4-integrin is another dominant 
integrin that required for adhesion. It can associate with either β1-integrin to form α4β1integrin 
(also known as very late antigen-4, VLA-4), which is observed in most mononuclear cells, or β7-
integrin to become α4β7 integrin (also known as lymphocyte Peyer's patch adhesion molecule, 
LPAM) which is found primarily in lymphocytes. The α4-integrins primarily mediate the adhesion, 
and rolling in some cases, of monocytes, lymphocytes, and eosinophils. On ECs, the identified 
ligands for these integrins are ICAM-1 and VCAM-1. Both ICAM-1 and VCAM-1 can be de novo 
synthesised upon the stimulation. The ICAM-1/β2-integrin binding is shown to be important for 
neutrophil recruitment, while VCAM-1/α4-integrin binding recruits monocytes, lymphocytes and 
eosinophils. It should be noticed that the function of those molecules are usually not restricted in 
one certain stage. In some cases, integrins are capable of mediating leukocyte rolling, while 
selectins can also be important for initiating adhesion [95, 97, 99, 101, 102]. 
 
1.4.1.4 Intraluminal crawling 
After firm adhesion, leukocytes crawl on the luminal surface of the endothelium to reach to their 
optimal extravasation sites. To initiate this stage, the binding between integrins and ICAM is 
required since blocking of ICAM-1 prevents adherent leukocyte from crawling and subsequent 
emigration. Additionally, the binding between ICAM-1 and β2 integrin activates the “outside-in 
signalling”: the interaction between ICAM-1 and integrin on the cell surface triggers the 
intracellular signalling cascade that increases the functionality of the integrins and that is required 
for the crawling of leukocytes. Although the mechanism is not fully understood, the “outside-in 
signalling” is shown to be critical for leukocyte intraluminal crawling. 
 
The activation of “outside-in signalling” leads to proper localization of proteins that are crucial for 
intraluminal crawling at the edge of lamellipodium. For example, the translocation of 
phosphoinositide 3-kinase δ (PI3Kδ) results in the accumulation of PI3K products at the 
lamellipodium, which is essential for the stabilization of cell polarity and chemotactic migration. 
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The subsequent interaction between mAbp1 and actin at the leading edge of polarized cells controls 
the shape change of lamellipodium, and therefore facilitates the intraluminal crawling. It was 
shown that leukocyte intraluminal crawling does not require a chemotactic gradient. However, the 
established gradient of chemokines in the vasculature is able to guide the leukocytes crawling 
towards their transmigration sites, with the mechanism not yet demonstrated [97, 101, 103, 104].  
 
1.4.1.5 Transendothelial migration  
Leukocytes migrate into inflammatory sites by passing through the layer of ECs. However, ECs 
are tightly connected to each other through junctional structures. Therefore, these junctions must 
apparently be opened for transmigrating leukocytes, while the vascular integrity remains intact. 
On ECs, there are several well-identified junctional expressed molecules that are involved in 
leukocytes transmigration, including JAM-A, JAM-B, JAM-C, PECAM and CD99. Vascular 
endothelial cadherin (VE-cadherin) is another junctional-expressed molecule which is critical for 
maintaining vascular integrity and regulating vascular permeability. These junctional expressed 
molecules are capable of homophilic interactions, which means a molecule on one cell can bind to 
the same molecule on the apposing cell. On leukocytes, PECAM, JAM-A, JAM-C and CD99 are 
also expressed. Besides, integrins such as VLA-4, Mac-1 and LFA-1 also bind to JAMs on ECs. 
Upon the stimulation by inflammatory cytokines, the rearrangement of junctional expressed 
molecules is observed in ECs. This step is required for leukocyte transmigration to proceed since 
the rearrangement increases the contacts of leukocytes with ECs and guides leukocytes into the 
junction between ECs. To complete the transmigration, a transient rise of intracellular free calcium 
is also required in ECs. Leukocytes can only adhere to the endothelium but cannot complete the 
transmigration if this transient calcium rise is cushioned. The increase of intracellular calcium also 
activates myosin light chain kinase (MLCK), which leads to unfolding of myosin II, and 
subsequent cell retraction which facilitates leukocyte passage [97, 101, 103-106].  
 
1.4.1.6 Fate of extravasated leukocytes  
Leukocyte transendothelial migration must follow the chemokine gradient which is produced by 
the endothelium. After transendothelial migration, the leukocyte must then migrate against this 
gradient towards the infection or damaged tissue. This suggests there is a new chemotactic signal 
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in the tissue which overrides the first gradient that exists on endothelium. A number of studies 
have shown the hierarchy of chemotactic signals in an inflamed tissue. For example, the 
chemoattractant molecules which are presented by infecting bacteria [such as bacteria-derived N-
formyl-methionyl-leucyl-phenylalanine (fMLP)] or the endogenous expressed complement 
component C5a override the endothelium-generated chemotactic signals [such as, interleukin 8 
(IL-8) and leukotriene B4 (LTB4)]. Therefore, according to their leukocyte attracting ability, 
chemoattractants can be divided into “end-target” and “intermediate” chemoattractants. 
Chemotaxis was controlled by the activation of several pathways, among them the 
phosphatidylinositol 3‑kinase (PI3K) signalling is most well-studied. The accumulation of PIP3 at 
the leading edge of chemotaxing neutrophils is required for their directional migration. Besides, 
p38 mitogen-activated protein kinase (p38 MAPK) signalling and extracellular signal-regulated 
kinase (ERK) signalling are also involved in the chemotaxis triggered by end-target 
chemoattractants [107, 108]. 
 
1.4.2 Leukocyte recruitment and microvasculature damage 
Besides the mechanism of monocyte/macrophage recruitment in the development of 
atherosclerosis (reviewed in 1.2.2), little is known about the mechanisms and the impact of 
leukocytes recruitment on microvasculature. There are two major limitations to perform an in vivo 
study on this: the limited methods to perform in vivo leukocyte tracking during inflammation, as 
well as the limited techniques to evaluation the long-term impact of leukocyte recruitment on the 
development of microangiopathy. Although the detailed mechanisms are not completely 
understood, evidence shows that leukocyte recruitment is highly involved in microvascular injury, 
especially in diabetic nephropathy. 
 
Endothelial dysfunction is associated with nearly all forms of diabetic microvascular 
complications. There is an increasing body of evidence showing that leukocyte transmigration 
increases vascular bed inflammation and changes the functions of ECs. For example, activated 
monocytes/macrophages release excessive ROS, NO, TNF-α, IL-1, metalloproteinases, and 
complement factors, all of which promote EC activation [79, 109]. Thus, the interactions between 
activated macrophages and ECs could result in endothelial dysfunction. Besides, macrophage-
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derived factors such as IL-1 and platelet-derived growth factor (PDGF) also induce the 
proliferation of mesangial cells in kidney, resulting in diabetic nephropathy [109]. On the other 
hand, activated T lymphocytes, which are widely observed in diabetes patients, also secrete 
inflammatory factors such as IFN-γ, TNF-α, which activate ECs and macrophages [110]. 
Neutrophils can induce endothelial dysfunction by producing reactive oxygen species (ROS) and 
releasing cytotoxic proteinases [111]. There is clear evidence that neutrophils from diabetes 
patients exert an activated phenotype, which is revealed by increased TNF-α-induced superoxide 
generation and enhanced spontaneous adhesion [109, 112]. It has also benn shown that neutrophils 
from diabetes patients have increased level of ROS, which may impair ECs and promote the 
development of diabetic nephropathy [109, 112]. Thus, the contact between neutrophils and ECs 
is potentially harmful. The increased recruitment and impaired functions of leukocytes were both 
observed in diabetes mouse models. Hanses et al. observed defects in neutrophil apoptosis and in 
their ability to clear staphylococcal infections in diabetic mice [113]. In the physiological condition, 
neutrophil apoptosis promotes their elimination by macrophages at the site of infection, which 
subsequently terminates the inflammatory process. Thus, these defects prolong production of 
proinflammatory TNF-α by neutrophils and may contribute to the chronic inflammation and 
impaired wound healing. Judging from the evidence above, leukocyte recruitment brings more 
damage than healing in the microvasculature. Although the mechanisms are poorly understood, it 
is clear that leukocyte recruitment is involved in the progression of diabetic microvascular 
complications.  
 
1.4.3 Intravital microscopy 
Intravital microscopy is a cutting-edge technique for studying the molecular mechanisms of 
leukocyte recruitment by visualizing leukocyte-EC interactions in vivo. Many studies using this 
technique are performed with translucent tissues, such as mesentery and cremaster muscle, using 
brightfield intravital microscopy (Figure 1-2). In fact, the identification of the neutrophil 
recruitment paradigm was largely dependent on the use of this technique. Recently, with the 
application of spinning-disc confocal and two-photon microscopes which are suitable for thicker 
tissue penetration, more organs and tissues, for example skin, lymph nodes, brain, lung and liver, 
can also be visualized and studied. These advanced techniques allowed people to visualise the 
18 
 
different cell populations or anatomical structures that are labelled by fluorescent antibodies, thus 
allowing a better understanding of the mechanism of leukocyte recruitment [96, 114]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-2. The schematic diagram of an intravital microscope system [114]. The mouse 
cremaster muscle is surgically exposed on an optically clear viewing pedestal, secured along the 
edges with 5-0 suture, and superfused with 37°C bicarbonate buffered saline. A CCD color video 
camera is connected to the upright microscope for brightfield intravital microscopy. The leukocyte 
recruitment in cremaster muscle is recorded by a color video camera and stored by a DVD recorder. 
A monochrome deep-cooled CCD digital camera is also connected to the microscope for 
fluorescence intravital microscopy used in the vascular permeability assay. (Figure is adapted from 
Xu et al. J Vis Exp. 2011; (55): 3296.) 
 
Figure 1-2 The schematic illustration of an intravital microscope system 
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1.5 Methylglyoxal (MG) 
1.5.1 The generation and metabolism of MG in vivo 
1.5.1.1 Formation 
MG is endogenously formed during glucose or fructose metabolism, protein catabolism and fatty 
acid oxidation. The primary source of MG is from the triosephosphate intermediates of glucose 
and fructose metabolism. In the first step of glycolysis, glucose is phosphorylated into glucose 6-
phosphate by hexokinase, the latter is then enzymatically converted into fructose-6-phosphate 
which is further metabolized into fructose 1,6-bisphosphate. Fructose 1,6-bisphosphate can be 
cleaved by aldolase A to generate two triosephosphate intermediates glyceraldehyde 3-phosphate 
(GA3P) and dihydroxyacetone phosphate (DHAP), and from here they can either be part of 
glycolysis and generate pyruvate or be the precursor of MG [115, 116]. DHAP and GA3P can be 
readily inter-converted by triosephosphate isomerase. In pathological conditions, both of them can 
spontaneously and non-enzymatically be degraded into MG [115]. However, it was shown that in 
microorganisms, DHAP can be metabolized into MG by MG synthase. MG synthase was first 
purified from E(scherichia) coli in 1971 [117, 118]. Since then it has been found in other 
prokaryotic and in mammalian systems [115, 119]. However, the role of MG synthase in 
hyperglycemia and hyperglycemia-induced vascular injury has not yet been studied (Figure 1-3).  
 
Under hyperglycemic condition, the overabundance of glucose influx saturates hexokinase and 
thus activates the polyol pathway (also known as aldose reductase pathway). In this pathway, 
glucose is converted into sorbitol by aldose reductase and then oxidised by sorbitol dehydrogenase 
to form fructose. Fructose can be quickly phosphorylated by fructokinase to fructose 1-phosphate 
and subsequently split by aldolase B into glyceraldehyde and DHAP. Considering the non-
enzymatic formation of MG from DHAP, any pathways that increase DHAP formation are 
possibly linked to MG formation, such as the glycolysis pathway under physiological conditions, 
the polyol pathway under hyperglycemic conditions as well as excessive fructose intake from the 
diet [115, 120].  
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Figure 1-3 The formation and degradation of MG 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-3. The formation and degradation of MG. Glyceraldehyde 3-phosphate (GA-3P) and 
dihydroxyacetone phosphate (DHAP) that produced through glycolysis or the polyol pathway are 
the main sources of MG formation. In addition, acetone from fatty acid oxidation and 
aminoacetone from protein catabolism also contribute to MG formation. The key enzymes are 
labelled in italics. 
 
 
Besides the pathways mentioned above, proteins and fatty acids can also be the sources for MG 
formation. Acetone from fatty acid oxidation and aminoacetone from protein catabolism are 
important precursors of MG. The conversion of acetone into MG involves two consecutive 
catalytic steps which require the activity of enzymes belonging to cytochrome P450 2E1 gene 
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subfamily [121]. First, acetone is oxidized by acetone monooxygenase to generate acetol as an 
intermediate. Then acetol is converted into MG by acetol monooxygenase [115]. On the other hand, 
MG can also be produced from the catabolism of the amino acids threonine and glycine. 
Aminoacetone is an intermediate of threonine and glycine metabolism and is known as the 
substrate of amine oxidases. Semicarbazide-sensitive amine oxidase (SSAO), the enzyme 
catalyzes the deamination of aminoacetone into MG, exists in two forms: the tissue bound form in 
the plasmalemmal membrane and the soluble form in plasma, and both are capable of converting 
aminoacetone into MG. It was shown that SSAO is located in the outer membrane surface and in 
the cytoplasm of adipose tissue, vascular smooth muscle cells, and ECs, indicating its potential 
role in hyperglycemia-induced vascular damage [115, 122, 123].  
 
1.5.1.2 Degradation 
The degradation of MG involves MG reductase, glyoxalase and MG dehydrogenase, each leading 
to a distinct pathway of MG degradation (Figure 1-3) [115]. Among them, the glyoxalase system 
in the cytosol of all mammalian cells is the most common pathway for MG break-down. In the 
presence of glyoxalase I and its cofactor reduced glutathione (GSH), MG is firstly converted 
irreversibly to D-lactoylglutathione, and then to D-lactate by glyoxalase II. Thus, the degradation 
of MG is largely dependent on the presence of cellular GSH and the activities of GSH-related 
enzymes, such as glutathione peroxidase (GSH-Px) and glutathione reductase (GSH-red). It should 
be pointed out that excessive MG formation inhibits the activity of glutathione reductase and 
reduces the level of GSH, which further prevents MG degradation [124-126].  
 
Besides the major degradation pathway, there are other pathways engaged in MG degradation. 
Since MG contains two functional groups that can be either reduced or oxidized, it is not surprising 
that the enzymes involved in oxidoreductions are able to convert MG. For example, MG reductase 
(also known as aldehyde reductase) located in cytosol is able to metabolise MG to lactaldehyde, 
which is then further converted to L-lactate with the help of aldehyde dehydrogenase. On the other 
hand, with NAD+ as cofactor, MG can be converted into pyruvate by MG dehydrogenase (also 
known as α-ketoaldehyde dehydrogenase or 2-oxoaldehyde dehydrogenase) [116]. Although well 
studied in microorganisms, the functions of these two degradation pathways in mammals are still 
poorly understood.  
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The third way to eliminate MG brings more harm than good to our body. MG promotes the 
formation of advanced glycation end-products (AGE) which are highly associated in the 
progression of diabetes and diabetic complications [115, 116]. MG firstly reacts with proteins at 
lysine, arginine, or cysteine residues, and the subsequent irreversible reaction yields AGE. 
Irreversible formation of AGE on proteins changes their structures and disturbs their 
physicochemical and biochemical properties as well as their stability. Moreover, AGE bind to and 
activate the receptor for AGE (RAGE) on the cell surface, leading to either excessive generation 
of ROS through NADPH oxidase or the activation of multiple signalling pathways, such as p38 
mitogen-activated protein kinases (MAPK) and c-jun N-terminal kinases (JNK) [127, 128]. By 
this way, MG causes damage to proteins, cells and the cardiovascular system.  
 
1.5.2 The debate of MG dose 
Despite the endogenous formation, there are multiple exogenous sources that bring MG into the 
body. The presence of MG was reported in rice, wheat and tobacco, so as a broad range of 
commercial foods and beverages, such as bread, coffee, honey, wine, and beer [129, 130]. 
Therefore, the important question is how much MG will put our body in danger. Unfortunately, 
the answer of this question is still largely debated. It is now commonly accepted that plasma MG 
levels in healthy humans is about 1 µmol/L or less, but is about 2―3 fold increased in type 2 
diabetes patients and 5―6 fold increased in type 1 diabetes patients. This conclusion is mainly 
based on the observation by McLellan et al. in 1994 [131], which showed the plasma MG level 
was 79.8 pmol/g range 25.3 to 892.9 in healthy people (21 subjects), 470.7 pmol/g range 85.6 to 
1044.3 in insulin-dependent patients (42 subjects) and 286.8 pmol/g range 54.7 to 2370 in non-
insulin-dependent patients (105 subjects). The following study by Lapolla et al. showed that in 
healthy individuals the plasma MG level was about 8.5 ± 0.5 µg/mL, whereas in diabetes patients 
it was increased to 29.3 ± 5.5 µg/mL [132]. Another study conducted by Wang et al. reported that 
the plasma MG levels in type 2 diabetes patients was 77% higher than those in non-diabetic 
subjects (5.9 ± 0.7 µM versus 3.3 ± 0.4 µM) [112]. Despite the differences in the unit of 
measurements in the above studies, the fold increase of MG in diabetes patients versus control 
subjects seems consistent. However, Beisswenger and colleagues reported that plasma MG levels 
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in control subjects were 123.0 ± 37.0 nM, and in diabetic subjects 189.3 ± 38.7 nM [133], which 
is about 30 times lower than Wang’s observation. The inconsistent MG values measured by 
different research groups complicates the research. Actually, the MG levels claimed by different 
research groups using in vitro or in vivo diabetic models have even greater differences.  
 
Regardless of the debate over MG measurement, it is widely accepted that the plasma MG level is 
significantly increased in diabetes patients [131]. Based on this, exogenous MG was added to 
cultured cell or given to animals to study the role of MG in the development of diabetes. However, 
the dose of MG used in these studies are also largely debated. Dhar et al. reported that in Sprague-
Dawley rats, 60 mg/kg/day and 28 days of chronic methylglyoxal infusion by minipump was 
required to increase the plasma MG level by about 2 fold, and with this dose the rat showed 
impaired glucose tolerance, apoptosis in pancreatic islets and reduced pancreatic insulin content 
[134]. This finding suggests that it requires large dose of exogenous MG to establish a diabetic 
animal model and reach the similar plasma MG level as in diabetic patient. In patients, the 
progression of diabetes takes several years, and during this process MG is not the only factor that 
causes damage to the cells and tissues. Therefore, it is reasonable and acceptable to use a high MG 
dose (sometimes even higher than pathological conditions) to establish the in vitro or in vivo model, 
especially in a short-term study. On the other side, the data regarding MG levels in the tissue in 
diabetes patients are still missing. Judging from high fructose diet-induced diabetic animal model, 
it is likely that MG tends to accumulate in certain tissues [135]. Randell et al. showed that in 
normal Sprague-Dawley rats, the MG level was highest in aorta followed by heart, liver, kidney 
and blood [136]. This result indicates that MG concentration in local tissue might be much higher 
than it is in the plasma. Taken together, in the studies using exogenous MG to induce diabetes-
related syndromes, especially in the short-term studies, the given dose of MG should not be judged 
only by the plasma MG level in diabetes patients.  
 
1.5.3 MG and insulin resistance 
Insulin resistance is commonly observed in conditions like diabetes and obesity [86]. Chronic 
hyperglycemia-induced insulin resistance is the primary etiological causes of diabetes and diabetic 
complications [137]. In the physiological condition, binding of insulin to its receptor induces the 
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autophosphorylation of tyrosine residues present in the intracellular portion of insulin receptor. 
Insulin receptor activation then results in the phosphorylation of tyrosine residues on the insulin 
receptor substrate (IRS), which will be further recognised by p85 regulatory subunit of PI3K. The 
activation of PI3K leads to the formation of PIP3. Being a key downstream effector of PIP3, Akt 
is attracted to the plasma membrane, where it is phosphorylated hence activated by 
phosphoinositide-dependent kinase-1 (PDK1). Once activated, Akt enters the cytoplasm to 
phosphorylate and inactivate glycogen synthase kinase 3 (GSK3). Glycogen synthase (GS) which 
catalyses the final step of glycogen synthesis is the downstream target of GSK3. GSK3 negatively 
regulates GS activity by phosphorylating GS on the serine residue. Therefore, the inactivation of 
GSK3 by Akt activates GS and promotes glucose storage as glycogen [138].  
 
However, under pathological conditions, the insulin pathway is blocked due to hyperglycemia. 
Both in vivo and in vitro evidence showed that the formation of MG may be responsible for this 
change [139, 140]. It was shown that MG inhibits insulin stimulated phosphorylation of Akt in 
cultured L6 muscle cells [140]. In cultured 3T3 adipocytes, MG significantly reduced PI3K 
activity and tyrosine phosphorylation of IRS-1, the effects that were reversed by N-acetyl cysteine 
(NAC), an MG scavenger [141]. It was also demonstrated that the incubation of MG with human 
insulin in vitro produced MG-insulin adducts which led to impaired autocrine control of insulin 
release from pancreatic β-cells, reduced insulin-mediated glucose uptake by the target cells, and 
decreased hepatic clearance of insulin in liver [142]. In the in vivo study, Dhar et al. showed that 
chronic MG infusion by minipump caused elevated fasting plasma glucose and reduced insulin in 
the rat. The impaired glucose tolerance, together with decreased insulin-stimulated glucose uptake 
in adipose tissue, as well as reduced GLUT4 level and PI3K activity were also observed. This 
study provides the direct evidence that MG itself is able to induce pancreatic β-cell dysfunction 
and type 2 diabetes [134]. All of the above evidence supports the critical role of MG in the impaired 
insulin-stimulated glucose uptake.  
 
25 
 
1.5.4 MG and oxidative stress 
1.5.4.1 Association of MG formation and ROS generation  
Oxidative stress is one of the important factors in causing diabetes and diabetes-related diseases 
[115]. Hyperactivities of xanthine oxidase, NADPH oxidase and mitochondrial dysfunction, which 
all cause excessive ROS production, are observed in pathological conditions such as aging, 
hypertension and diabetes [115, 143]. Under the hyperglycemic conditions, with the activation of 
enzymes in the polyol pathway, glucose is first converted into sorbitol, and then into fructose 
(reviewed in 1.5.1). The conversion of sorbitol into fructose consumes NADPH which is an 
important reducing agent for maintaining redox balance in the cells [144]. Thus, paralleled with 
MG generation, the over activation of the polyol pathway also increases oxidative stress. Likewise, 
fructose metabolism promotes oxidative stress as well. Unlike glycolysis, fructolysis doesn’t have 
a negative feedback mechanism, which means all the ingested fructose will be metabolized without 
any storage. The first step of fructolysis, which converts fructose into fructose-1-phosphate, 
consumes adenosine triphosphate (ATP) and generates adenosine diphosphate (ADP). Therefore, 
the overload of fructose will lead to ADP accumulation. With the catalyzing of multi-enzymes, 
ADP will be metabolised into adenosine monophosphate (AMP), inosine monophosphate (IMP), 
hypoxanthine, xanthine and finally uric acid. The last step of this reaction requires the activity of 
xanthine oxidase and produces superoxide as the by-product [145-147]. Therefore, fructose 
overload can eventually lead to increased oxidative stress. It is evident that excessive fructose 
intake for 2 weeks leads to insulin resistance and hypertension in rats, the process of which is 
highly related to increased oxidative stress [148]. 
 
1.5.4.2 MG induces ROS formation  
MG-induced ROS formation has been shown in many types of cells. In vascular smooth muscle 
cells (VSMCs), both cell line cells and primary cultured cells from rat mesenteric artery showed 
that incubation with MG increased total ROS in a time- and concentration-dependent manner [31, 
149]. The induction of oxidative stress by MG has been also reported in Jurkat T leukemia cells 
and cultured rat hepatocytes [150, 151]. Moreover, the in vivo study using spontaneously 
hypertensive rats showed that, the level of MG in VSMCs from hypertensive rats were more than 
2-fold higher than in VSMCs from normotensive Wistar-Kyoto rats [126]. Accordingly, 
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exogenous MG induced a greater increase in oxidative stress in VSMCs from hypertensive rats 
compared with normotensive rats [126]. These findings support the link between increased MG 
levels and elevated ROS formation in either in vitro cell models or in vivo animal models. Our 
own observation in the hybrid human umbilical vein EC line cells also showed that MG induced a 
dose- and time-dependent increase of superoxide and total ROS [152]. The in vivo permeability 
assay showed that MG induces hyperpermeability in postcapillary venules, an effect that can be 
blocked by ROS scavengers [153]. These results suggest that MG induces ROS formation which 
may be related to the progression of vascular disease. 
 
1.5.4.3 The mechanism of MG-induced oxidative stress  
1.5.4.3.1 MG-induced mitochondrial superoxide generation 
The mitochondrial respiratory chain uses glucose to generate ATP via oxidative phosphorylation. 
During mitochondrial respiration, electrons from donors pass through the complexes I–IV of the 
respiration chain. The dysfunction or disruption of the mitochondrial respiratory chain contributes 
to ROS formation due to the leakage of electrons to oxygen [154]. There are two main sites of 
electron leakage, complex I (NADH-ubiquinone oxidoreductase) and complex III (ubiquinol-
cytochrome c reductase) of the electron transport chain [154]. In diabetes, with the excessive 
glucose supplementation, it has been speculated that excess production of ROS could change the 
mitochondrial membrane potential, thus decreases ATP synthesis, leading to energy depletion [155, 
156]. The role of MG in inducing mitochondrial superoxide generation has been widely reported. 
It has been shown that MG is able to inhibit mitochondrial complex activities and to increase 
mitochondrial superoxide generation [157]. In isolated rat renal mitochondria, MG incubation 
dose-dependently reduced the mitochondrial respiration rate [158]. In VSMCs, MG specifically 
inhibited complex III activity and increased mitochondrial superoxide generation, the effect 
possibly due to MG-induced AGE formation [157]. In osteoblastic MC3T3-E1 cells, MG 
decreased osteoblast differentiation and caused osteoblast cytotoxicity by inducing oxidative stress 
and mitochondrial dysfunction [159]. A similar phenomenon was also observed in neuroblastoma 
cell line cells [160].  
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1.5.4.3.2 MG-induced NADPH oxidase activation 
MG-induced NADPH oxidase activation was first studied in rat kidney mesangial cells. It was 
shown that the superoxide production in mesangial cells was rapidly elevated after 2-h incubation 
with MG, and stayed at a high level for 24 h [161]. This effect was significantly reduced by an 
NADPH-oxidase inhibitor pretreatment, suggesting NADPH oxidase is responsible for the 
formation of superoxide and may be subsequently responsible for renal fibrosis under diabetic 
conditions [161]. The study in VSMCs similarly showed that MG-induced superoxide production 
was suppressed by NADPH-oxidase inhibitor diphenylene iodonium (DPI) [31]. In parallel with 
the decreased NADPH-oxidase activity, MG-induced VSMCs proliferation was also inhibited 
[115]. In both human umbilical vein ECs and rat aortic ECs, MG-induced superoxide production 
was blocked by another NADPH oxidase inhibitor, apocynin (Apo) [70]. Accordingly, MG-
induced endothelial dysfunction was also partially restored [70]. Despite enormous evidence 
shown in in vitro and in vivo studies, the mechanism of MG-induced NADPH oxidase activation 
is not fully understood. It was shown that MG-induced AGE formation and the binding of AGE to 
its receptor RAGE may activate NADPH oxidases and promote the generation of ROS [162]. It is 
clear that MG-induced NADPH-oxidase activation plays an important role in the development of 
diabetic vascular complications.  
 
1.5.4.3.3 MG-induced peroxynitrite formation 
Peroxynitrite is a strong endogenous oxidation and nitration agent which damages a wide number 
of molecules, including DNA and proteins [163]. In patients, nitrosylated proteins is considered as 
a biomarker of peroxynitrite-related stress in diabetic patients with macroangiopathy [164]. In in 
vitro studies, peroxynitrite-mediated oxidative stress were observed from high glucose-treated 
retinal ECs [165]. Furthermore, peroxynitrite has been shown to induce vascular permeability 
increases in the retinal microvasculature [165]. The formation of peroxynitrite was also related to 
retinal ischemia/reperfusion injury [166]. Observations in human aortic ECs confirmed that high 
glucose induces tyrosine nitration via peroxynitrite formation, which leads to functional changes 
of enzymes as well as apoptosis [167]. In streptozotocin-induced diabetic mice and leptin deficient 
ob/ob mice, peroxynitrite decomposition improves neuronal functions and counteracts peripheral 
neuropathy [168-170].  
28 
 
 
Formation of peroxynitrite in vivo is mainly through the spontaneous reaction of nitric oxide (NO) 
and superoxide. In MG-treated cells, MG-induced NADPH oxidase activation provides large 
amount of superoxide, and NO can be produced either by endothelial nitric oxide synthase (eNOS) 
or inducible nitric oxide synthase (iNOS) depending on the different cell types [31, 115]. In ECs, 
eNOS is the dominant form of NOS, whereas iNOS is primarily expressed in VSMCs or 
macrophages upon stimulation [171]. Both in vitro and in vivo studies showed that in VSMCs, 
iNOS expression and NO were increased and associated with increased MG level, suggesting the 
role of MG in stimulating NO production [124, 172]. In ECs, eNOS is constitutively expressed, 
thus peroxynitrite is produced upon the activation of eNOS and the generation of superoxide [171]. 
However, unlike VSMCs, research data also showed that the expression of eNOS and 
bioavailability of NO were actually decreased with the elevated MG concentration [70]. In our 
own study, we found that the expression of 3-nitrotyrosine, which indicates the level of protein 
nitration thus reflecting the level of peroxynitrite, was increased in MG-treated ECs, indicating 
increased peroxynitrite formation even with decreased NO levels [70, 152]. Despite the differential 
role of MG in regulating NOS activity in ECs and VSMCs, the bioavailability of NO was decreased 
in both types of cells [31, 70]. In VSMCs, the formation of peroxynitrite was shown to be one of 
the reasons of MG-induced NO depletion, while in ECs both peroxynitrite formation and eNOS 
inhibition were involved [31, 70, 152].  
 
1.5.4.3.4 MG-induced depression of antioxidant systems 
MG increases intracellular oxidative stress levels by supressing antioxidative defense systems and 
reducing cellular antioxidant levels. Superoxide dismutase (SOD), glutathione peroxidase (GSH-
Px), glutathione reductase (GSH-red), catalase, and glutathione (GSH) are usually the targets of 
MG [173, 174]. Under physiological condition, the superoxide produced in cells is dismutated by 
SOD into hydrogen peroxide (H2O2) [175]. H2O2 is decomposed by catalase or glutathione 
peroxidase into water [176]. In the glutathione peroxidase pathway, the decomposition of H2O2 
requires the abundance of GSH [115]. With the catalyzing of GSH-Px, H2O2 and GSH are 
converted into water and glutathione disulfide (GSSG). The GSH-red then converts GSSG back 
into GSH, thus recycles GSSG to GSH [177]. It was reported that the activities of the purified 
SOD, GSH-Px and GSH-red were inhibited after incubation with MG in test tubes [173, 174]. In 
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VSMCs and ECs, the activities of SOD, GSH-Px, GSH-red and the levels of GSH were both 
significantly decreased upon incubation with MG [134, 157]. The in vivo studies showed that MG 
administration decreased SOD and catalase activities in the mouse liver [178]. In rats, chronic MG 
infusion by minipump also significantly reduced GSH levels in the plasma, skeletal muscle, and 
pancreas [134]. It was found that AGE formation is involved in MG-induced depression of the 
cellular antioxidant systems. Evidence showed that AGE formation directly impairs the functions 
of SOD and GSH-Px, while alagebrium, an AGE breaker, partially reduced MG-increased 
superoxide generation in VSMCs [157, 174]. Although the mechanism is not fully understood, it 
is clear that MG suppresses the activity of cellular antioxidant systems and thus further increases 
the oxidative stress.  
 
1.5.5 MG and AGE formation 
Spontaneous formation of AGE at lysine, arginine, or cysteine residues of proteins changes protein 
structures, and disturbs their physicochemical and biochemical properties as well as their stability 
[28, 29, 179]. Increased AGE formation in the blood and tissues occurs with aging. However, it is 
excessively increased during hyperglycemia and in diabetes [115, 124]. In Type 1 diabetes patients, 
levels of AGE in kidney and the retina were correlated with the development of nephropathy and 
retinopathy [180]. Studies in patients with type 2 diabetes showed that the increased AGE level in 
blood was correlated with decreased endothelium-dependent vasodilation, the thickness of intima-
media of blood vessels, vascular stiffness, and increased systolic blood pressure [181, 182]. In 
diabetic rats, increased renal AGE level causes glomerular basement membrane thickening, the 
morphological change associated with diabetic nephropathy [183]. The increased retina AGE level 
is related to abnormal EC proliferation, the pathological change that is also associated with diabetic 
retinopathy [184]. Based on the enormous evidence found in patients and in animal models, 
increased AGE level is considered as the leading cause of vascular complications in diabetes. 
 
MG has an essential role in AGE formation. It produces various types of AGE by reacting with 
lysine, arginine, or cysteine residues in proteins [185]. For example, its reaction with arginine 
residue produces 5-hydro-5-methylimidazolone (MG-H1) and argpyrimidine, the reaction with 
lysine residue generates N(ε)-carboxyethyl-lysine (CEL), methylglyoxal-derived lysine dimer 
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(MOLD), and the reaction with cysteine residue forms carboxyethyl cysteine (CEC) [28, 29, 179]. 
The in vitro studies showed that incubating purified human insulin with MG at 37°C for 24-72 h 
modifies insulin at the arginine residue of the β chain, while its incubation with purified Akt1 leads 
to the modification of Akt1 at the cysteine residue [142, 186]. On the other hand, the experiments 
using MG inhibitor also showed decreased AGE level associated with suppressed MG level. 
Alagebrium, an AGE breaker, was shown to have the ability to scavenge MG [187]. In VSMCs, 
the application of alagebrium completely prevented MG-induced AGE formation [134, 187]. 
Another MG inhibitor, aminoguanidine (also known as pimagedine), also inhibited AGE formation 
by directly reacting with MG and significantly reduceding cellular MG levels in high glucose- or 
MG-treated ECs [70]. Metformin, an oral hypoglycemic drug which also reacts with MG to 
generate stable triazepinone derivatives, reduced AGE formation in the lens, kidney and nerves in 
diabetic rats [188]. It is believed that the application of MG inhibitors which react with MG to 
form stable adducts reduces the chances of MG to react with proteins, thus reduces MG-induced 
AGE formation and cytotoxicity. These findings further support the role of MG in AGE formation. 
 
1.5.6 MG-activated and MG-related signalling pathways 
1.5.6.1 MAPKs pathway 
The mitogen activated protein kinases (MAPKs), which are responsible for various cellular 
activities downstream of cell membrane receptors, comprise mainly three members: extracellular 
signal regulated kinases (ERKs), p38 MAPKs and c-Jun N-terminal kinases (JNKs) [189]. Among 
them, p38 MAPKs and JNK are shown to be associated with the progression of diabetes [190-192]. 
Recent evidence suggests that due to its influences on vascular smooth muscle cells, vascular ECs, 
and monocytes/macrophages, p38 MAPKs may be the key linking endothelial dysfunction, insulin 
resistance, and the pathogenesis of type 2 diseases [191]. Consistently, inhibition of JNK using a 
cell-permeable peptide restores insulin sensitivity in mice, while genetic disruption of the JNK 
gene inhibits the progression of insulin resistance in diabetic and obese mice [192].  
 
The role of MG in activating MAPK pathway has been shown in many cell types. In mouse 
fibroblast cell line and human embryonic kidney cell line, MG treatment was demonstrated to 
induce the activation of ERKs [193, 194], an important signalling of cell proliferation [195]. In 
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Jurkat leukemia T cells, MG induces apoptosis by activating JNK [196]. In human ECs, MG 
mediates JNK- and p38-dependent inflammatory responses such as the over expression of 
cyclooxygenase-2 (COX2) [197]. In immune cells such as neutrophils and monocytes, the 
activation of MAPK pathway results in cell adhesion, chemotaxis, oxidative burst and 
degranulation [198-201]. The activation of immune cells is suggested to be important in producing 
chronic low-degree inflammation in the macro- and micro-vasculature. However, under 
hyperglycemic conditions, whether MG induces immune cells activation via MAPK pathway is 
still unclear.  
 
1.5.6.2 PKC pathway 
Protein kinase C (PKC) is a family of protein kinase enzymes that are involved in regulating the 
functions of other proteins by phosphorylating the downstream proteins on their serine and 
threonine residues. The PKC family consists of fifteen isozymes in humans. It can be activated by 
calcium ion (Ca2+), diacylglycerol (DAG), or phospholipid such as phosphatidylserine [202, 203]. 
Under hyperglycemic conditions, the synthesis of DAG is increased due to the over production of 
dihydroxyacetone phosphate (DHAP), an intermediate product of glycolysis [204]. Thus, it is not 
surprising that the activation of PKC was observed in high glucose-treated VSMCs and ECs [205, 
206]. The downstream events of PKC activation include NADPH oxidase activation, NF-κB 
activation, TGF-β1, fibronectin and collagen expression, and eNOS inhibition [206-209]. The 
consequence of PKC activation includes basement membrane thickening, vasoconstriction and 
chronic inflammation in the vasculature [210].   
 
It is known that MG induces PKC activation via AGE formation. Inhibition of AGE decreased 
PKC activation in cultured VSMCs and in the kidney of STZ-diabetic rats [211]. In addition, Hadas 
et al. reported that MG-induced accelerated thrombus formation and decreased thrombus stability 
is PKC dependent [212]. At the molecular level, MG activates the PKC pathway by increasing 
intracellular Ca2+ levels [213]. However, how MG increases intracellular Ca2+ level is still a 
mystery.  
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1.5.6.3 AGE-RAGE pathway 
The receptor-dependent effects of AGE are mediated via the binding with RAGE. The AGE-
RAGE interactions trigger the activation of a series of downstream pathways such as PKC, MAPK 
and NF-κB [214, 215]. The promoter region of RAGE contains the binding sequence of NF-κB, 
thus one of the consequences of NF-κB activation is RAGE up-regulation [216, 217]. Soluble 
RAGE (also known as sRAGE) is an isoform of the RAGE protein without the transmembrane 
and the signalling domain. It binds to AGE, but does not activate downstream signalling pathways 
as a full-length receptor [218]. It was shown that administration of sRAGE inhibited vascular 
hyperpermeability in the intestine, skin, and kidney of diabetic rats, and also suppressed 
hyperglycemia-induced atherosclerosis in the diabetic mouse model [219]. Besides, the interaction 
between RAGE and its ligands is involved in pro-inflammatory gene activation. In ECs, AGE-
induced VCAM-1 expression and Molt-4 cells (a human T lymphoblast cell line) adhesion were 
inhibited by sRAGE administration, indicating the role of AGE-RAGE pathway in vascular 
inflammation [220].  
 
It is well established that MG treatment induces the formation of AGE and up-regulates the 
expression of RAGE, but the mechanism of RAGE up-regulation is still unknown. Since the 
activation of NF-κB also up-regulates RAGE expression [221], it is reasonable to infer that the 
expression of RAGE and activation of NF-κB may establish a vicious circle and amplify the 
inflammation signal in the cells. 
 
1.5.6.4 GSK3 pathway  
It was reported that many chronic inflammation-related diseases such as Alzheimer’s disease, 
diabetes, and cancer are associated with GSK3 activity [222]. In diabetes, GSK3 regulates glucose 
homeostasis via insulin-activated PI3K/Akt/GSK3 pathway (reviewed in 1.5.3). In addition, GSK3 
also plays a proinflammatory role through the activation of NF-kB [223], and thus, lies at the 
mechanistic interface of both diabetes and inflammation. It was shown that type 2 diabetes patient 
have approximately 2 times higher GSK3 activity than those without diabetes in their biopsy 
skeletal muscle samples [224]. Accordingly, the inhibition of GSK3 showed promising therapeutic 
effects. GSK3 inhibitors dose-dependently lowered the plasma glucose levels in diabetic animal 
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models [225-229]. For example, a GSK3 peptide inhibitor is shown to be effective in improving 
glucose tolerance in insulin-resistant obese C57BL/6 mice [230], suggesting the suppression of 
GSK3 improves glucose regulation. Consistently, GSK3 overexpression is shown to be related to 
glucose intolerance [231]. Based on the findings above, the inhibition of GSK3 has become a 
promising therapeutic target in diabetes. 
 
Despite the potential role of GSK3 in the development of diabetes, the effects of MG on GSK3 
activity are barely understood. MG-induced activation of GSK3 was previously reported in 
pancreatic β cells [232]. Similarly, MG was shown to foster Tau protein hyperphosphorylation by 
activating GSK3 in neuroblastoma 2a cells [233]. However, in VSMC, MG was shown to activate 
Akt, the upstream negative regulator of GSK3, thus inhibiting the activity of GSK3 by increasing 
the inhibitory phosphorylation on serine residue [186]. In ECs, MG was shown to have no effect 
on Akt, while the downstream GSK3 activity was not known [70]. These results suggest that the 
effect of MG on GSK3 could be cell-specific. Given the proinflammatory effect of GSK3, it is 
worthy to study the role of GSK3 in both ECs and leukocytes in the context of MG-induced 
diabetic vascular inflammation.  
 
1.5.6.5 SGK1 pathway 
Being another signalling molecule involved in both diabetes and inflammation, SGK1 was 
reported to have dual effect in the pathophysiology of diabetes. It assists the development of 
obesity, which increases the risk for the development of type 2 diabetes. On the other hand, the 
expression of SGK1 itself is also upregulated by hyperglycemia, and shown to be involved in the 
progression of hypertension, fibrosis and excessive coagulation in diabetes patients [234]. SGK1 
promotes the progression of obesity at least partly by accelerating the intestinal uptake of glucose 
through Na+-coupled glucose transporter 1 (SGLT1) upregulation [235]. Given the upregulation 
of SGK1 by hyperglycemia, the increased plasma glucose levels may, at least in theory, cause 
intestinal SGK1 overexpression, which further enhances SGK1-dependent SGLT1 expression, 
thus establishes a vicious cycle that maintains obesity [234]. Additionally, SGK1 was shown to 
affect helper T-cell function [236], macrophage polarization [237] and regulation of neutrophil 
apoptosis [238] alluding to its role in immunity. Beyond the regulation of EC survival, migration 
and vascular remodelling [239, 240], the functions of endothelial-expressed SGK1 are not 
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completely understood. Noticeably, SGK1 was shown to foster the activation of NF-κB [241] and 
cyclic AMP response element-binding protein (CREB) [242], two transcription factors that are 
important in inflammatory responses. However, the role of MG on SGK1 activity has never been 
shown before. Similar to GSK3, the proinflammatory and pro-diabetic effects of SGK1 suggest 
that it can be involved in MG-induced diabetic vascular inflammation, although more evidence is 
needed.  
 
1.5.6.6 NF-κB pathway 
NF-κB, a heterodimeric complex consisting of p50 and p65, exists in the cytoplasm in an inactive 
form when binding with the inhibitory protein κB (IκB). The activation of NF-κB starts with the 
activation of IκB kinase (IKK). Activated IKK phosphorylates IκB, leading to the ubiquitination 
and degradation of IκB. The exposed p65 and p50 heterodimeric complex is translocated into the 
nucleus where it binds to specific sequences of DNA and initiates the downstream gene 
transcription. The activation of NF-κB has been found to be important in many pathological 
processes such as the development of inflammation, cancer, neurodegeneration disease and 
diabetes. A large number of genes that are involved in the immune response, inflammation, 
apoptosis, cell proliferation and differentiation are proven to be regulated by NF-κB pathway [243-
245].  
 
In diabetic animal model, the activation of NF-κB was observed in different vascular tissues 
associated with increased MG levels. In VSMCs and ECs, high glucose-induced NF-κB activation 
results in VSMCs proliferation and EC dysfunction via the expression of growth factors (such as 
VEGF) and proinflammatory cytokines (such as TNF-α and IL-1β) [246, 247]. Studies using 
exogenous MG showed that MG directly activates NF-κB in cultured VSMCs and retinal capillary 
pericytes [126, 248]. These findings indicate that MG formation may be the reason for high 
glucose-induced NF-κB activation. It is believed that MG induces NF-κB activation mainly 
through ROS or AGE formation [126, 221]. Blockade of ROS or AGE partially inhibits MG-
induced NF-κB activation and its downstream gene expression [75, 249].  
 
It is well known that NF-κB plays a central role in the development of inflammation by 
upregulating the expression of pro-inflammatory cytokines, adhesion molecules such as P-selectin, 
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E-selectin, ICAM-1 and VCAM-1, as well as other pro-inflammatory molecules such as COX2 
and iNOS [250]. These changes are considered to be involved in the progression of vascular 
inflammation in diabetes. Wang et al. reported that the neutrophils from T2DM patients presented 
a greater tendency for apoptosis, and MG-induced cytokine release may be responsible for this 
phenomenon [112]. Our own study revealed that MG induces endothelial adhesion molecule 
expression via the activation of NF-κB, and this effect promotes leukocyte recruitment in 
microvasculature [75]. Therefore, MG-induced NF-κB activation may play an important role in 
the progression of vascular inflammation in diabetes. 
 
1.5.7 MG and leukocyte recruitment  
Elevated MG levels and increased leukocyte recruitment are both involved in the progression of 
diabetic vascular complications [28, 109]. Accumulating data from clinical and experimental 
studies suggest that increased formation of MG is linked to the development of diabetic vascular 
complications as well as the dysfunctions of various cells including ECs, vascular smooth muscle 
cells and neutrophils [31, 251, 252]. However, the role of MG in inducing leukocyte recruitment 
is a whole new research area. Increased recruitment but impaired functions of leukocytes during 
inflammation were observed in mouse models of type 1 and type 2 diabetes [253], but whether it 
is related to MG formation is not clear. Our own observation showed that exogenous MG is able 
to induce leukocyte recruitment in mouse cremasteric microvasculature, indicating that MG-
induced leukocyte recruitment may be one of the mechanisms underlying hyperglycemia-induced 
vascular inflammation in diabetes [75]. Using intravital microscopy, immunohistochemistry and 
biochemical analysis, we are able to determine the types of leukocytes that are recruited by 
exogenous MG, the molecules that are upregulated in leukocytes and ECs, and the signalling 
pathways that are activated in leukocytes and ECs. Revealing the mechanisms of MG-induced 
inflammation may unveil the mystery of vascular complications and immune dysfunctions in 
diabetes and may provide a new clue for possible therapeutic strategies for diabetes. 
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 CHAPTER 2 HYPOTHESIS AND 
OBJECTIVES 
 
HYPOTHESIS AND OBJECTIVES 
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2.1 Rationale and hypothesis 
In the past decades, increased production of MG has been observed in both diabetes patients and 
diabetic animal models [112, 131]. In blood vessels, the abnormal elevation of MG increases 
oxidative stress, promotes AGE formation and activates cellular signalling pathways [31, 124, 254] 
leading to endothelial dysfunction and vascular inflammation [255]. Being the first responders of 
inflammation, leukocytes are recruited at the site of inflammation. However, under pathological 
conditions, hyperglycemia-induced interactions between leukocytes and ECs are believed to bring 
more damage than cure to the microvasculature [109, 112, 113]. Despite the critical role of 
leukocyte recruitment in the development of diabetic vascular inflammation, the mechanism of 
hyperglycemia-induced leukocyte recruitment is poorly understood. It is not clear whether and 
how MG is involved in this process. However, given the reported role of MG in inducing 
endothelial dysfunction [70], we speculate that the increase of MG levels is likely to play a critical 
role in inducing leukocyte recruitment in the microvasculature. The study of MG-induced 
leukocyte recruitment will not only help us to understand the pathogenesis of diabetic vascular 
inflammation, but may also reveal the potential therapeutic target for the treatment of disease. 
 
Hypotheses: MG-regulated GSK3/SGK1 signalling and eNOS uncoupling are responsible for the 
upregulation of endothelial adhesion molecules which promote leukocyte-EC interaction and 
leukocyte recruitment in the microvasculature. 
 
2.2 Objectives and experimental approaches 
To investigate whether exogenous MG administration induces leukocyte recruitment in 
cremasteric microvasculature 
Although both elevated MG levels and increased leukocyte recruitment are shown to be involved 
in the development of diabetic vascular inflammation, whether MG induces leukocyte recruitment 
has never been studied. Our aim is to determine the effect of MG in inducing leukocyte recruitment, 
and establish an acute MG treatment model for further mechanistic studies. Using intravital 
microscopy, the leukocyte rolling velocity, rolling flux, adhesion, and emigration after MG 
treatment will be determined. Based on these results, an optimal MG dose will be established. 
Additionally, immunohistochemistry will be used to identify the subtypes of recruited leukocytes 
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in the cremasteric microvasculature, the result of which will demonstrate the nature of MG-
induced vascular inflammation. 
 
To investigate the role of endothelial adhesion molecules in MG-induced leukocyte recruitment 
Leukocyte recruitment is a well-defined cascade of cellular events, and many of the steps require 
the presence and functions of endothelial adhesion molecules. Additionally, the overexpression of 
adhesion molecules is important in the early stage of diabetic vascular complications [256]. The 
aim here is to demonstrate the role of endothelial adhesion molecules in MG-induced leukocyte 
recruitment. Using intravital microscopy combined with functional blocking antibodies, we are 
able to functionally block P-selectin, E-selectin and ICAM-1, respectively, and observe the 
changes in recruitment parameters. This study will demonstrate the importance of endothelial 
adhesion molecules in MG-induced leukocyte recruitment, and reveal the role of P-selectin, E-
selectin and ICAM-1 in this process. 
 
To investigate the signalling pathways involved in MG-induced upregulation of endothelial 
adhesion molecules 
The expression of adhesion molecules is regulated by the activity of transcriptional factors [250]. 
However, the signalling mechanisms involved in MG-induced endothelial adhesion molecule 
upregulation is not clear. Using enzyme-linked immunosorbent assay (ELISA), Western blotting 
combined with pharmacological inhibition and gene silencing, we will determine the role of 
transcriptional factors NF-κB and CREB in MG-induced adhesion molecule upregulation in in 
vitro and in vivo models. Additionally, GSK3 and SGK1, the upstream signalling molecules of 
NF-κB, are reportedly positioning at the mechanistic interface of both diabetes and inflammation 
[223, 234, 241]. Using cultured EC line cells, we will investigate whether GSK3 and SGK1 are 
activated upon MG administration. The specific inhibitors of these signalling pathways will be 
used to reveal the role of GSK3 and SGK1 signalling in MG-induced leukocyte recruitment. The 
in vitro kinetics study of MG-induced GSK3 and SGK1 activation in ECs and the in vivo study of 
MG-induced leukocyte recruitment upon the administration of GSK3 or SGK1 inhibitors will 
reveal the network of these signalling pathways and their importance in MG-induced leukocyte 
recruitment. 
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To investigate the role of eNOS uncoupling in MG-induced leukocyte recruitment 
A growing body of evidence suggests that MG decreases NO availability in ECs, and this effect 
plays an important role in endothelial dysfunction and diabetic vascular inflammation [70, 115]. 
The mechanistic studies showed that the reduced NO availability is possibly due to MG-induced 
inhibition of eNOS and the formation of peroxynitrite [31, 70]. Recently, the observation of eNOS 
uncoupling, which shifts the functions of eNOS from producing NO to superoxide in diabetic and 
aging animal models, provides a novel insight into the mechanism of reduced NO availability in 
ECs [257-259]. Therefore, the aim of this part of my study is to determine whether MG is able to 
induce eNOS uncoupling in ECs and to reveal the role of eNOS uncoupling in MG-induced 
leukocyte recruitment. Using non-reducing SDS-PAGE and Western blotting, I will determine 
whether MG induces eNOS uncoupling in cultured EC line cells. The levels of tetrahydrobiopterin 
(BH4), 3-nitrotyrosine (3NT) and guanosine triphosphate cyclohydrolase I (GTPCH1) will also be 
determined to reveal the mechanisms of MG-induced eNOS uncoupling. Intravital microscopy 
together with specific inhibitors will be used to study the role of eNOS uncoupling in MG-induced 
leukocyte recruitment. 
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 CHAPTER 3 THE ROLE OF ENDOTHELIAL 
CELL ADHESION MOLECULES P-SELECTIN, E-
SELECTIN AND ICAM-1 IN LEUKOCYTE 
RECRUITMENT INDUCED BY EXOGENOUS 
METHYLGLYOXAL 
THE ROLE OF ENDOTHELIAL CELL ADHESION MOLECULES P-
SELECTIN, E-SELECTIN AND ICAM-1 IN LEUKOCYTE 
RECRUITMENT INDUCED BY EXOGENOUS METHYLGLYOXAL 
 
As the first approach of this project, we demonstrated that exogenous MG-elicited leukocyte 
recruitment in mouse cremasteric microvasculature is largely dependent on the expression of 
adhesion molecules on endothelium. The study shown in this chapter aimed at the role of MG-
induced adhesion molecules expression as the research interest, and our results also provides the 
foundation for pursuing the mechanism underlying MG-induced adhesion molecules in the 
following chapter. 
 
This chapter has been published as a research paper by Yang Su, Xi Lei, Lingyun Wu, Lixin Liu 
in Immunology 2012 Sep; 137(1):65-79. Contents of this chapter have been adapted/reproduced 
from the published article with permission from the journal Immunology. In this paper Y.S. 
conducted all the experiments, acquired and analyzed all the data, and also participated in the 
design of the study and manuscript writing. 
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3.1 Abstract 
Methylglyoxal (MG) is a reactive dicarbonyl metabolite formed during glucose, protein and fatty 
acid metabolism. In hyperglycemic conditionss, increased MG level has been linked to the 
development of diabetes and its vascular complications at the macro- and micro-vascular levels 
where inflammation plays a role. To study the mechanism of MG-induced inflammation in vivo, 
we applied MG locally to healthy mice and used intravital microscopy to investigate the role of 
EC adhesion molecules in MG-induced leukocyte recruitment in cremasteric microvasculature. 
Administration of MG (25 and 50 mg/kg) to the tissue dose-dependently induced leukocyte 
recruitment at 4.0―5.5 h, with 84―92% recruited cells being neutrophils. Such MG treatment 
upregulated the expression of EC adhesion molecules P-selectin, E-selectin, ICAM-1, but not 
VCAM-1. The activation of NF-κB signalling pathway contributed to MG-induced upregulation 
of these adhesion molecules and leukocyte recruitment. The role of the upregulated EC adhesion 
molecules in MG-induced leukocyte recruitment was determined by applying specific functional 
blocking antibodies to MG-treated animals and observing changes in leukocyte recruitment 
parameters. Our data demonstrate that the upregulation of P-selectin, E-selectin and ICAM-1 
contributes to the increased leukocyte rolling flux, reduced leukocyte rolling velocity, and 
increased leukocyte adhesion, respectively. Our results reveal the role of EC adhesion molecules 
in MG-induced leukocyte recruitment in microvasculature, an inflammatory condition related to 
diabetic vascular complications. 
 
3.2 Introduction 
Vascular dysfunction is a main feature of diabetic complications and involves both micro- and 
macro-angiopathy [13]. The progression of diabetic vascular complications results in 
cardiovascular disease, chronic renal failure, retinal damage, neuropathy and poor wound healing. 
The pathological changes in the macro- and micro-vasculature in diabetes are linked to 
inflammation [67, 260-262]. In blood vessels and tissues, an abnormal elevation of the highly 
reactive glycolytic byproduct methylglyoxal (MG) increases oxidative stress and the generation of 
advanced glycation end-products (AGE) [31, 124, 254], which lead to vascular inflammation [255]. 
However, the mechanism of vascular inflammation induced by MG itself in diabetes and diabetic 
vascular complications is unclear.  
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MG is a reactive carbonyl metabolite formed during glucose, protein and fatty acid metabolism 
[124]. In physiological conditions, MG is endogenously produced by various metabolic pathways 
[125, 263]. It is one of the most powerful glycation agents of proteins and other important cellular 
components such as DNA and key enzymes. Increased MG levels have been reported in diabetes 
patients and animals [112, 264]. Besides its strong glycation capability, increased MG level is 
involved in the inflammatory response in diabetes by upregulating the expression of inflammatory 
mediators [251, 265-267]. It is reported that increased plasma MG level is related to the expression 
of cytokines in diabetic nephropathy patients and type 2 diabetes mellitus patients [112, 251]. 
Yamawaki et al. showed that MG is a very strong inducer of inflammation in human ECs [197]. It 
has also been shown that MG activates various signalling pathways such as nuclear factor-κ B 
(NF-κB), c-Jun N-terminal kinase (JNK) and p38 mitogen-activated protein kinase (MAP kinase) 
pathways in ECs and leukocytes [197, 268, 269]. The activation of these pathways further triggers 
downstream inflammatory cascade events [197, 270, 271] such as the production of cytokines and 
chemokines and upregulation of cell adhesion molecules which mediate leukocyte recruitment. 
Thus elevated MG may play a role in inducing inflammation in diabetes patients.  
 
Leukocyte recruitment from the blood stream into the extravascular space is essential for 
developing an appropriate inflammatory response to injury or infection. In many tissues, this 
process follows a well-defined cascade of events, beginning with the capture of free-flowing blood 
leukocytes to the vessel wall, and followed by rolling and adhesion of leukocytes to the inflamed 
endothelium and, then by leukocyte transendothelial migration. Studies have shown that various 
cytokines, chemokines and adhesion molecules are essential for this process [95, 272]. In the initial 
phase of the adhesion cascade, leukocyte rolling is mediated by members of the selectin family 
(L-selectin on leukocytes, and P-selectin and E-selectin on activated ECs), and adhesion by 
intercellular adhesion molecule-1 (ICAM-1), which binds to β2 integrins such as LFA-1 and Mac-
1 on the leukocyte membrane. This latter interaction results in the arrest and firm adhesion of the 
leukocytes to the endothelium, and is required for the subsequent leukocyte transendothelial 
migration. Although the process of leukocyte-EC interaction has been extensively investigated, 
the mechanism of MG-induced inflammatory response in macro- and micro-vasculature in diabetic 
vascular complications is not clear. The questions of whether and which adhesion molecules are 
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upregulated and which particular step in the recruitment process is affected by their upregulation 
still remain unanswered.  
 
Previous studies demonstrated that the expression of ICAM-1, E-selectin and VCAM-1 in the 
blood vessels is increased in spontaneously hypertensive rats [273, 274]. The serum concentrations 
of VCAM-1 and ICAM-1 are increased in patients with systemic vascular inflammation, type 2 
diabetes and cardiovascular diseases [275-278]. Since these diseases are related to hyperglycemia, 
inflammation and increased MG formation, it is reasonable to infer that there is a potential 
relationship between MG production, EC adhesion molecule expression, and inflammation. In this 
study, we used intravital microscopy to investigate the effects of MG on leukocyte recruitment and 
the role of EC adhesion molecules P-selectin, E-selectin and ICAM-1 in MG-induced leukocyte 
recruitment. We evaluated the changes in recruitment parameters (leukocyte rolling, adhesion and 
emigration) in the microvasculature of the cremaster muscle after intrascrotal injection of different 
doses of MG at different time points. We also explored the involvement of NF-κB signalling 
pathway in this process. Based on the time-course data, we established an MG-induced 
inflammation model and investigated the mechanism of MG-induced leukocyte recruitment. The 
expression of P-selectin, E-selectin, ICAM-1 and VCAM-1 after MG treatment was determined 
by immunohistochemistry. The role of each upregulated adhesion molecule was determined by 
using functional blocking antibodies. The role of NF-κB involved in MG-induced leukocyte 
recruitment was investigated by using specific inhibitor. 
 
3.3 Materials and methods 
Animals 
Male C57BL/6 mice between 8 and 12 weeks old were obtained from Charles River Canada (Saint-
Constant, QC, Canada). All animal protocols were approved by the University of Saskatchewan 
Committee on Animal Care and Supply, and met the standards of the Canadian Council on Animal 
Care. 
 
Cell culture 
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EA.hy926 cell, a hybrid human umbilical vein EC line, was obtained from American Type Culture 
Collection (Rockville, MD, USA). Cells were cultured in Dulbecco’s modified Eagle’s medium 
(Cellgro, VA, USA) with 10% fetal bovine serum (Hyclone, UT, USA) and 100 U/mL penicillin-
streptomycin (Amresco, OH, USA) with 5% CO2 and maximal humidity at 37 ºC. Cells between 
passage 3 and 6 were used for the experiments.  
 
MG administration  
MG (Sigma-Aldrich, Oakville, ON, Canada) was dissolved in saline. To give MG doses of 0, 1, 5, 
25, 50 mg/kg, 200 μL of the MG solution were injected into the right side of the scrotum using a 
30G needle beneath the scrotum skin without puncturing any underlying tissue (intrascrotal 
injection). At various time points after MG injection, the mice were prepared for intravital 
microscopy (described below). Intrascrotal injection of 500 ng recombinant murine TNF-α (R & 
D systems, MN, USA) in 200 μL saline was used as positive control for immunohistochemistry 
studies. 
 
MG assay 
MG levels in plasma and cremaster muscle tissue were measured by a specific and sensitive HPLC 
method as described previously [252, 279]. Briefly, MG was derivatized with o-phenylenediamine 
(o-PD) to specifically form 2-methylquinoxaline. Samples were incubated in the dark for 24 h with 
PCA solution (1 M HClO4, 4 mM Na2S2O5, 0.1 mM EDTA) and 100 mM o-PD at room 
temperature. 2-Methylquinoxaline and quinoxaline internal standard (5-methylquinoxaline) were 
quantified on a Hitachi D-7000 HPLC system (Hitachi, Ltd., Mississauga, ON, Canada) via Nova-
Pak® C18 column (3.9×150 mm, and 4 μm particle diameter, Waters, MA, USA). The protein 
concentrations in the samples were determined by BCA assay kit (Sigma-Aldrich).  
 
Intravital microscopy  
Mice were anesthetized by intraperitoneal injection of a mixture of 10 mg/kg xylazine (Bayer Inc., 
Toronto, ON, Canada) and 200 mg/kg ketamine hydrochloride (Bioniche Inc., Belleville, ON, 
Canada). The right jugular vein was cannulated for the administration of additional anesthetics and 
the antibodies. An incision was made in the scrotal skin to expose the left cremaster muscle, which 
was then carefully separated from the associated fascia. A lengthwise incision was made on the 
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ventral surface of the cremaster muscle. The testicle and epididymis were separated from the 
underlying muscle and reintroduced into the abdominal cavity. The muscle was then spread out 
over an optically clear viewing pedestal, secured along the edges with 5―0 suture, and superfused 
with 37°C bicarbonate buffered saline (pH 7.4). The cremaster microcirculation was observed on 
a TV monitor through an intravital microscope (BX61WI, Olympus, Tokyo, Japan) using 10× 
eyepieces and a 20× objective lens. Single unbranched venules (25―35 µm in diameter) were 
selected for study and images of the microcirculation were recorded using a video camera (model 
DXC-990, SONY, Tokyo, Japan) and video recorder (model LRH-890, LG, Seoul, South Korea). 
To minimize variability, the same section of cremasteric venule was observed throughout the 
experiment. The number of rolling, adherent, and emigrated leukocytes was determined offline 
during video playback analysis. Rolling leukocytes were defined as cells moving at a velocity less 
than that of erythrocytes within a given vessel. The flux of rolling cells was measured as the 
number of rolling cells passing a given point in the venule per minute. The rolling velocity was 
determined as 100-µm length of distance on the venule divided by the average time that the first 
20 rolling cells covered this distance at the recording time point. A leukocyte was considered to 
be adherent if it remained stationary for ≥30 s, and total leukocyte adhesion was quantified as the 
number of adherent cells within a 100-µm length of venule in 5 min. Leukocyte emigration was 
defined as the number of cells in the extravascular space within 443 × 286 μm2 area (2 fields of 
view on TV monitor) on both sides of the venule. Only cells adjacent to and clearly outside the 
vessel under study were counted as emigrated [280]. 
 
Histological examination 
Haematoxylin and eosin (H & E) staining 
H & E staining of paraffin sections was used to determine the subtypes of emigrated leukocytes. 
After intravital microscopy, the cremaster muscle was collected and fixed for 16 h in 4% 
paraformaldehyde (Sigma-Aldrich) in PBS solution (pH 7.4). After fixation, the tissue was 
processed by an automatic vacuum tissue processor (model RVG/1, Belair, NJ, USA) for 
dehydration, clearing and infiltration with embedding medium. The tissue was then embedded into 
paraffin blocks and sliced at 5 μm by a microtome. H & E staining was carried out as previously 
described [281]. After H & E staining, cremasteric venules (25–35 µm diameter) were selected 
under a microscope, the emigrated cells in the same area (443 × 286 μm2) as intravital microscopy 
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experiment were observed and counted. The subtypes of leukocytes recruited in the extravascular 
space were determined by their morphology under the microscope.  
 
Immunohistochemistry 
Immunohistochemistry of frozen sections of cremaster muscle was used to determine the 
expression of adhesion molecules. After intravital microscopy, the cremaster muscle was collected 
and fixed for 16 h by 4% buffered paraformaldehyde solution. After fixation, the tissue was 
dehydrated by hypertonic sucrose solution (10% 4 h, 15% 4 h, and 30% 16 h). Then the tissue was 
embedded in OCT compound and sectioned by a cryostat microtone (model HM 500, Microm, 
Walldorf, Germany) at 7 μm. The blocks were kept at -70ºC until use.  
Tissue slices were mounted on microscope slides and washed in TBST (50 mM Tris-HCl, 150 mM 
NaCl, 0.1% Triton X-100, pH 7.4) twice (10 min each) for permeabilization, and then in TBS (50 
mM Tris-HCl, 150 mM NaCl, pH 7.4) 3 times. The sections were immersed in 0.3% (v/v) H2O2 
in TBS for 15 min to remove the endogenous peroxidase activity. After washing twice with TBS, 
blocking solution [10% goat serum (Abcam, MA, USA) plus 5%BSA in TBS] was added for 2 h. 
After blocking, sections were incubated for 16 h in a humidity chamber at 4ºC with diluted primary 
antibodies: anti-E-selectin (UZ6, Abcam) at 1:100, anti-P-selectin (polyclonal, LifeSpan 
BioSciences, WA, USA) at 1:50, anti-ICAM-1 (YN1/1.7.4, Abcam) at 1:100 or anti-VCAM-1 
(MVCAM.A (429), Abcam) at 1:100. After washing with TBS 3 times (10 min each), the diluted 
secondary antibodies HRP-conjugated goat anti-rabbit (Abcam) at 1:200 and HRP-conjugated goat 
anti-rat (Abcam) at 1:200 were applied for 1 h in a humidity chamber at room temperature. Slides 
were washed with TBS 3 times (10 min each), developed with diaminobenzidine chromogen for 3 
min, and rinsed in distilled water for 5 min. Coverslips were mounted with permanent mounting 
medium.  
 
Western blotting  
After treating with PBS (control), MG or TNF-α, EA.hy926 cells were harvested and lysed on ice 
for 30 min by RIPA buffer (50 mM Tris-HCl pH 8.0, 150 mM NaCl, 1% NP-40, 0.5% sodium 
deoxycholate, 0.1% SDS and protease inhibitors cocktail). The lysate was centrifuged at 10,000× 
g for 10 min, and the supernatant was collected, mixed with 4× sample loading buffer (200 mM 
Tris-HCl pH 6.8, 50% glycerol, 2% SDS, 20% β-mercaptoethanol, 0.04% bromophenol bule), 
47 
 
boiled for 5 min and centrifuged at 10,000× g for 5 min before loading. The same amount of 
proteins in cell lysates were separated on 7.5% SDS-PAGE, electrotransferred to a nitrocellulose 
membrane (Bio-Rad, CA, USA), blocked with 5% nonfat milk in TBS-Tween buffer for 1.5 h at 
room temperature, and incubated overnight at 4°C with the primary antibodies against P-selectin 
(1:1000, Lifespan BioSciences), E-selectin (1:1000, Abcam), ICAM-1 (1:1000, Abcam), and β-
actin (1:2000, Santa Cruz, CA, USA), and then incubated with horseradish peroxidase-conjugated 
secondary antibody (Abcam) for 1 h at room temperature. After extensive washing, the bands were 
visualized with enhanced chemiluminescence reagents (GE Healthcare Life Sciences, NJ, USA) 
and exposed to X-ray film (Kodak scientific imaging film, ON, Canada). 
 
Functional blocking study 
Mice were injected with MG and prepared for intravital microscopy as above. The functional 
blocking antibody was injected i.v. 5 min after the start of intravital microscopy. The antibodies 
were: anti-E-selectin antibody (9A9, 100 μg/mouse; a gift from Dr. Paul Kubes, University of 
Calgary, AB, Canada), anti-P-selectin antibody (RB40.34, 25 μg/mouse; BD Pharmingen, CA, 
USA), anti-ICAM-1 antibody (YN1/1.7.4, 100 μg/mouse; eBioscience, CA, USA), rat anti-mouse 
negative control IgG1 (for E-selectin and P-selectin; BD Pharmingen) and rat anti-mouse negative 
control IgG2b (for ICAM-1; eBioscience).  
 
Administration of NF-κB inhibitor 
BAY 11-7082 (Sigma-Aldrich), a specific NF-κB inhibitor, was first dissolved in DMSO as a 30 
mg/mL stock solution, the appropriate amount of which was dissolved by 0.4 mL saline and 
injected to the animal at 20 mg/kg i.p. 30 min before MG administration. The same concentration 
of DMSO was used in the vehicle control group.  
 
Statistical analysis 
Data are expressed as mean ± SEM from at least three independent experiments. Statistical 
differences between mean values in two groups were analyzed by Student's t test, and the 
differences among more than two groups were analyzed by one-way ANOVA and Tukey's post-
hoc test. P < 0.05 was considered as statistically significant. 
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3.4 Results 
MG levels in plasma and cremaster muscle after exogenous MG administration 
We measured MG levels in plasma and cremaster muscle after 4-h MG intrascrotal injection. Table 
3-1 shows that as MG dose increased (0－50 mg/kg), the mean MG levels in plasma dose-
dependently increased from 0.934 μM to 1.660 μM, and the mean MG levels in the local tissue 
increased from 0.999 nmol/mg protein to 3.878 nmol/mg protein. MG local injection significantly 
increased MG levels in plasma and local tissue in a dose-dependent manner. The MG levels in 
plasma and tissue in our model are consistent with those in previously established acute MG-
treated animal models [134, 187].  
 
Dose-response effects of MG on leukocyte recruitment  
To determine the effect of a local MG increase on leukocyte recruitment in microvasculature, we 
examined leukocyte recruitment after intrascrotal injection of various doses of MG (1, 5, 25, and 
50 mg/kg). Figure 3-1 shows leukocyte recruitment in cremaster muscle at 4.0―5.5 h after local 
administration of MG. In response to increasing doses of MG, leukocyte rolling flux did not 
increase until the dose of MG reached 25 mg/kg, and leukocyte rolling velocity was dose-
dependently decreased when MG was 5 mg/kg or higher. The adhesion and emigration of 
leukocytes were increased in an MG dose-dependent manner. As the MG dose increased, the 
leukocyte adhesion and emigration increased from 2 cells to > 10 cells, and from 0 to > 8 cells, 
respectively. Low dose MG treatment at 1 mg/kg or 5 mg/kg showed no significant statistical 
change compared to saline control group. For 25 mg/kg and 50 mg/kg MG treatment groups, 
significant differences were always observed on rolling flux, rolling velocity, adhesion, and 
emigration. These results indicate that MG induces a dose-dependent increase of leukocyte 
recruitment.  
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Table 3-1. The levels of MG in plasma and local tissue 
MG doses 
Amount of MG detected by HPLC 
Plasma (μM) Cremaster muscle (nmol/mg protein) 
0 mg/kg 0.934 ± 0.055 0.999 ± 0.040 
1 mg/kg 1.051 ± 0.061 1.476 ± 0.135* 
5 mg/kg 1.170 ± 0.061* 2.494 ± 0.007* 
25 mg/kg 1.486 ± 0.109* 3.149 ± 0.172* 
50 mg/kg 1.660 ± 0.096* 3.878 ± 0.166* 
 
Table 3-1. The MG levels in plasma and cremaster muscle were analyzed by HPLC after 4-h MG 
local treatment. The values are mean ± SEM (n = 3). *, P < 0.05 compared with saline-treated 
control group (0 mg/kg). 
 
The time course of leukocyte recruitment after MG treatment  
To investigate the kinetics of leukocyte recruitment after MG treatment, we examined leukocyte 
recruitment 4, 8, 16 or 24 h after 25 or 50 mg/kg MG. The results showed that the effects of MG 
treatment on leukocyte recruitment peaked at 8 h (Figure 3-2). For both 25 and 50 mg/kg treatment 
groups, the lowest rolling velocity, and highest adhesion and emigration were all observed in 8 h. 
After 8 h, the rolling velocity increased, and the adhesion and emigration decreased, towards the 
untreated level. These data indicate that MG treatment induces rapid leukocyte recruitment in local 
tissue, and the peak response happens at 8 h.  
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Figure 3-1. Dose-response effect of MG on leukocyte recruitment in cremasteric 
postcapillary venules. MG at different doses (dissolved in 200 μL saline) was injected 
intrascrotally, and the mouse cremaster muscle was prepared for intravital microscopy at 4 h. 
Leukocyte rolling flux (A), rolling velocity (B), number of adherent leukocytes (C) and the number 
of emigrated leukocytes (D) were determined at 4.0―5.5 h after MG treatment. Values are means 
± SEM (n=4). *, P < 0.05 compared with saline-treated control group. 
Figure 3-1 Dose-response effect of MG on leukocyte recruitment in cremasteric postcapillary venules 
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Figure 3-2 Time-course effect of MG on leukocyte recruitment in cremasteric postcapillary venules 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-2. Time-course effect of MG on leukocyte recruitment in cremasteric postcapillary 
venules. MG, 25 mg/kg or 50 mg/kg (dissolved in 200 μL saline), was injected intrascrotally, and 
the mouse cremaster muscle was prepared for intravital microscopy at 4 h, 8 h, 16 h and 24 h, 
respectively. Leukocyte rolling flux (A), rolling velocity (B), number of adherent leukocytes (C) 
and the number of emigrated leukocytes (D) were determined. The 4 h saline group is shown as 
the control. Values are means ± SEM (n=3). *, P < 0.05 compared with the 4 h MG treatment 
group. 
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Neutrophils predominantly recruited by acute MG treatment  
To determine whether MG induces a typical acute inflammation response in cremaster muscle, we 
measured the percentage of neutrophils and other subtypes of leukocytes in emigrated cells 5.5 h 
after the intrascrotal injection of 25 or 50 mg/kg of MG. The majority (~ 84―92%) of the 
emigrated leukocytes were neutrophils, ~ 7―14% were lymphocytes and monocytes, while 
eosinophils and basophils accounted for < 2% (Figure 3-3 and Table 3-2). Our results reveal that 
MG local treatment causes a typical, neutrophil-dominent, acute inflammation response in 
cremaster muscle.  
 
 
 
 
 
 
 
 
 
 
 
Figure 3-3. H & E staining of cremaster muscle sections. After 5.5 h MG or saline treatment, 
the cremaster muscles were collected and processed as described in Materials and Methods. After 
H & E staining, cremasteric venules (25–35 µm diameter) and adjacent tissues were examined 
under the microscope, and the emigrated leukocytes in the same area as intravital microscopy were 
counted (Table 3-2). The subtypes of leukocytes in the extravascular space were determined by 
their morphology (Magnification: 400×).  
 
 
 
 
Figure 3-3 H & E staining of cremaster muscle sections 
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Table 3-2. The subtypes and percentage of recruited leukocytes after MG treatment 
Dose and time 
of MG treatment 
The percentage of each subtype of recruited leukocytes 
Eosinophils Basophils Neutrophils 
Lymphocytes/ 
Monocytes 
25mg/kg, 5.5 h 0.38% 0.49% 91.78% 7.34% 
50mg/kg, 5.5 h 0.91% 0.85% 84.24% 14.00% 
 
Table 3-2. After H & E staining, the emigrated leukocytes in the same area as intravital microscopy 
experiment were examined and counted. The subtypes of cells in the extravenular space were 
determined by their morphology under microscope. For each treatment group, > 500 leukocytes in 
extravascular space were counted.  
 
The acute inflammation model induced by MG 
We found that MG treatment for 8 h or longer increased tissue damages such as scrotum swelling 
and interstitial tissue stickiness which were more apparent at 16 and 24 h, and that 25 mg/kg MG 
local treatment for 4.0―5.5 h induces a typical acute inflammation response with a high 
percentage of recruitment cells being neutrophils (Figure 3-1 and Table 3-2). In the following 
experiments, we chose 25 mg/kg MG local treatment for 4 h to study the role of EC adhesion 
molecules in MG-induced leukocyte recruitment. 
 
Upregulation of endothelial adhesion molecule expression by MG treatment  
By using immunohistochemistry, we determined the expression of EC adhesion molecules P-
selectin, E-selectin, ICAM-1 and VCAM-1 on cremasteric postcapillary venules. After 25 mg/kg 
MG treatment for 4.0―5.5 h, the expression of P-selectin (Figure 3-4), E-selectin (Figure 3-5) and 
ICAM-1 (Figure 3-6) were increased, whereas VCAM-1 expression did not change (Figure 3-7).  
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Figure 3-4 Immunohistochemistry staining of P-selectin in cremasteric endothelium after MG treatment 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-4. Immunohistochemistry staining of P-selectin in cremasteric endothelium after 
MG treatment. MG at 25 or 50 mg/kg (dissolved in 200 μL saline) was injected intrascrotally for 
5.5 h, and the mouse cremaster muscles were collected and processed as described in Materials 
and Methods. The brown staining on the ECs of cremasteric postcapillary venules reveals the 
expression of P-selectin. Saline and 500 ng TNF-α were used as negative and positive control, 
respectively (Magnification: 400×). 
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Figure 3-5 Immunohistochemistry staining of E-selectin on cremasteric endothlium after MG treatment  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-5. Immunohistochemistry staining of E-selectin on cremasteric endothlium after 
MG treatment. MG at 25 or 50 mg/kg (dissolved in 200 μL saline) was injected intrascrotally for 
5.5 h, and the mouse cremaster muscles were collected and processed as described in Materials 
and Methods. The brown staining on the ECs of cremasteric postcapillary venules reveals the 
expression of E-selectin. Saline and 500 ng TNF-α were used as negative and positive control, 
respectively (Magnification: 400×). 
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Figure 3-6 Immunohistochemistry staining of ICAM-1 on cremasteric endothelium after MG treatment  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-6. Immunohistochemistry staining of ICAM-1 on cremasteric endothelium after 
MG treatment. MG at 25 or 50 mg/kg (dissolved in 200 μL saline) was injected intrascrotally for 
5.5 h, and the mouse cremaster muscles were collected and processed as described in Materials 
and Methods. The brown staining on the ECs of cremasteric postcapillary venules reveals the 
expression of ICAM-1. Saline and 500 ng TNF-α were used as negative and positive control, 
respectively (Magnification: 400×). 
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Figure 3-7 Immunohistochemistry staining of VCAM-1 on cremasteric endothelium after MG treatment 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-7. Immunohistochemistry staining of VCAM-1 on cremasteric endothelium after 
MG treatment. MG at 25 or 50 mg/kg (dissolved in 200μL saline) was injected intrascrotally for 
5.5 h, and the mouse cremaster muscles were collected and processed as described in Materials 
and Methods. Saline and 500 ng TNF-α were used as negative and positive control respectively. 
The brown staining on the ECs of cremasteric postcapillary venules reveals the expression of 
VCAM-1 in TNF-α treated group. Both MG treatment groups show no apparent change of VCAM-
1 expression after 5.5 h MG treatment compared to saline control group (Magnification: 400×). 
 
 
The direct activation effect of MG on ECs 
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Figure 3-8 MG-induced expression of P-
selectin, E-selectin and ICAM-1 in cultured 
ECs 
To investigate whether MG is directly activating ECs, we tested the effect of MG on the expression 
of endothelial adhesion molecules using in vitro system. Cultured EA.hy926 ECs were treated with 
100 μM MG, PBS or 20 ng/mL TNF-α for 4 h, and the expression of P-selectin, E-selectin and 
ICAM-1 was determined by Western blot. Figure 3-8 shows that MG treatment increased the 
expression of these adhesion molecules in cultured EA.hy926 ECs demonstrating that the effect of 
MG was directly on the ECs.  
 
 
 
 
 
 
 
 
 
Figure 3-8. MG-induced expression of P-selectin, E-selectin and ICAM-1 in cultured ECs. 
EA.hy926 ECs were cultured to 90% confluence and treated with PBS (negative control), 100 μM 
MG or 20 ng/mL TNF-α (positive control) for 4 h. The expression of P-selectin, E-selectin and 
ICAM-1 in cell lysates were determined by Western blot. 
 
 
The role of P-selectin, E-selectin and ICAM-1 in MG-induced leukocyte recruitment 
To investigate the role of P-selectin, E-selectin and ICAM-1 during MG-induced leukocyte 
recruitment, we administered the functional blocking antibodies against these adhesion molecules 
4 h after MG treatment, and determined leukocyte rolling velocity, rolling flux, adhesion and 
emigration by intravital microscopy over the next 1.5 h.  
 
Suppression of MG-induced increase of leukocyte rolling flux by P-selectin blockade 
Figure 3-9 illustrates that after anti-P-selectin antibody injection, the leukocyte rolling flux 
dropped to 0, indicating that the rolling of leukocytes on the venular wall depends on the functions 
of P-selectin. Since there were no leukocytes rolling on the venular wall after P-selectin blockade, 
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the rolling velocity was unable to be determined, and the further increases of leukocyte adhesion 
and emigration after MG were subsequently prevented (Figures 3-9C and 3-9D). These data 
indicate that MG-induced P-selectin upregulation results in more leukocytes rolling on the 
endothelium which increases the interactions between leukocytes and ECs. 
 
Restoration of MG-induced reduction of leukocyte rolling velocity by E-selectin blockade 
The intravital microscopy data demonstrate that anti-E-selectin antibody treatment significantly 
blocked the MG-induced decrease in rolling velocity, whereas the rolling flux had no significant 
change compared to the animals treated with the same dose of MG only (Figure 3-10). After 
blocking the functions of E-selecin, the rolling velocity increased back to the normal level and the 
adhesion and emigration were significantly decreased. Increasing the leukocyte rolling velocity 
reduces the time for leukocyte-EC interactions and decreases the subsequent increase of adhesion 
and emigration of leukocytes after MG treatment (Figures 3-10C and 3-10D). This result indicates 
that after MG treatment, the expression of E-selectin is important for the decrease in leukocyte 
rolling velocity.  
 
Decreased MG-induced leukocyte adhesion by ICAM-1 blockade 
After anti-ICAM-1 antibody administration, the adhesion cell number induced by MG dropped 
from ~7 to < 3, while the rolling velocity and rolling flux were not significantly changed (Figure 
3-11). As adhesion was significantly decreased by anti-ICAM-1 treatment, the increased leukocyte 
emigration induced by MG was suppressed, and the emigration cell number remained ~4. These 
data indicate that ICAM-1 plays an important role in MG-induced adhesion of leukocytes to ECs, 
and may be crucial for MG-induced leukocyte emigration.  
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Figure 3-9 Effect of P-selectin blocking antibody on leukocyte recruitment in cremasteric postcapillary venules after MG 
treatment 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-9. Effect of P-selectin blocking antibody on leukocyte recruitment in cremasteric 
postcapillary venules after MG treatment. Mice were treated with MG (25 mg/kg) as described 
in the legend of Figure 3-1, and leukocyte recruitment in cremaster muscle was measured at 
4.0―5.5 h using intravital microscopy. After baseline measurement at 4 h, 25 μg anti-P-selectin 
antibody was infused i.v. (arrow). The leukocyte rolling flux (A), rolling velocity (B), number of 
adherent leukocytes (C) and the number of emigrated leukocytes (D) after antibody treatment were 
determined. Values are means ± SEM (n=3). *, P < 0.05 compared with 25 mg/kg MG-treated 
group without antibody. 
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Figure 3-10 Effect of E-selectin blocking antibody on leukocyte recruitment in cremasteric postcapillary venules after MG 
treatment 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-10. Effect of E-selectin blocking antibody on leukocyte recruitment in cremasteric 
postcapillary venules after MG treatment. Mice were treated with MG (25 mg/kg) as described 
in the legend of Figure 3-1, and leukocyte recruitment in cremaster muscle was measured at 
4.0―5.5 h using intravital microscopy. After baseline measurement at 4 h, 100 μg anti-E-selectin 
antibody was infused i.v. (arrow). The leukocyte rolling flux (A), rolling velocity (B), number of 
adherent leukocytes (C) and the number of emigrated leukocytes (D) after antibody treatment were 
determined. Values are means ± SEM (n=3). *, P < 0.05 compared with 25 mg/kg MG-treated 
group without antibody. 
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Figure 3-11 Effect of ICAM-1 blocking antibody on leukocyte recruitment in cremasteric postcapillary venules after MG 
treatment 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-11. Effect of ICAM-1 blocking antibody on leukocyte recruitment in cremasteric 
postcapillary venules after MG treatment. Mice were treated with MG (25 mg/kg) as described 
in the legend of Figure 3-1, and leukocyte recruitment in cremaster muscle was measured at 
4.0―5.5 h using intravital microscopy. After baseline measurement at 4 h, 100 μg anti-ICAM-1 
antibody was infused i.v. (arrow). The leukocyte rolling flux (A), rolling velocity (B), number of 
adherent leukocytes (C) and the number of emigrated leukocytes (D) after antibody treatment were 
determined. Values are means ± SEM (n=3). *, P < 0.05 compared with 25 mg/kg MG-treated 
group without antibody. 
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The contribution of NF-κB signalling pathway to MG-induced adhesion molecule upregulation 
and leukocyte recruitment  
To determine whether NF-κB pathway is involved in MG-induced adhesion molecule upregulation, 
we applied a specific NF-κB inhibitor, BAY 11-7082, 30 min before MG administration to observe 
the changes on adhesion molecule expression and leukocyte recruitment. Figure 3-12 shows that 
BAY 11-7082 pretreatment significantly suppressed the expression of MG-induced endothelial 
adhesion molecules P-selectin, E-selectin and ICAM-1, and attenuated MG-induced leukocyte 
recruitment. The immunostaining of P-selectin, E-selectin and ICAM-1 were much lighter in 25 
mg/kg MG + NF-κB inhibitor-treated group than 25 mg/kg MG-treated group (Figure 3-12A). 
MG-induced leukocyte adhesion and emigration were also significantly reduced by BAY 11-7082 
treatment (Figures 3-12D and 3-12E). Our data indicate that the activation of NF-κB pathway is 
involved in MG-induced endothelial adhesion molecule upregulation and leukocyte recruitment.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-12 Effect of NF-κB inhibition on MG-induced endothelial adhesion molecule expression 
and leukocyte recruitment 
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Figure 3-12. Effect of NF-κB inhibition on MG-induced endothelial adhesion molecule 
expression and leukocyte recruitment. BAY 11-7082 at 20 mg/kg was i.p. injected to the mice 
30 min before 25 mg/kg MG administration. The vehicle control group was injected with the same 
concentration of the solvent for BAY 11-7082. After 4-h MG injection, the mouse cremaster 
muscle was prepared for intravital microscopy. The muscle samples were then collected and 
processed for immunostaining after 1.5 h intravital microscopy. The brown staining on the ECs of 
cremasteric postcapillary venules reveals the expression levels of P-selectin, E-selectin and ICAM-
1 (Magnification: 400×) in the upper, middle and lower panels respectively (A). The inhibitory 
effects of BAY 11-7082 on MG-induced leukocyte rolling flux (B), rolling velocity (C), the 
number of adherent leukocytes (D) and the number of emigrated leukocytes (E) were determined. 
Values in B－E are means ± SEM (n=3). *, P < 0.05 compared with 25 mg/kg MG treatment group 
without BAY 11-7082.  
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3.5 Discussion 
In the present study, using intravital microscopy, immunohistochemistry and functional blocking 
antibodies in vivo, we investigated the role of EC adhesion molecules P-selectin, E-selectin, 
ICAM-1 in leukocyte recruitment induced by exogenous MG. We applied MG locally to healthy 
mice to induce leukocyte recruitment in cremasteric microvasculature. MG-induced leukocyte 
recruitment is neutrophil-dominant, MG dose- and time-dependent; the decrease of leukocyte 
rolling velocity, and the increases of leukocyte rolling flux, adhesion and emigration are MG dose-
dependent. MG treatment upregulates the expression of EC adhesion molecules P-selectin, E-
selectin and ICAM-1, but not VCAM-1. Functional blocking studies confirmed that the expression 
of P-selectin and E-selectin is responsible for the decreased leukocyte rolling velocity and 
increased leukocyte rolling flux, respectively, and ICAM-1 upregulation is important for leukocyte 
adhesion. We show that the activation of NF-κB is involved and contributes to MG-induced 
endothelial adhesion molecule expression and leukocyte recruitment and that the effect of MG is, 
at least in part, directly through its action on ECs. 
 
Accumulating data from clinical and experimental studies suggest that increased formation of MG 
is linked to the development of diabetic vascular complications and the dysfunction of various 
cells including ECs, neutrophils and vascular smooth muscle cells that are associated with vascular 
damage [31, 70, 251]. Plasma MG levels in healthy humans are 1 µmol/L or less but are 2―6 fold 
higher in diabetes patients [112, 131]. However, plasma MG concentrations as high as 400 µmol/L 
have been reported in poorly controlled human diabetes patients [282]. It has been suggested that 
local MG concentration in tissues could be much higher than its plasma levels [136, 197] although 
the exact local concentration of MG in diabetes patients is unclear. It was reported that cultured 
cells may produce larger amounts of MG (as much as 310 µM in cell extracts) [283]. In this study, 
we used MG local treatment to study the acute effect of MG on leucocyte recuitment, and 
determined the optimal dose and treatment time for MG based on intravital microscopy. We 
observed that systemic (i.p.) MG treatment for 4 h induced leukocyte recruitment similarly to the 
recruitment response elicited by local MG treatment but the systemic MG had to be at higher dose 
to have the same magnitude of recruitment response as local MG treatment (data not shown). 
Therefore, we used 25 mg/kg MG local injection for 4 h as the acute inflammation model to study 
the role of EC adhesion molecules in MG-induced leukocyte recruitment. We found that in 25 
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mg/kg MG-treated mice, plasma MG level was lower than 1.60 μM at all time points (5 min to 4 
h) we tested (our unpublished observations) and even in the 50 mg/kg group, the plasma MG level 
(Table 3-1) was still lower than it was reported in diabetes patients [112, 124]. We also found that 
low dose of paraformaldehyde, a biological active chemical with active aldehyde group (similarly 
to MG) in solutions, induced leukocyte recruitment similar to MG but less potent than MG at 4 h, 
whereas the 4-h treatment with biological inactive D-glucose did not elicit leukocyte recruitment 
(data not shown), suggesting that the effect of MG in inducing leukocyte recruitment is possibly 
due to the presence of the biological active aldehyde group in its molecule. This suggests that the 
effect of MG may be indeed very local, that leukocyte recruitment induced by local MG treatment 
may not be the same as the systemic MG effect, and that there is a clear relationship between local 
MG dose and the degree of leukocyte recruitment in the tissue.  
 
In this study, we focused on the role of EC adhesion molecules in MG-induced leukocyte 
recruitment. The upregulated EC adhesion molecules are the biomarkers of endothelial activation 
and dysfunction [284, 285] and the indication of the progression of diabetic complications in type 
1 and type 2 diabetes [286-288]. It has been revealed that the role of adhesion molecules is 
important in the early stage of diabetic vascular complications [256, 289]. Evidence from patients 
also indicates that the increased expression of adhesion molecules in kidneys is directly associated 
with endothelial dysfunctions, renal tubular damage, and the progression of diabetic nephropathy 
[290, 291]. We found the upregulated expression of P-selectin, E-selectin and ICAM-1 but not 
VCAM-1 after acute MG local treatment. Because neutrophils are the first cells emigrated to the 
inflammation site, it is not surprising that they are the dominant leukocytes being recruited in tissue 
after acute MG treatment. We noted that after acute MG treatment, the level of VCAM-1 did not 
change. VCAM-1 is important for the recruitment of leukocytes other than neutrophils, such as 
lymphocytes, monocytes, eosinophils and basophils. In our results, these cells consisted of only a 
small percentage of the recruited leukocytes (Table 3-2). It has been shown that the level of 
VCAM-1 is increased with the progression of diabetic complications in type 1 and type 2 diabetes 
patients [292]. The unchanged VCAM-1 level in our experiment may be due to the short treatment 
time and/or relatively low MG dose. In this line, our experiments indeed found evidence of 
increased percentage of recruited lymphocyte, monocytes, eosinophils, and basophils with the 
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increasing MG dose (Table 3-2). Whether VCAM-1 expression and functions are increased as 
increasing time and dose of MG treatment warrants further investigation. 
 
In this study, the role of each MG-upregulated EC adhesion molecule was determined by 
functional blocking studies. Our data suggest that acute MG treatment increases leukocyte rolling 
flux by upregulating P-selectin expression, reduces leukocyte rolling velocity by upregulating E-
selectin expression, and increases cell adhesion by upregulating ICAM-1 expression. All these 
lead to the increased leukocyte-EC interactions that result in leukocyte emigration. How MG 
increases the expression or functions of these EC adhesion molecules is still unclear, but our data 
reveal that NF-κB signalling pathway appears to be involved. The activation of various 
intracellular signalling pathways including NF-κB is known to upregulate the expression 
inflammatory cytokines and chemokines and endothelial adhesion molecules [246]. Some studies 
have shown clear evidence that MG activates other signalling pathways such as JNK and p38 MAP 
kinases in ECs [197, 293]. Other studies have demonstrated that, in various cell types, MG induces 
the expression and production of cytokines such as TNF-α and IL-8 that are pro-inflammatory and 
able to induce leukocyte recruitment [266, 267, 294, 295]. In addition, research data from clinical 
studies show that MG levels are elevated in type 2 diabetes mellitus patients and diabetic 
nephropathy patients and are related to the increased expression of inflammatory cytokines such 
as TNF-α, IL-8 and IL-6 [112, 251]. Therefore, it is likely that, in our model system, MG 
upregulates the expression of EC adhesion molecules and induces leukocyte recruitment in the 
tissue at least in part through the activation of NF-κB signalling pathway in ECs.  
 
In conclusion, our present study describes the role of EC adhesion molecules P-selectin, E-selectin 
and ICAM-1 in exogenous MG-induced leukocyte recruitment in local tissue. We demonstrate that 
increased MG in local tissue dose-dependently reduces leukocyte rolling velocity, increases 
leukocyte rolling flux and promotes cell adhesion by upregulating the expression of P-selectin, E-
selectin and ICAM-1, respectively, and NF-κB is involved in these functional responses induced 
by MG. MG-induced upregulation of EC adhesion molecules may be important in leukocyte 
infiltration in the early stage of diabetic vascular complications and that revealing the mechanisms 
of MG-induced inflammation may unveil the mystery of vascular complications and immune 
dysfunctions in diabetes and may provide a new clue for possible therapeutic strategies.  
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REGULATION OF METHYLGLYOXAL-ELICITED LEUKOCYTE 
RECRUITMENT BY ENDOTHELIAL SGK1/GSK3 SIGNALLING 
 
 
For the molecular mechanistic study of the phenomena shown in the last chapter, in this chapter, 
we reveal that endothelial SGK1/GSK3 signalling plays an important regulatory role in MG-
elicited adhesion molecule expression on endothelium. Here, we demonstrate SGK1/GSK3 
signalling-regulated adhesion molecules expression in ECs as one of the mechanisms underlying 
MG-elicited leukocyte recruitment. 
 
 
This chapter has been accepted as a research paper by Yang Su, Syed M. Qadri, Francisco S. 
Cayabyab, Lingyun Wu and Lixin Liu in Biochimica et Biophysica Acta (BBA)-Molecular Cell 
Research. Contents of this chapter have been adapted/reproduced from the accepted article with 
permission from the journal BBA-Molecular Cell Research. In this study, Y.S. conducted all the 
experiments, acquired and analyzed all the data, and also participated in the design of the study 
and manuscript writing. 
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4.1 Abstract 
Excessive levels of the glycolysis metabolite methylglyoxal (MG) elicit enhanced expression of 
adhesion molecules which foster leukocyte-endothelial cell interactions. Signaling mechanisms of 
MG-induced leukocyte recruitment, however, remain elusive. To address this, we investigated 
signal transduction of leukocyte- and endothelial-expressed phosphoinositide 3-kinase (PI3K) 
effector kinases glycogen synthase kinase 3 (GSK3) and serum- and glucocorticoid-inducible 
kinase 1 (SGK1) in the regulation of MG-elicited leukocyte recruitment. Using intravital 
microscopy of mouse cremasteric microvasculature, we demonstrate that GSK3 inhibitors lithium 
and SB216763 mitigate MG-elicited leukocyte recruitment and microvascular hyperpermeability. 
In SVEC4-10EE2 endothelial cells, but not in neutrophils, MG transiently activates GSK3 as it 
reduces inhibitory phospho-GSK3α/β (Ser21/9)  which parallels decrease of phospho-Akt at early 
time points (˂ 30 min). At later time points ( 1 h), MG induces GSK3 deactivation which is 
dissipated by siRNA silencing of SGK. MG treatment potentiates endothelial SGK1 mRNA, total 
SGK1, phospho-SGK1 and phospho-NDRG1. The SGK1 inhibitor GSK650394 attenuates MG-
elicited leukocyte recruitment. Pharmacological inhibition or silencing endothelial GSK3 or SGK 
attenuates MG-triggered nuclear factor (NF)-κB activity. Inhibition of SGK1 or GSK3 mitigates 
the expression of endothelial adhesion molecules P- and E-selectins and ICAM-1. Silencing SGK 
blunts MG-triggered redox-sensitive phosphorylation of endothelial transcription factor CREB. 
Moreover, SGK1-dependent CREB activation participates in MG-elicited ICAM-1 upregulation. 
We conclude that temporal activation of endothelial SGK1 and GSK3 is decisive in MG-elicited 
upregulation of transcription factors, adhesion molecule expression, and leukocyte-vascular 
endothelium interactions. This novel regulatory pathway may link excessive MG levels in vivo to 
inflammation, thus, unravelling potential therapeutic targets. 
 
4.2 Introduction 
In conditions such as diabetes, which is associated with excessive levels of the glycolysis 
metabolite methylglyoxal (MG), pathological vascular changes and impaired leukocyte-
endothelial cell interactions contribute to the pathophysiology of inflammatory sequelae [253, 296]. 
Contrary to the widely documented cytotoxic effects of MG, various studies have reported the 
relative safety of its treatment in vivo [297, 298] in addition to its anti-cancer [297, 299-301], anti-
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microbial [302] and anxiolytic effects [303]. Ramifications of excessive levels of MG include 
increased expression of adhesion molecules on leukocytes and endothelial cells which fosters 
redox-sensitive leukocyte recruitment [75, 153, 255, 304]. MG modulates immune functions by 
stimulating macrophages [294], suppressing T-cell functions [265], triggering neutrophil apoptosis 
[255] and inducing cytokine production [267]. Putative signalling mechanisms that regulate 
leukocyte-endothelial interactions associated with excessive MG levels, however, remain elusive.  
 
Phosphoinositide 3-kinases (PI3K) are crucial signal transducers in leukocyte recruitment and 
microvascular leakage during inflammation [305, 306]. The glycogen synthase kinase GSK3 is a 
pleiotropic serine/threonine kinase and critical downstream effector, in addition to Akt, of PI3K 
signalling [307]. Both Akt and serum- and glucocorticoid-inducible kinase 1 (SGK1) 
phosphorylate and inactivate GSK3 [308, 309]. GSK3 regulates glucose homeostasis and is 
inhibited by the stimulation of insulin receptors [307], thus playing a crucial role in energy 
metabolism. Remarkably, GSK3 is critical in inflammatory processes by playing either a positive 
or negative regulatory role [310]. GSK3 was previously shown to participate in leukocyte motility 
[311] and survival [312]. Interestingly, endothelial GSK3 was reported to regulate E-selectin 
expression [313] and vascular permeability [314], thus highlighting the significance of GSK3 
signalling in non-hematopoietic endothelial cells. The GSK3 inhibitors lithium and SB216763 
increase the inhibitory phosphorylation of GSK3 (Ser-21/9) and have been widely used to study 
putative functions of GSK3 [315].  
 
Similar to Akt, the ubiquitously expressed SGK1 is activated by PI3K and phosphoinositide-
dependent kinase-1 (PDK1) and is genomically regulated by a wide array of stimuli [316] 
including hyperglycemia [317]. In addition to its regulatory role in insulin secretion [318], SGK1 
was previously shown to affect helper T-cell function [236], macrophage polarization [237] and 
regulation of neutrophil apoptosis [238] alluding to its role in immunity. Beyond the regulation of 
endothelial cell survival, migration and vascular remodelling [239, 240], the functions of 
endothelial-expressed SGK1 are not well understood. Noticeably, SGK1 was shown to activate 
nuclear factor-κB (NF-κB) [241] and cyclic AMP response element-binding protein (CREB) [242], 
two transcription factors that are important in mediating inflammatory responses. The small-
71 
 
molecular inhibitor GSK650394 formulated for in vivo use is known to potently suppress the 
enzymatic activity of SGK1 [319].  
 
SGK1- and GSK3-dependent signalling, therefore, lies at the mechanistic interface of both 
hyperglycemic pathophysiology and inflammation. In this study, using targeted gene silencing and 
pharmacological inhibition, we elucidate the regulatory role of SGK1 and GSK3 signalling on 
endothelial transcription factors and adhesion molecule expression, and use intravital microscopy 
to unravel their role in MG-triggered leukocyte-endothelial cell interactions in vivo. 
 
4.3 Material and methods 
Mice and intravital microscopy 
Male C57BL/6 mice (Charles River, Saint-Constant, QC, Canada) aged between 8 and 12 wk-old 
were used in this study with the approval of animal protocols from UCACS (# 20070028) at the 
University of Saskatchewan. Mice were anesthetised using an i.p. injection of 10 mg/kg xylazine 
(Bayer, Toronto, ON, Canada) and 200 mg/kg ketamine hydrochloride (Rogar, Montreal, QC, 
Canada). The mouse cremaster muscle preparation was used to study dynamic leukocyte-
endothelial interactions in microvasculature as described previously [75, 153, 306]. Velocity of 
rolling leukocytes (μm/sec), and the number of adherent (cells/100-μm venule), and emigrated 
leukocytes (cells/443×286 μm2 field) were determined in the cremasteric postcapillary venule 
(25−40 μm diameter) using video playback analysis [75, 153, 306]. MG-triggered microvascular 
leakage was determined in postcapillary venules of the cremaster muscle by intravital microscopy 
measuring fluorescence intensity of FITC-labelled BSA (25 mg/kg b.w. i.v.; Sigma) inside and 
outside the vessel as described previously [153]. Where indicated, MG (50 mg/kg b.w. or 100 µM; 
Sigma, Oakville, ON, Canada), SB216763 (10 mg/kg b.w. or 20 µM; Sigma), lithium (LiCl, 20 
mg/kg b.w.; Sigma), BAY11-7082 (20 mg/kg; Sigma) or GSK650394 (50 mg/kg b.w.; Sigma) 
were administered by an intrascrotal injection or superfusion.  
 
Cell culture and gene silencing 
Murine microvascular SVEC4-10EE2 endothelial cell line cells (EE2 ECs; ATCC, Manassas, VA) 
were cultured as described earlier [320]. Where indicated, Tempol (300 µM; Sigma) and other 
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pharmacological modulators were added at specified concentrations. Gene knock-down was 
accomplished by a 48-h transfection of EE2 ECs with siRNA specifically targeting GSK3 (Cell 
Signalling), CREB (Cell Signalling) and SGK (Santa Cruz) and by using siRNA transfection 
medium and reagent (Santa Cruz) as described previously [321]. The control cells were transfected 
with negative control scrambled siRNA (Santa Cruz) having no homology to any known RNA 
sequence.  
 
Neutrophil isolation 
Neutrophils from murine femurs and tibia were isolated using 3-step Percoll (GE Healthcare, 
Uppsala, Sweden) gradient (72%, 64% and 52%) centrifugation at 1060 g for 30 min as described 
[320].  
 
FACS analysis  
Neutrophil Mac-1 expression was determined using fluorescent anti-Mac-1 antibody (Anti-mouse 
CD11b FITC; clone M1/70; eBioscience) or its respective isotype control (Rat IgG2bκ FITC; 
eBioscience) using a previously reported protocol [322].  
 
Immunoblotting 
ECs or cremaster tissue homogenates were lysed using Phosphate Extraction Reagent (Novagen) 
or Nuclear Extraction Kit (Cayman). Proteins were solubilized in Laemmli buffer and resolved by 
8−10% SDS-PAGE, and thereafter transferred to a nitrocellulose membrane and immunoblotted 
as described previously [320]. Primary antibodies (1:1000) were used against the following 
proteins of interest: CREB, GSK3 and phospho-GSK3-Ser-21/9 (Cell Signalling); phospho-CREB 
and phospho-GSK3-Tyr-279/216 (Millipore), Akt and phospho-Akt-Ser-473 (BD Pharmingen); 
P-selectin (LifeSpan Biosciences); E-selectin, ICAM-1, and SGK1 (Abcam); NDRG1 and 
phospho-NDRG1-Thr346 (Cell signalling) and phospo-SGK1-Thr-256 (Santa Cruz). Intensity 
values for the proteins were normalized to β-actin using anti-β-actin antibody (Santa Cruz). 
 
Real-time PCR  
RT-PCR was performed to determine SGK1 mRNA expression as described previously [264]. 
Briefly, RNA was isolated from the cells using RNA isolation kit (Qiagen) and reverse-transcribed 
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using reverse transcription kit (Qiagen). RT-PCR was carried out by SYBR green PCR kit (Qiagen) 
in an iCycler iQ apparatus (Bio-Rad, Hercules, CA) with primers targeting SGK1 (QT02379685; 
Qiagen), ICAM-1 (QT00155078; Qiagen) and β-actin (QT00095242; Qiagen). All PCRs were 
performed in triplicate and ran for 45 cycles at 95°C for 30 sec, 55°C for 30 sec, and 72°C for 40 
sec. The PCR product that increased within 30 cycles are considered as positive results. 
 
Immunohistochemistry 
Determination of adhesion molecule (E- and P-selectins and ICAM-1) expression in whole 
cremaster muscle was performed using the same primary antibodies in immunoblotting and a 
previously described method [75]. 
 
Analysis of NF-κB activity  
After the indicated treatments, whole cremasteric tissue and EE2 ECs were subjected to nuclear 
extraction with Nuclear Extraction Kit (Cayman). Equal amounts of nuclear extracts were loaded 
on a 96-well plate of the NF-κB p65 Transcription Factor Activation Assay Kit (Abcam) and the 
manufacturer’s instructions were followed.  
 
Confocal imaging 
EE2 ECs treated under different conditions (as indicated in the Results) were fixed using 4% 
paraformaldehyde for 30 min, washed twice with PBS, blocked for 1 h with 5% goat serum 
(Abcam) and then incubated overnight at 4°C with antibodies against P-selectin (1:100; RB40.34; 
BD Pharmingen), E-selectin (1:100, 9A9, a gift from Dr. Paul Kubes, University of Calgary, AB, 
Canada) or ICAM-1 (eBioscience). After washing, the slides were incubated for 1 h with 
fluorescence goat anti-rat antibody (Alexa Fluor 488; Invitrogen) and cells were washed, 
permeabilized with 0.1% Triton-X-100 and stained with Hoechst 33342 (Invitrogen). The slides 
were mounted in ProLong® Gold Antifade Reagent (Invitrogen) and observed under a laser 
scanning confocal microscope (Zeiss, ConfoCor2/LSM510).  
 
Statistical analysis 
Data are shown as arithmetic mean ± SEM. Statistical analysis was made using Student t test or 
ANOVA with Tukey’s post-hoc comparison test. n denotes the number of different mice, different 
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batches of cremasteric tissues or ECs studied in each group. Values of p < 0.05 were considered 
statistically significant.  
 
4.4 Results 
Inhibition of GSK3 ameliorates MG-induced upregulation of endothelial adhesion molecules, 
leukocyte recruitment and microvascular leakage 
Firstly, we explored the effect of pharmacological GSK3 inhibitors SB216763 and lithium on MG-
elicited leukocyte recruitment. The representative intravital images of cremasteric 
microvasculature are depicted in Fig. 4-1A. Both inhibitors themselves had no effect on leukocyte 
recruitment (data not shown). Fig. 4-1B shows increased numbers of adherent and emigrated 
leukocytes after MG treatment compared to saline treatment. Pretreatment with SB216763 or 
lithium significantly attenuated MG-induced increases in adherent and emigrated cells. Treatment 
with SB216763 or lithium significantly restored MG-triggered reduction of leukocyte rolling 
velocity (Fig. 4-1B). To determine whether pharmacological inhibition of GSK3 modulates 
microvascular permeability during leukocyte recruitment, we measured fluorescence changes of 
FITC-conjugated albumin inside and outside cremasteric postcapillary venule. Permeability index 
analysis revealed that superfusion of MG on the cremaster muscle increased microvascular 
permeability, an effect that was significantly inhibited by co-superfusion with SB216763 (Fig. 4-
1C). We further examined whether GSK3 inhibition modulated the expression of endothelial 
adhesion molecules P- and E-selectins and ICAM-1. Histological evaluation of whole cremasteric 
tissue revealed enhanced expression of P- and E-selectins and ICAM-1 following treatment with 
MG, an effect that was blunted by treatment with SB216763 (Fig. 4-1D). These findings were 
further corroborated in murine EE2 ECs by silencing GSK3 with siRNA or treatment with 
SB216763. To this end, treatment of EE2 ECs with MG enhanced the expression of P- and E-
selectins and ICAM-1, an effect that was significantly reduced by SB216763 or GSK3 silencing 
but not by the negative control siRNA (Fig. 4-1E). 
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Figure 4-1 GSK3 inhibition ameliorates methylglyoxal-induced leukocyte recruitment, microvascular 
leakage and adhesion molecule upregulation 
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Figure 4-1. GSK3 inhibition ameliorates methylglyoxal-induced leukocyte recruitment, 
microvascular leakage and adhesion molecule upregulation. (A) Representative intravital 
images with adherent (white arrowheads) and emigrated (black arrowheads) leukocytes and (B) 
means ± SEM (n=6) of leukocyte rolling velocity (μm/sec), adherent (cells/100-μm venule) and 
emigrated (cells/443×286 μm2 field) leukocytes in mouse cremasteric postcapillary venules 
determined 4 h after an intrascrotal injection of saline (Control), MG (50 mg/kg) or co-treatment 
of MG with SB216763 (10 mg/kg) or lithium (20 mg/kg), both inhibitors administered 30 min 
prior to MG. (C) Representative fluorescence intravital images and means ± SEM (n=6) of 
permeability index analysis of mouse cremasteric postcapillary venules showing the leakage of 
FITC-conjugated BSA before (0 min) and 1 h after superfusion with MG (100 µM) alone or 
superfusion with SB216763 (20 µM) 30 min prior to and during 1-h MG superfusion. (D) 
Representative immunohistochemistry showing the staining of P-selectin, E-selectin and ICAM-1 
determined in mouse cremasteric endothelium 4 h after an intrascrotal injection of saline (Control) 
or MG (50 mg/kg) or co-treatment of MG with SB216763 (10 mg/kg, intrascrotal, 30 min prior to 
MG). Arrow indicates cremasteric venule. (E) Original Western blot and means ± SEM (n=4) 
showing the expression of P-selectin, E-selectin and ICAM-1 (relative to β-actin) in EE2 ECs in 
the absence (Control) or in the presence of MG without (+) or treated with negative control siRNA, 
GSK3-targeted siRNA or SB216763 (20 µM, 30 min prior to the addition of MG). * (p<0.05) from 
Control. # (p < 0.05) from MG alone. 
 
MG elicits acute and transient endothelial GSK3 activation 
In view of the modulatory effects of GSK3 inhibitors on MG-elicited leukocyte recruitment, we 
studied the effect of MG on endothelial GSK3 downstream of PI3K signaling. To elucidate the 
activation of GSK3 by MG in EE2 ECs, we analyzed time-dependent changes in inhibitory (Ser-
21/9) and activational (Tyr-279/216) GSK3α/β phosphorylation. As a result, MG treatment of EE2 
ECs elicited a significant and transient reduction in Ser-21/9 and increase in Tyr-279/216 GSK3α/β 
phosphorylation at 15 min, with both phosphorylation returning to the basal level at 30 min. After 
1−4 h of MG treatment, Ser-21/9 phosphorylation was significantly increased and Tyr-279/216 
phosphorylation was significantly reduced (Fig. 4-2A). Fig. 4-2B shows that exposure of MG-
treated EE2 ECs to SB216763, completely abrogated MG-induced GSK3 activation (reduced Ser-
21/9 and increased Tyr-279/216 phosphorylation) at 15 min without affecting the GSK3 
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deactivation at later time points (1―4 h), indicative of the specificity of SB216763 in blocking 
GSK3 activation. To further define the role of Akt, the upstream negative regulator of GSK3, in 
MG-triggered modulation of GSK3 activity, we determined Akt phosphorylation in MG-treated 
EE2 ECs. Exposure of EE2 ECs to MG caused a transient and significant reduction of 
phosphorylated Akt (Ser-473) at 15 and 30 min, but not after 1−4 h MG exposure suggesting the 
inhibitory effect of MG on Akt in PI3K signalling only at early time points (Fig. 4-2C). 
 
Neutrophil-expressed GSK3 does not participate in MG-induced leukocyte recruitment 
We then sought to elucidate the role of neutrophil-expressed GSK3 in leukocyte recruitment by 
examining the effect of MG on neutrophil GSK3 activity. Treatment of neutrophils with MG for 
different time points significantly enhanced Tyr-279/216 and significantly reduced Ser-21/9 GSK3 
phosphorylation, an effect reaching statistical significance at 30 min following MG exposure (Fig. 
4-3A). To elucidate the relevance of GSK3 activation in neutrophils, we tested whether 
pharmacological GSK3 inhibition modulates the hitherto known effect of MG on the expression 
of neutrophil β2 integrin Mac-1 [255], the decisive molecule in leukocyte adhesion to endothelial 
cells [323]. Exposure of neutrophils to MG significantly enhanced Mac-1 expression, an effect 
that was not modified by SB216763 but was significantly reduced by Tempol, the scavenger of 
reactive oxygen species (ROS), suggesting that GSK3 in endothelial cells but not in neutrophils is 
critical in MG-elicited leukocyte recruitment (Fig. 4-3B).  
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Figure 4-2. Methylglyoxal-sensitive modulation of endothelial Akt and GSK3 
phosphorylation. Original Western blot and means ± SEM (n=4) showing total GSK3α/β and 
phosphorylated GSK3α/β (Ser-21/9 and Tyr-279/216) in the absence (A) or in the presence (B) of 
20 µM SB216763 (added 30 min prior to MG treatment) determined in MG-treated (100 µM for 
0−4 h) EE2 ECs (relative to β-actin). (C) Original Western blot and means ± SEM (n=4) showing 
total Akt and phosphorylated Akt (Ser-473) determined in MG-treated (100 µM for 0−4 h) EE2 
ECs (relative to β-actin). * (p<0.05) from 0 min. * (p<0.05) from 0 min. 
Figure 4-2 Methylglyoxal-sensitive modulation of endothelial Akt and GSK3 phosphorylation 
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Figure 4-3. Effect of methylglyoxal on neutrophil-expressed GSK3. (A) Original Western blot 
and means ± SEM (n=4) showing total GSK3α/β and phosphorylated GSK3α/β (Ser-21/9 and Tyr-
279/216) determined in MG-treated (100 µM for 0−4 h) bone marrow neutrophils (relative to β-
actin). * (p<0.05) from 0 min. (B) Means ± SEM (n=4) of Mac-1-dependent fluorescence in 
neutrophils incubated without (Control) or with MG (100 µM for 1 h) in the absence (+) or in the 
presence of SB216763 (20 µM) or Tempol (300 µM) added 30 min prior to the addition of MG. * 
(p < 0.05) from Control. # (p<0.05) from MG alone. 
 
 
MG triggers endothelial SGK1 upregulation and temporally late SGK1-dependent GSK3 
inactivation 
In addition to Akt, GSK3 is phosphorylated and inactivated by SGK1, a PI3K effector kinase [308]. 
We, therefore, explored the role of SGK1 in MG-induced leukocyte recruitment. First, we 
elucidated the transcriptional upregulation of endothelial SGK1 triggered by MG. Fig. 4-4A shows 
that endothelial SGK1 mRNA levels were significantly increased following MG treatment 
reaching statistical significance after 1 h MG exposure. The levels of phosphorylated (Thr-256) 
and total endothelial SGK1 were significantly enhanced at 1 h and 2 h, respectively, following 
MG-treatment of EE2 ECs (Fig. 4-4B). Furthermore, siRNA-targeted silencing of endothelial 
SGK1 (Fig. 4-4C) did not significantly modify the acute and transient GSK3 activation (15 min) 
that is depicted in Fig. 4-2A, but abrogated GSK3 deactivation after 1−4 h of MG treatment (Fig. 
4-2A and Fig. 4-4D) indicating that SGK1 is not involved in early GSK3 activation but is a crucial 
upstream molecule in endothelial GSK3 deactivation at 1−4 h of MG treatment.  
Figure 4-3 Effect of methylglyoxal on neutrophil-expressed GSK3 
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Figure 4-4. Effect of methylglyoxal on endothelial SGK1 expression. (A) Mean ± SEM of 
mRNA levels (n = 6) encoding SGK1 and (B) original Western blot and means ± SEM (n=4) 
showing total SGK1 and phosphorylated SGK1 (Thr-256) determined in MG-treated (100 µM for 
0−4 h) EE2 ECs (relative to β-actin). (C) SGK-targeted siRNA silencing showing decreased SGK1 
protein expression in EE2 ECs. (D) Original Western blot and arithmetic means ± SEM (n=4) 
showing total GSK3α/β and phosphorylated GSK3α/β (Ser-21/9 and Tyr-279/216) after SGK 
silencing determined in MG-treated (100 µM for 0−4 h) EE2 ECs (relative to β-actin). * (p<0.05) 
from 0 min. 
 
 
Endothelial but not neutrophil SGK1 contributes to MG-induced leukocyte recruitment 
Further experiments addressed the effect of SGK1 inhibition on MG-elicited leukocyte recruitment 
in vivo. Intravital microscopy analysis of mouse cremasteric microvasculature in Fig. 4-5A 
revealed that SGK1 inhibitor GSK650394 significantly reduced the number of adherent and 
emigrated leukocytes triggered by MG treatment. Leukocyte rolling velocity tended to be higher 
Figure 4-4 Effect of methylglyoxal on endothelial SGK1 expression 
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in mice treated with both MG and GSK650394 compared to mice treated with MG alone, an effect 
not reaching statistical significance (Fig. 4-5A). MG treatment presented a dramatic upregulation 
of total and phosphorylated SGK1 in whole cremasteric tissue (Fig. 4-5B), thus, corroborating 
enhanced abundance of total and phosphorylated SGK1 observed in vitro (Fig. 4-4B). Furthermore, 
the specificity and efficacy of GSK650394 was determined by the phosphorylation of N-myc 
downstream-regulated gene 1 (NDRG1), a specific target of SGK1 [324, 325]. MG treatment 
enhanced NDRG1 phosphorylation in whole cremasteric tissue, an effect that was significantly 
blunted by GSK650394 (Fig. 4-5C) suggesting that GSK650394 specifically targets SGK1 in our 
model system. We further observed that in neutrophils, MG exposure for different durations had 
no appreciable changes in total or phosphorylated SGK1 (Fig. 4-5D), suggesting that SGK1 
expressed in endothelial cells, but not in neutrophils, is critical in MG-induced leukocyte 
recruitment. To disclose the underlying mechanisms of SGK1-sensitive leukocyte recruitment, 
expression of endothelial adhesion molecules was determined in whole cremaster muscle using 
immunoblotting and visualized in EE2 ECs using confocal imaging. As depicted in Fig. 4-5E and 
4-5F, exposure to MG  enhanced the expression of P- and E-selectins and ICAM-1 in whole 
cremaster muscle and in EE2 ECs respectively, an effect abrogated after SGK knockdown or 
GSK650394 treatment. 
 
MG induces GSK3- and SGK1-dependent activation of NF-κB 
Expression of endothelial adhesion molecules is effectively accomplished by activation of 
transcription factors. Using GSK3- or SGK-targeted siRNA silencing, we examined dynamic 
changes of NF-κB activation in MG-treated EE2 ECs and whole cremasteric tissue. Silencing 
GSK3 or SGK significantly reduced NF-κB activity in silenced versus non-silenced MG-treated 
EE2 ECs, an effect reaching statistical significance at 15 min (for GSK3 silencing) and 1 h (for 
SGK silencing) respectively (Fig. 4-6A). To substantiate these data in vivo, we analysed NF-κB 
activity in whole cremasteric tissue. Treatment with MG significantly increased NF-κB activity as 
compared to saline treated cremaster muscle. Pretreatment with SB216763, GSK650394 or the 
NF-κB inhibitor BAY11-7082 significantly attenuated MG-induced NF-κB activation (Fig. 4-6B). 
These observations indicate that both GSK3 and SGK are sensitive to MG and decisive in the 
regulation of MG-triggered NF-κB activity in endothelial cells, albeit at different time points. 
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Figure 4-5 Participation of SGK1 in methylglyoxal-induced leukocyte recruitment 
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Figure 4-5. Participation of SGK1 in methylglyoxal-induced leukocyte recruitment. (A) 
Means ± SEM (n=6) of leukocyte rolling velocity (μm/sec), adhesion (cells/100-μm venule) and 
emigration (cells/443×286 μm2 field) determined 4 h after an intrascrotal injection of saline 
(Control) or MG (50 mg/kg) with or without treatment with GSK650394 (50 mg/kg, 30 min prior 
to MG). (B) Original Western blot and means ± SEM (n=4) showing total SGK1and 
phosphorylated SGK1 (Thr-256) determined in whole cremaster tissue (relative to β-actin) 4 h 
after an intrascrotal injection of saline (Control) or MG (50 mg/kg). (C) Original Western blot and 
means ± SEM (n=4) showing total NDRG1 and phosphorylated NDRG1 (Thr-346) determined in 
whole cremaster tissue (relative to β-actin) at 4 h after an intrascrotal injection of saline (Control), 
or MG (50 mg/kg) with or without treatment with GSK650394 (50 mg/kg, 30 min prior to MG). * 
(p<0.05) from Control. # (p< 0.05) from MG alone. (D) Original Western blot and means ± SEM 
(n=4) showing total SGK1 and phosphorylated SGK1 (Thr-256) determined in MG-treated (100 
µM for 0−4 h) neutrophils (relative to β-actin). (E) Original Western blot and means ± SEM (n=4) 
showing the expression of P-selectin, E-selectin and ICAM-1 determined in whole cremaster tissue 
(relative to β-actin) in the absence (Control) or MG (50 mg/kg) with or without treatment with 
GSK650394 (50 mg/kg, 30 min prior to MG). * (p<0.05) from Control. # (p<0.05) from MG alone. 
(F) Representative confocal micrographs of P-selectin, E-selectin and ICAM-1 immunostaining in 
EE2 ECs in the absence (Control) or in the presence of MG (100 µM, 4 h) alone (+) or co-treatment 
with negative control siRNA, SGK-targeted siRNA or SGK1 inhibitor GSK650394 (20 µM, 30 
min prior to MG). 
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Figure 4-6. SGK1 and GSK3 orchestrate methylglyoxal-induced endothelial NF-κB 
activation. (A) Means ± SEM (n=4) of relative NF-κB activity determined in MG-treated EE2 
ECs (100 µM for 0−4 h) in the absence (MG) or in the presence of prior treatment with negative 
control siRNA, GSK3-targeted siRNA or SGK1-targeted siRNA. * (p<0.05) from negative 
Control siRNA. (B) Means ± SEM (n=3) of relative NF-κB activity determined in determined 4 h 
after an intrascrotal injection of saline (Control), MG (50 mg/kg) or co-treatment of MG with 
GSK650394 (50 mg/kg), SB216763 (10 mg/kg) or BAY11-7082 (20 mg/kg), the inhibitors being 
administered 30 min prior to MG. * (p<0.05) from Control. # (p<0.05) from MG alone. 
 
 
MG-elicited redox-sensitive activation of endothelial CREB transcription factor is regulated by 
SGK1 
We further characterized the transcriptional regulation of endothelial adhesion molecule 
expression fostered by SGK1 by evaluating endothelial CREB expression and phosphorylation in 
nucleus after exposure of EE2 ECs to MG. As shown in Fig. 4-7A, the CREB phosphorylation and 
total CREB expression were significantly increased on exposure to MG, an effect reaching 
statistical significance at 1 h (phospho-CREB) and 2 h (total CREB) respectively. Silencing SGK 
in EE2 ECs completely abolished the increased total- and phospho-CREB expression induced by 
MG (Fig. 4-7A). Silencing CREB (Fig. 4-7B) significantly attenuated MG-triggered ICAM-1 
Figure 4-6 SGK1 and GSK3 orchestrate methylglyoxal-induced endothelial NF-κB 
activation 
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expression, but not the expression of P- and E-selectins (Fig. 4-7C), suggesting that transcriptional 
regulation by SGK1-dependent CREB is endothelial adhesion molecule-specific. We also tested 
whether ROS was involved in MG-triggered CREB activation. As shown in Fig. 4-7D, 
upregulation of total- and phospho-CREB in EE2 ECs triggered by MG was significantly blunted 
by the treatment with the antioxidant Tempol indicating that CREB activation elicited by MG is 
ROS-dependent. To corroborate our in vitro findings, we further examined the expression of total 
and phosphorylated CREB in whole cremasteric tissue. As shown in Fig. 4-7E, MG-elicited 
upregulation of total- and phospho-CREB in whole cremasteric tissue was significantly mitigated 
by treatment with GSK650394 or Tempol. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-7 Activation of CREB by methylglyoxal 
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Figure 4-7.  Activation of CREB by methylglyoxal. (A) Original Western blot and means ± SEM 
(n=4) showing total CREB and phosphorylated CREB (Ser-133) determined in MG-treated (100 
µM for 0−4 h) EE2 ECs and in MG-treated SGK-silenced EE2 ECs (relative to β-actin). * (p<0.05) 
from 0 min. # (p<0.05) from absence of SGK silencing. (B) CREB-targeted siRNA silencing 
showing decreased CREB protein expression in EE2 ECs. (C) Original Western blot and means ± 
SEM (n=4) showing P-selectin, E-selectin and ICAM-1 expression (relative to β-actin) in EE2 
ECs in the absence (Control) or in the presence of MG (100 µM, 4 h) without or with CREB 
silencing. * (p<0.05) from Control. # (p<0.05) from absence of CREB silencing. (D) Original 
Western blot and means ± SEM (n=4) showing total CREB and phosphorylated CREB (Ser-133) 
expression determined in EE2 ECs (relative to β-actin) in the absence (Control) or in the presence 
of MG (100 µM, 4 h) without (MG) or with Tempol (300 µM, 30 min prior to MG). * (p<0.05) 
from Control. # (p<0.05) from MG alone. (E) Original Western blot and means ± SEM (n=4) 
showing total CREB and phosphorylated CREB (Ser-133) expression determined 4 h after an 
intrascrotal injection of saline (Control), MG (50 mg/kg) or co-treatment of MG with GSK650394 
(50 mg/kg) or Tempol (50 mg/kg), both agents administered 30 min prior to MG. * (p<0.05) from 
Control. # (p<0.05) from MG alone. 
 
4.5 Discussion 
Endothelial adhesion molecules on the vascular lining are requisite elements during leukocyte 
recruitment at the site of inflammation. The present study unravels signaling mechanisms by which 
endothelial-expressed GSK3 and SGK1 orchestrate rolling, adhesion and transendothelial 
migration of leukocytes. By utilizing a previously established mouse model simulating diabetes-
associated inflammation [75, 153], we elucidate the hitherto unknown role of endothelial PI3K 
signaling effectors SGK1 and GSK3 in MG-induced leukocyte-endothelial cell interactions. In this 
study, we demonstrate the temporal endothelial SGK1 and GSK3 signalling mechanism in MG-
induced leukocyte recruitment (depicted in Fig. 4-8). Excessive MG triggers Akt-dependent 
transient GSK3 activation in endothelial cells, which is responsible for NF-κB activation at early 
time-points. After 1 h, the GSK3 activity decreases due to the activation of SGK1 and the activated 
SGK1 maintains the crucial NF-κB activity at later time-points. This temporal activation of GSK3 
and SGK1 is pivotal for endothelial adhesion molecules P- and E-selectins and ICAM-1expression 
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Figure 4-8 Scheme of methylglyoxal-elicited endothelial SGK1/GSK3 signalling 
 
and consequently MG-induced leukocyte recruitment in vivo. The activation of SGK1 is also 
responsible for CREB activation, which regulates the expression of ICAM-1. MG activates GSK3 
in neutrophils only after 30 min treatment, an effect, however, not responsible for Mac-1 
expression. Both GSK3 and SGK1 in neutrophils are not involved in MG-elicited leukocyte 
recruitment. The physiological relevance of methylglyoxal (MG) concentrations used in this study 
is based on previous reports [326, 327]. It has recently been shown that a single administration of 
50 mg/kg MG (intrascrotally for 4 h) yielded concentrations of MG at approximately 1.7 μM and 
3.9 nmol/mg protein in plasma and tissue respectively [75]. The concentration of MG detected in 
cremaster tissue is comparable to that detected in other organs [134, 187]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-8. Scheme of methylglyoxal-elicited endothelial SGK1/GSK3 signalling. MG first 
induces Akt-dependent transient GSK3 activation in ECs at early time points (< 30 min). The 
activation of GSK3 is responsible for NF-κB activation at early time-points. After 1h, MG induces 
SGK1 activation, which further maintains NF-κB activity and responsible for GSK3 inactivation 
at later time-points. NF-κB activity is critical for endothelial adhesion molecule expression P-
selectin, E-selectin and ICAM-1 expression. The activation of SGK1 is also responsible for CREB 
activation, which regulates the expression of ICAM-1. The expression of adhesion molecule on 
ECs finally leads to leukocyte adhesion and transmigration. 
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Here, we demonstrate that MG-triggered GSK3 activation in endothelial cells, but not in 
neutrophils, is acute and transient and parallels decreased phosphorylation of the upstream kinase 
Akt. The inhibitory effect of MG on PI3K signaling and subsequent activation of GSK3 was 
previously reported in pancreatic beta cells [232]. Similarly, MG was shown to foster platelet 
aggregation by attenuation of Akt phosphorylation [212]. Consistent with our findings in 
endothelial cells, short exposure of L6 muscle cells to MG blunted Akt phosphorylation [140]. On 
the contrary and suggestive of the cell-specific effects of MG, Akt phosphorylation in adipocytes 
[328] and vascular smooth muscle cells [186] was increased after treatment with MG. Similar to 
MG treatment, transient activation of GSK3 in endothelial cells was previously observed after 
treatment with either thrombin or TNFα [329]. Our results also show that following prolonged 
exposure to MG, inhibitory phosphorylation of endothelial GSK3 was increased. Intriguingly, 
GSK3 activation in neutrophils, unlike endothelial cells, is enhanced after prolonged exposure to 
MG.  
 
Our results show that, with transient decrease in inhibitory phosphorylation, GSK3 acquires a 
proinflammatory activity in the context of MG-induced endothelial activation for leukocyte 
recruitment which is ameliorated by pharmacological GSK3 inhibition. Paradoxically, we 
observed that inhibition of SGK1 similarly mitigates leukocyte recruitment in vivo given that 
SGK1 is known to inactivate GSK3. Clearly, endothelial SGK1 is genomically upregulated by 
exposure to MG and our in vitro results show that at later time points (˃ 1 h), both total and 
phospho-SGK1 levels are increased in contrast to the acute and transient activation of GSK3. From 
our in vitro results, it is apparent that SGK1 and GSK3 signaling in endothelial cells is temporal 
with Akt-paralleled GSK3 signaling being decisive at early time points (15 min). At later time 
points SGK1 silencing virtually abrogated MG-induced phosphorylation of endothelial GSK3 
(Ser-21/9). However, biological ramification of this effect on GSK3 is unknown. Furthermore, 
SGK silencing blunts NF-κB activity at later time points ( 1 h) in contrast to GSK3 silencing 
which curtails NF-κB activation at early time points. It is, therefore, tempting to speculate that at 
later time points SGK1 directly mediates NF-κB activation independently of its effect on GSK3.   
 
Mechanistically, the role of SGK1 in inflammatory sequelae is largely unknown. Here we unravel 
that MG treatment potentiates SGK1 transcript levels in endothelial cells. Previously, NADPH 
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oxidases were shown to be critically involved in the upregulation of SGK1 [241]. MG-induced 
endothelial SGK1 upregulation is presumably redox-sensitive because MG triggers ROS 
production which contributes to leukocyte-endothelial cell interactions [152, 153]. Surprisingly, 
SGK1 was not upregulated in neutrophils exposed to MG in contrast to the effect on GSK3 
activation. The role of leukocyte-expressed SGK1, however, is not completely understood. The 
hematopoietic growth factor granulocyte-macrophage colony-stimulating factor (GM-CSF) was 
recently shown to augment SGK1 transcript and protein levels in neutrophils and the SGK1 
inhibitor GSK650394 reduced GM-CSF-induced neutrophil survival [330]. SGK1 was shown to 
be effective by regulating Orai1/STIM1 and, thus, influences Ca2+-dependent functions such as 
cell migration [331]. Along this line, Orai1 was shown to be decisive in neutrophil arrest and 
migration [332]. From the present study, however, it is unclear whether these mechanisms are 
operative for SGK1-sensitivity in leukocytes in MG-induced leukocyte-endothelial cell 
interactions.  
 
Previous observations demonstrated that MG induces NF-κB-dependent upregulation of 
endothelial adhesion molecules [75]. We observed that targeted gene silencing or pharmacological 
inhibition of either GSK3 or SGK1 blunted the expression of endothelial adhesion molecules 
elicited by MG. It is documented that GSK3 inhibition curtails endothelial E-selectin [313], 
VCAM-1 [329], P-selectin and ICAM-1 expression [333, 334]. Mounting evidence suggests that 
GSK3 is an essential element for NF-κB activation [223, 329, 335]. Accordingly, our results 
showed that knockdown of GSK3 gene dramatically reduced both activation of NF-κB and 
expression of endothelial adhesion molecules, substantiating the in vivo effects of GSK3 inhibitors 
on MG-induced leukocyte recruitment.  
 
Our study is the first to demonstrate the modulatory role of SGK1 in leukocyte recruitment in vivo 
by regulating the expression of endothelial adhesion molecules. SGK1 was previously reported to 
mediate NF-κB-dependent ICAM-1 expression in mesangial cells [336]. In accordance with our 
results, knockdown of SGK1 gene was previously shown to attenuate NF-κB activation in renal 
collecting duct cells [337]. SGK1 phosphorylates and activates NDRG1, a mechanism associated 
with degradation of NF-κB inhibitory proteins [240]. We demonstrate in this study that upon 
stimulation with MG, endothelial CREB is phosphorylated in an SGK1-dependent manner. Upon 
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stimulation with glucocorticoids, the SGK kinases were shown to physically associate with CREB 
[242]. Recently, CREB was reported to be essential in endothelial ICAM-1 [338, 339] VE-
cadherin [340] and VCAM-1 upregulation [338]. Our data show that MG-triggered upregulation 
of endothelial ICAM-1, but not P- and E-selectins, was at least partially mediated by CREB. 
Additionally, CREB phosphorylation was documented to be ROS-sensitive [341], a decisive 
mechanism in MG-elicited leukocyte-endothelial interactions [153]. This mechanism is validated 
in our present study by the inhibitory effect of the antioxidant Tempol on MG-triggered CREB 
phosphorylation.  
 
In summary, we provide biological evidence that temporal Akt-dependent GSK3 activity and 
SGK1 signaling in endothelial cells are pivotal in MG-elicited up-regulation of transcription 
factors, adhesion molecule expression, and leukocyte interactions with the activated vascular 
endothelium. Pharmacologically targeting GSK3 or SGK1 alleviates acute inflammation induced 
by MG, thus, unravelling potential therapeutic targets in inflammation associated with excessive 
MG levels. 
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 CHAPTER 5 METHYLGLYOXAL MODULATES 
ENDOTHELIAL NITRIC OXIDE SYNTHASE-
ASSOCIATED FUNCTIONS IN EA.HY926 
ENDOTHELIAL CELLS 
METHYLGLYOXAL MODULATES ENDOTHELIAL NITRIC OXIDE 
SYNTHASE-ASSOCIATED FUNCTIONS IN EA.HY926 ENDOTHELIAL 
CELLS 
 
In Chapter 5 and the following Chapter 6, we reveal MG-induced eNOS uncoupling as another 
mechanism underlying MG-elicited leukocyte recruitment. In this chapter (Chapter 5), we show 
that MG induces eNOS uncoupling which shifts its function from producing NO to producing 
superoxide in human endothelial cell line cells. The identification of this novel source of 
superoxide lays the foundation for investigating the role of eNOS-derived superoxide production 
in MG-elicited leukocyte recruitment, and the latter will be shown in the next Chapter 6. 
 
This chapter has been published as a research paper by Yang Su, Syed M. Qadri, Lingyun Wu,and 
Lixin Liu in Cardiovascular Diabetology 2013 Sep 19; 12:134. Contents of this chapter have been 
adapted / reproduced from the published article with permission from the journal Cardiovascular 
Diabetology. In this study, Y.S. conducted all the experiments, acquired and analyzed all the data, 
and also participated in the design of the study and manuscript writing. 
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5.1 Abstract 
Background 
Increased levels of the sugar metabolite methylglyoxal (MG) in vivo were shown to participate in 
the pathophysiology of vascular complications in diabetes. Alterations of endothelial nitric oxide 
synthase (eNOS) activity by hypophosphorylation of the enzyme and enhanced monomerization 
are found in the diabetic milieu, and the regulation of this still remains undefined. Using various 
pharmacological approaches, we elucidate putative mechanisms by which MG modulates eNOS-
associated functions of MG-stimulated superoxide (O2) production, phosphorylation status and 
eNOS uncoupling in EA.hy926 human ECs.  
 
Methods 
In cultured EA.hy926 ECs, the effects of MG treatment, tetrahydrobiopterin (BH4; 100 µM) and 
sepiapterin (20 µM) supplementation, NOS inhibition by NG-nitro-L-arginine methyl ester (L-
NAME; 50 µM), and inhibition of peroxynitrite (ONOO) formation (300 µM Tempol plus 50 µM 
L-NAME) on eNOS dimer/monomer ratios, Ser-1177 eNOS phosphorylation and 3-nitrotyrosine 
(3NT) abundance were quantified using immunoblotting. O2-dependent fluorescence was 
determined using a commercially available kit and tissue biopterin levels were measured by 
fluorometric HPLC analysis.  
 
Results 
In EA.hy926 cells, MG treatment significantly enhanced O2 generation and 3NT expression and 
reduced Ser-1177 eNOS phosphorylation, eNOS dimer/monomer ratio and cellular biopterin 
levels indicative of eNOS uncoupling. These effects were significantly mitigated by administration 
of BH4, sepiapterin and suppression of ONOO formation. L-NAME treatment significantly 
blunted eNOS-derived O2 generation but did not modify eNOS phosphorylation or 
monomerization.  
 
Conclusion 
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MG triggers eNOS uncoupling and hypophosphorylation in EA.hy926 ECs associated with O2 
generation and biopterin depletion. The observed effects of the glycolysis metabolite MG 
presumably account, at least in part, for endothelial dysfunction in diabetes. 
 
5.2 Introduction 
Chronic hyperglycemia fosters endothelial dysfunction that accounts for the pathophysiology of 
microvascular sequelae in diabetes [342, 343]. The elevated glycolysis metabolite methylglyoxal 
(MG) has been implicated in vascular complications such as hypertension [344], impaired 
microcirculation [345] and thrombosis [255] in diabetes. The increased MG affects multi-organ 
homeostasis by modulating immune cell functions [265], cytokine induction [267], cytosolic Ca2+ 
[213], cellular energy and redox balance [157] and adhesion molecules expression [75] and 
induces both necrotic [346] and apoptotic cell death [345].  
 
Endothelial nitric oxide synthase (eNOS) is the predominant and constitutively expressed NOS in 
vascular ECs and catalyzes the reaction for generation of nitric oxide (NO) from L-arginine in the 
presence of the cofactors tetrahydrobiopterin (BH4) and NADPH [347]. Regulation of eNOS 
activity is coupled to cytosolic Ca2+ [348] whereas the expression is regulated by a wide range of 
transcriptional and posttranscriptional mechanisms [349]. Alterations of NO balance contribute to 
the pathophysiology of diabetic complications [350]. Deficiency of either L-arginine or BH4 
results in reduced NO but enhanced superoxide (O2) production, a functional change of eNOS 
that is defined as eNOS uncoupling [347]. eNOS uncoupling is associated with increased eNOS 
monomerization, tyrosine nitration and formation of dihydrobiopterin (BH2) and decreased 
cellular BH4 [351, 352]. Sepiapterin is a stable precursor of BH4 and serves as a valuable 
pharmacological agent for the study of eNOS uncoupling due to its high cell permeability as 
compared to BH4 [353, 354]. O2 avidly reacts with NO to form peroxynitrite (ONOO) which 
triggers the oxidation of BH4, impairs eNOS activity and induces eNOS uncoupling [347, 351, 
355].  
 
Uncoupling of eNOS is the underlying mechanism of endothelial dysfunction associated with 
cardiovascular conditions such as hypertension, stroke, and heart failure [356, 357]. Recently, 
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eNOS uncoupling was shown to participate in endothelial dysfunction in diabetic mice [358] and 
to mediate peripheral neuropathy in diabetic rats [359]. In Zucker diabetic fatty rats, endothelial 
dysfunction and decreased NO availability were attributed to dissociation of eNOS from HSP90, 
an effect elicited by increased calpain activity [360]. As a myriad of molecules are dysregulated 
in diabetes, the specific effects of MG on eNOS uncoupling, however, remain elusive. 
 
Ramifications of elevated MG levels in hyperglycemia include impaired NO production and redox 
imbalance [115]. Various studies promulgate a possible link between endothelial dysfunction and 
functional alterations of eNOS after MG treatment. To date, however, discrepant data prevail on 
MG sensitivity of eNOS functions in different model systems. On the one hand, MG was shown 
to stimulate transcription of eNOS [361]; while on the other, abundance of eNOS protein was 
reduced following MG treatment [362, 363]. In contrast, MG was shown to suppress eNOS 
phosphorylation on serine-1179 without affecting eNOS protein expression [70]. Increased MG 
levels in preeclamptic vasculature were shown to be coupled with enhanced arginase, LOX-1 and 
tyrosine nitration [364]. The association between MG-triggered eNOS phosphorylation, eNOS 
uncoupling, and oxidative stress in vascular endothelial dysfunction, however, remains ill-defined. 
 
The present study explores the mechanisms of MG-induced endothelial dysfunction by examining 
putative eNOS-associated functions. We elucidate the effects of exogenous BH4 and sepiapterin 
administration, NOS inhibition and suppression of peroxynitrite (ONOO) formation on O2 
generation, eNOS monomerization, cellular biopterin levels, tyrosine nitration, and 
phosphorylation of eNOS in EA.hy926 ECs in vitro. 
 
5.3 Materials and methods 
Cell culture and pharmacological treatments 
EA.hy926 cells, the hybrid human umbilical vein endothelial cell line cells [365], were obtained 
from American Type Culture Collection (Rockville, MD, USA) and cultured in Dulbecco’s 
modified Eagle’s medium (Cellgro, VA, USA) with 10% fetal bovine serum (Hyclone, UT, USA), 
100 U/mL penicillin and 100 μg/mL streptomycin (Amresco, OH, USA) with 5% CO2 and 
maximal humidity at 37 °C. Cells between passage 3 and 6 were used for the experiments. As 
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indicated in the figure legends, various pharmacological approaches were used to elucidate eNOS-
associated functions. To maintain eNOS dimerization, the NOS cofactor 5,6,7,8-
tetrahydrobiopterin (BH4, 100 µM; Sigma-Aldrich, Oakville, ON, Canada) or the negative control, 
a pteridine analogue, 5,6,7,8-tetrahydroneopterin (NH4, 100 µM; Schircks Laboratories, Jona, 
Switzerland) were freshly-prepared and administered. NH4 has similar antioxidant effects as BH4 
but, unlike BH4, is ineffective in restoring uncoupled eNOS [366]. Sepiapterin (20 μM; Cayman, 
Ann Arbor, MI, USA), a substrate for BH4 synthesis via the pterin salvage pathway, was used to 
increase cellular BH4 levels [367]. The NOS inhibitor NG-nitro-L-arginine methyl ester (L-NAME, 
50 µM; Sigma-Aldrich), was administered to inhibit uncoupled eNOS-derived O2− [258]. For 
suppression of ONOO generation, EA.hy926 cells were treated with a combination of the ROS 
scavenger 1-oxyl-2,2,6,6-tetramethyl-4-hydroxypiperidine (Tempol, 300 µM; Santa Cruz, Dallas, 
TX, USA) and NOS inhibitor L-NAME (50 µM) for 24 h prior to the addition of MG [31, 368]. 
O2− reacts with NO at equimolar ratios to generate ONOO [31], and from our unpublished 
observations, pretreatment with a combination of L-NAME and Tempol more potently inhibits 
ONOO formation than pretreatment with either pharmacological agent alone.  
 
Determination of O2
− production 
O2 levels were determined using a commercial superoxide detection kit (Enzo, Brockville, ON, 
Canada) according to the manufacturer’s instructions as described previously [369, 370]. The 
superoxide detection reagent when oxidized produces an orange fluorescent compound which is 
retained in the cell. Cells were seeded in a 96-well plate and stained with the membrane-permeable 
and nonfluorescent O2 detection probe (5 μM, 30 min, 37°C in the dark). Excessive probe was 
removed by washing with PBS. The fluorescence in cells was detected using excitation and 
emission wavelengths of 544 nm and 590 nm respectively. The data are expressed as arbitrary 
units.  
 
Analysis of biopterin levels by HPLC 
Measurement of BH4 and total biopterins was performed by fluorometric HPLC analysis as 
described previously with slight modifications [258]. After indicated treatments, EA.hy926 cells 
were lysed in a lysis buffer (pH 7.4; containing 50 mM Tris-HCl, 1 mM DTT and 1 mM EDTA) 
with 0.1 μM neopterin (Sigma-Aldrich) as an internal recovery standard. The samples were 
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deproteinated with 10% 1:1 mixture of 1.5 M HClO4 and 2 M H3PO4 and centrifuged (12,000 × g 
for 10 min).  The supernatant was split into portions and subjected to acid- and alkali-oxidation 
respectively. For determination of total biopterins (BH4, BH2 and non-reduced biopterins) by 
acid-oxidation, 10 μl iodine solution (1% iodine in 2% KI solution) was added into every 90 μl 
supernatant and for quantification of BH2 and non-reduced biopterins by alkali-oxidation, 10 μl 
of 1 M NaOH and 10 μl of iodine solution were added to 80 μl supernatant. Following incubation 
(1 h, room temperature in the dark), the alkali-oxidation samples were acidified with 1 M H3PO4, 
the iodine in both acid- and alkali-oxidation samples was reduced using 5% ascorbic acid (Sigma) 
and the samples were centrifuged (12,000 × g for 10 min). The supernatant was collected for HPLC 
analysis using a Hitachi D-7000 HPLC system (Hitachi, Mississauga, ON, Canada) via Symmetry 
C18 reverse-phase column with a methanol-water (1.5:98.5, v/v) mobile phase running at 0.5 
mL/min. Fluorescence was detected at excitation and emission wavelengths of 348 nm and 444 
nm respectively. The level of BH4 was calculated by subtracting BH2 and non-reduced biopterins 
from total biopterins and expressed as pmol per mg protein. The biopterin levels in NH4-treated 
cells were calculated without adding 0.1 μM neopterin. 
 
Western blotting 
Non-reducing SDS-PAGE was performed to detect eNOS dimers and monomers [258]. Briefly, 
cultured EA.hy926 cells were harvested and lysed on ice for 30 min by using RIPA buffer (50 mM 
Tris-HCl, 150 mM NaCl, 1 % NP-40, 0.5% sodium deoxycholate, 0.1 % SDS and protease 
inhibitors cocktail, pH 8.0). The lysate was centrifuged at 10,000 × g for 10 min, and the 
supernatant was collected, incubated with 4 × Laemmli buffer without β-mercaptoethanol (200 
mM Tris-HCl, 50 % glycerol, 2% SDS, 0.04% bromophenol blue, pH 6.8) at 37°C for 5 min. 
Aliquots of cell lysates (50 μg of protein each) were separated on 7% SDS-PAGE. Gels and buffers 
were equilibrated at 4°C before electrophoresis, and the buffer tank was placed in an ice bath 
during electrophoresis to maintain the low temperature. Subsequent to non-reducing SDS-PAGE, 
the gels were electrotransferred to a nitrocellulose membrane (Bio-Rad, CA, USA), and the blots 
were probed by primary antibody against eNOS (1:1000; BD Pharmingen, USA) and horseradish 
peroxidase-conjugated secondary antibody (Santa Cruz) as routine Western blot. In separate gels, 
total eNOS (1:1000), β-actin (1:1000; Santa Cruz, CA, USA), phospho-eNOS (Ser-1177, 1:1000; 
BD Pharmingen, CA, USA) and 3-nitrotyrosine (3NT, 1:1000; Enzo) from cell lysates of the same 
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experiments were detected by routine Western blot under reduced condition. The bands were 
visualized with enhanced chemiluminescence reagents (GE Healthcare Life Sciences, NJ, USA) 
and exposed to X-ray film (Kodak scientific imaging film, ON, Canada). Densitometric 
quantification of the detected bands was performed using Quantity One® Software (Bio-rad). The 
ratio of eNOS dimer to monomer was normalized to one in the absence of MG.   
 
Statistical analysis 
Data are expressed as arithmetic means ± SEM from at least three independent experiments. 
Statistical analysis was made using one way analysis of variance (ANOVA) with Tukey’s post-
hoc comparison test. n denotes the number of different batches of cells tested in each treatment 
group. Values of p < 0.05 were considered statistically significant. 
 
5.4 Results 
To elucidate the redox imbalance triggered by MG treatment on vascular ECs in vitro, we analyzed 
MG-triggered O2 generation using a fluorescence-based assay. Treatment of EA.hy926 ECs with 
MG (50 – 200 µM) for 2, 4, 6 and 8 h respectively, significantly increased O2 production in a 
concentration- and time-dependent manner (Fig. 5-1A). In another series of experiments, we 
analyzed the effect of biopterin supplementation (BH4, 100 µM; sepiapterin, 20 µM), 
pharmacological inhibition of NOS using L-NAME (50 µM) or suppression of ONOO formation 
using combined 24-h pretreatment with Tempol (300 µM) and L-NAME (50 µM) on MG-induced 
O2 production. As shown in Fig. 5-1B, inhibition of NOS, suppression of ONOO formation, or 
supplementation of either BH4 or sepiapterin significantly attenuated MG-induced O2 production. 
Treatment of EA.hy926 cells with the BH4 control NH4 (100 µM), however, did not significantly 
alter MG-induced O2 production (Fig. 5-1B). These results suggest eNOS-derived O2 
production in MG-treated EA.hy296 ECs.  
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Figure 5-1. Methylglyoxal-stimulated O2 production in EA.hy926 ECs. A. O2 generation 
determined in EA.hy296 ECs treated with different concentrations of MG (0, 50, 100 and 200 µM) 
for 0, 2, 4, 6 and 8 h respectively. Data are arithmetic means ± SEM (n = 6). * indicates significant 
difference (p < 0.05) from the absence of MG (ANOVA). B. O2 generation determined in 
EA.hy296 ECs treated with MG (100 µM) for 8 h in the absence (Control) or in the presence of L-
NAME (50 µM), BH4 (100 µM), NH4 (100 µM) or sepiapterin (20 µM) in the last 4 h of MG 
treatment or 24-h pre-treatment with 300 µM Tempol and 50 µM L-NAME (ONOO suppression) 
prior to the addition of MG. Data are arithmetic means ± SEM (n = 6). * indicates significant 
difference (p < 0.05) from Control (ANOVA). 
 
Figure 5-1 Methylglyoxal-stimulated O2•- production in EA.hy926 ECs 
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Next, we explored the effect of MG on eNOS monomerization in EA.hy926 ECs. Treatment of 
EA.hy926 cells with MG (50 – 200 µM) for 0.5, 2, 4, and 8 h respectively, significantly decreased 
eNOS dimer/monomer ratio in a concentration- and time-dependent manner (Fig. 5-2A and 5-2B). 
These results, together with the effect of L-NAME inhibition on MG-induced O2  production (Fig. 
5-1B), suggest that MG treatment induces eNOS uncoupling in EA.hy926 cells. We further tested 
the effect of biopterin supplementation, L-NAME addition and suppression of ONOO formation 
on MG-elicited eNOS monomerization. As shown in Fig. 5-2C and 5-2D, treatment of EA.hy926 
cells with MG (100 µM) for 8 h significantly reduced eNOS dimer/monomer ratio, an effect that 
was significantly blunted by the administration of BH4 (100 µM, 4 h), sepiapterin (20 µM, 4 h) or 
by ONOO suppression (300 µM Tempol and 50 µM L-NAME, 24 h). Treatment with L-NAME 
(50 µM, 4 h) alone or the BH4 control NH4 (100 µM, 4 h) did not modify eNOS dimer/monomer 
ratio (Fig. 5-2C and 5-2D). 
 
To further elucidate MG-induced eNOS uncoupling, we determined the cellular BH4 levels in 
EA.hy926 cells following MG treatment. As depicted in Fig. 5-3A, treatment of EA.hy926 cells 
with MG (50 – 200 µM) for 8 h significantly decreased total cellular biopterin and BH4 levels in 
a concentration-dependent manner. More importantly, treatment of EA.hy926 cells resulted in a 
reduction of BH4/total biopterin ratio, an effect reaching statistical significance at 100 µM MG 
concentration (Fig. 5-3B). We then explored the effect of biopterin supplementation, L-NAME 
addition and suppression of ONOO formation on MG-induced reduction in cellular BH4 levels. 
As illustrated in Fig. 5-3C, 4-h supplementation of BH4 (100 µM) or sepiapterin (20 µM) in MG-
treated EA.hy926 cells significantly increased total cellular biopterin and BH4 levels suggesting 
that exogenous biopterin repletion dissipated MG-induced reduction in cellular BH4 contents 
associated with eNOS uncoupling. Suppression of ONOO, however, did not significantly modify 
total cellular biopterin levels but significantly increased cellular BH4 levels in MG-treated cells 
(Fig. 5-3C). Neither the BH4 control NH4 (100 µM) nor L-NAME (50 µM) alone significantly 
altered cellular BH4 and total biopterin levels (Fig. 5-3C). Similarly, MG-induced reduction of 
cellular BH4/total biopterin ratio was significantly attenuated by supplementation with BH4 or 
sepiapterin or by ONOO suppression but not by the BH4 control NH4 or by L-NAME alone (Fig. 
5-3D).  
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Figure 5-2 Methylglyoxal-induced eNOS monomerization in EA.hy926 ECs 
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Figure 5-2. Methylglyoxal-induced eNOS monomerization in EA.hy926 ECs. A and B. 
Original Western blots (A) and the respective densitometric analysis (B) of the relative abundance 
of eNOS dimers over eNOS monomers (relative to β-actin) in EA.hy296 ECs treated with different 
concentrations of MG (0 µM, circles; 50 µM, triangles; 100 µM, squares; and 200 µM, diamonds) 
for 0.5, 2, 4, and 8 h respectively. Data are arithmetic means ± SEM (A, representative of five 
experiments; B, n = 5). * indicates significant difference (p < 0.05) from the absence of MG 
(ANOVA). # indicates significant difference (p < 0.05) from time 0.5 h (ANOVA). 
C and D. Original Western blots (C) and the respective densitometric analysis (D) of the relative 
abundance of eNOS dimers over eNOS monomers (relative to β-actin) in EA.hy296 ECs incubated 
in the absence () or in the presence of MG (100 µM) for 8 h alone (+) or with 100 µM BH4, 100 
µM NH4, 20 µM sepiapterin or 50 µM L-NAME in the last 4 h of MG treatment or with 24-h pre-
treatment with 300 µM Tempol and 50 µM L-NAME (ONOO suppression). Data are arithmetic 
means ± SEM (C, representative of four experiments; D, n = 4). * indicates significant difference 
(p < 0.05) from the absence of MG (ANOVA). # indicates significant difference (p < 0.05) from 
MG treatment alone (ANOVA). 
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Figure 5-3. Effect of methylglyoxal on cellular biopterin levels in EA.hy926 ECs. A and B. 
Total cellular biopterin (pmol/mg protein; black bars; A) and BH4 (pmol/mg protein; white bars; 
A) and the respective BH4/total biopterin ratio (B) determined in EA.hy296 ECs treated with 
different concentrations of MG (0, 50, 100 and 200 µM) for 8 h. Data are arithmetic means ± SEM 
(n = 5). * indicates significant difference (p < 0.05) from the absence of MG (ANOVA). C and D. 
Total cellular biopterin (pmol/mg protein; black bars; C) and BH4 (pmol/mg protein; white bars; 
C) and the respective BH4/total biopterin ratio (D) determined in EA.hy296 ECs treated with MG 
(100 µM) for 8 h in the absence (Control) or in the presence of L-NAME (50 µM), BH4 (100 µM), 
NH4 (100 µM) or sepiapterin (20 µM) in the last 4 h of MG treatment or with 24-h pre-treatment 
with 300 µM Tempol and 50 µM L-NAME (ONOO suppression). Data are arithmetic means ± 
SEM (n = 5). * indicates significant difference (p < 0.05) from Control (ANOVA). 
Figure 5-3 Effect of methylglyoxal on cellular biopterin levels in EA.hy926 ECs 
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Uncoupling of eNOS is associated with enhanced cellular nitration of tyrosine [352]. In a further 
series of experiments we examined the abundance of 3NT in EA.hy926 cells treated with MG and 
the effect of biopterins, L-NAME or ONOO suppression after MG. As shown in Fig. 5-4, 
treatment of EA.hy926 cells with 100 µM of MG for 8 h significantly increased the expression of 
3NT, an effect that was significantly blunted by BH4 (100 µM, 4 h), sepiapterin (20 µM, 4 h) or 
ONOO suppression (300 µM Tempol and 50 µM L-NAME, 24 h) but not by the BH4 control 
NH4 (100 µM, 4 h) or L-NAME (50 µM, 4 h) suggesting that biopterin-sensitive eNOS uncoupling 
was triggered by MG (Fig. 5-4A and 5-4B). The effect of ONOO suppression on the reduction of 
3NT expression by the combination of Tempol (300 µM) and L-NAME (50 µM) was higher than 
the administration of Tempol (300 µM) alone (data not shown). 
 
 
To further unravel the modulation of eNOS functions by MG, we investigated the effect of 
biopterin supplementation, ONOO  suppression and NOS inhibition on eNOS phosphorylation 
(Ser-1177) associated with eNOS uncoupling. To this end, treatment of EA.hy926 cells with 100 
µM of MG for 8 h did not modify total eNOS but significantly decreased phosphorylation of eNOS 
(Ser-1177), an effect that was significantly blunted by BH4 (100 µM), sepiapterin (20 µM) or 
ONOO suppression but not by the BH4 control NH4 (100 µM) or L-NAME (50 µM) suggesting 
that both eNOS phosphorylation (Ser-1177) and eNOS uncoupling are closely linked to MG-
triggered endothelial dysfunction (Fig. 5-5A and 5-5B). 
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Figure 5-4. Effect of methylglyoxal on tyrosine nitration in EA.hy926 ECs. A and B. Original 
Western blots (A) and the respective densitometric analysis (B) of the relative abundance of 3-
nitrotyrosine (relative to β-actin) in EA.hy296 ECs incubated in the absence () or in the presence 
of MG (100 µM) for 8 h alone (+) or with 100 µM BH4, 100 µM NH4, 20 µM sepiapterin, or 50 
µM L-NAME in the last 4 h of MG treatment or with 24-h pre-treatment with 300 µM Tempol 
and 50 µM L-NAME (ONOO suppression). Data are arithmetic means ± SEM (A, representative 
of three experiments; B, n = 3). * indicates significant difference (p < 0.05) from the absence of 
MG (ANOVA). # indicates significant difference (p < 0.05) from MG treatment alone (ANOVA). 
 
 
 
Figure 5-4 Effect of methylglyoxal on tyrosine nitration in EA.hy926 ECs 
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Figure 5-5. Effect of methylglyoxal on eNOS phosphorylation in EA.hy926 ECs. A and B. 
Original Western blots (A) and the respective densitometric analysis (B) of the relative abundance 
of total eNOS protein (white bars; relative to β-actin) and Ser-1177 phospho-eNOS (black bars; 
relative to β-actin) in EA.hy296 ECs incubated in the absence () or in the presence of MG (100 
µM) for 8 h alone (+) or with 100 µM BH4, 100 µM NH4, 20 µM sepiapterin or 50 µM L-NAME 
in the last 4 h of MG treatment or with 24 h pre-treatment with 300 µM Tempol and 50 µM L-
NAME (ONOO suppression). Data are arithmetic means ± SEM (A, representative of three 
experiments; B, n = 3). * indicates significant difference (p < 0.05) from the absence of MG 
(ANOVA). # indicates significant difference (p < 0.05) from MG treatment alone (ANOVA). 
Figure 5-5 Effect of methylglyoxal on eNOS phosphorylation in EA.hy926 ECs 
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5.5 Discussion 
In this study we provide conclusive biological evidence that treatment of EA.hy926 ECs with MG 
triggers eNOS hypophosphorylation and eNOS uncoupling in vitro. We show that MG treatment 
enhances O2 generation and 3NT expression and decreases Ser-1177 phosphorylated eNOS, 
eNOS dimer/monomer ratio and cellular levels of BH4 and BH4/total biopterin ratio in ECs. 
Moreover, we demonstrate that pharmacological suppression of eNOS uncoupling by L-NAME, 
exogenous BH4 or sepiapterin administration, and ONOO suppression counteracted MG-induced 
eNOS uncoupling, 3NT upregulation and eNOS hypophosphorylation.  
 
Oxidative stress is a salient feature of the pathophysiology of diabetes. The glycolysis metabolite 
MG was previously shown to affect redox balance by stimulating ROS production and modulating 
the expression and functions of cytoprotective molecules such as glutathione [371], superoxide 
dismutase [174], glyoxalase [372] and H2S [373]. Increased NADPH oxidase-derived O2 reacts 
with eNOS-derived NO to generate ONOO which oxidizes BH4 to BH2. BH4 reduction has been 
implicated in the pathogenesis of a variety of conditions such as hyperphenylalaninemia [374], 
diabetes [375], ischemia-reperfusion injury [376], hypertension [377], Alzheimer disease and 
Parkinson’s disease [378], and many of these pathological conditions were shown to be 
ameliorated by exogenous BH4 [374-377] or sepiapterin [379-381] supplementation. BH4 is 
critical for the maintenance of eNOS dimers and is functionally related to S-glutathionylation, a 
powerful regulator of eNOS uncoupling [382]. Our data that MG-triggered O2 generation was 
inhibitable by L-NAME addition, BH4 or sepiapterin supplementation and ONOO suppression 
clearly suggest the presence and contribution of uncoupled eNOS to O2 generation in EC 
functions triggered by MG.  
 
Mounting evidence suggests that phosphorylation of the residue Ser-1177 of eNOS via AKT 
stimulates NO production [383]. The effects of eNOS phosphorylation on eNOS uncoupling and 
O2 production are not completely understood. Ser-1177 phosphorylation was shown to inhibit 
the Ca2+ sensitivity of eNOS and thus fosters Ca2+-independent O2 generation [384]. In this study 
we tested the effect of BH4 supplementation on the hitherto known reduction of eNOS 
phosphorylation triggered by MG [70]. Our data show that supplementation of either BH4 or 
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sepiapterin reversed MG-triggered reduction in Ser-1177 eNOS phosphorylation and enhanced 
eNOS uncoupling. Similar to BH4, other pharmacological agents such as nifedipine [385], 
nicorandil [386], and telmisartan [387] were shown to inhibit eNOS uncoupling and enhance 
eNOS phosphorylation and may, therefore, be beneficial in diabetic endothelial dysfunction. 
Furthermore, endogenous mediators such as C-reactive protein [388], IGF-1 [389], calcitriol [390], 
and 20-hydroxyeicosatetraenoic acid [391] were reported to modulate eNOS-associated functions. 
In this study we demonstrate for the first time the eNOS monomerization induced by the glycolysis 
metabolite MG and the effects of BH4 and sepiapterin supplementation on MG-modulated eNOS-
associated functions in ECs.  
 
Uncoupling of eNOS is characterized by augmented tyrosine nitration which strongly indicates 
ONOO-triggered cellular injury in diabetic hyperglycemia [392]. Increased placental protein 
tyrosine nitration was documented in diabetes patients [393] and, in animal models of diabetes, 
3NT was shown to be enhanced in the kidney [394] and in the ventricle and lens [395]. Similarly, 
3NT is upregulated in diabetic cardiomyopathy [396]. Our finding that BH4 but not NH4 
supplementation abrogated enhanced 3NT expression in MG-treated ECs supports the view that 
MG-induced depletion of eNOS factor BH4 is critical for MG-triggered eNOS uncoupling and 
endothelial dysfunction. Similar observations were also made in the diabetic heart subjected to 
ischemia-reperfusion injury [376], clearly indicating that exogenous BH4 supplementation may 
ameliorate diabetes-associated multi-organ pathologies.  
 
Conflicting reports on eNOS expression in diabetic endothelial dysfunction suggest the complexity 
of the signalling mechanisms associated with eNOS during hyperglycemia. Treatment of ECs with 
high concentrations of glucose was reported to have decreased eNOS protein expression in vitro 
[397]. It was also reported that the abundance of total and phosphorylated eNOS was reduced in 
internal mammary arteries of diabetes patients [398]. In old Zucker diabetic fatty rats, eNOS 
protein expression was demonstrated to be decreased [399]. On the contrary, in diabetic and 
apolipoprotein E-deficient mice, eNOS mRNA levels were augmented [400]. In a contrasting 
report, however, eNOS expression was shown to be unaltered in type 2 diabetic db/db mice [401]. 
Along those lines, the discordant effects of MG treatment on eNOS functions reported previously 
may, thus, not be unexpected [70, 361-363]. It is, however, intriguing to speculate that MG may 
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be one of the essential metabolites that triggers eNOS hypophosphorylation and uncoupling 
encountered in diabetes.  
 
5.6 Conclusions 
We conclude that the intermediate glycolysis metabolite MG is a powerful modulator of eNOS 
functions in vascular ECs in vitro. Administration of BH4 or its precursor sepiapterin or 
suppression of ONOO formation replenishes cellular BH4 levels, reverse hypophosphorylation of 
eNOS and ameliorates O2 generation, 3NT upregulation and eNOS monomerization that are 
associated with MG-triggered eNOS uncoupling in ECs. These pharmacological measures may 
indicate promising therapeutic benefits in MG-sensitive endothelial dysfunction in diabetes.  
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 CHAPTER 6 UNCOUPLING OF eNOS 
CONTRIBUTES TO REDOX-SENSITIVE LEUKOCYTE 
RECRUITMENT AND MICROVASCULAR LEAKAGE 
ELICITED BY METHYLGLYOXAL 
UNCOUPLING OF eNOS CONTRIBUTES TO REDOX-SENSITIVE 
LEUKOCYTE RECRUITMENT AND MICROVASCULAR LEAKAGE 
ELICITED BY METHYLGLYOXAL 
 
For the further exploration of the phenomena shown in Chapter 5, in this chapter, we demonstrate 
the role of eNOS-derived superoxide in MG-induced leukocyte recruitment. We show that 
blockade of eNOS-derived superoxide abrogated MG-induced microvascular hyperpermeability, 
as well as MG-elicited leukocyte adhesion and emigration. Together with Chapter 5, we unravel 
MG-induced eNOS uncoupling and eNOS-derived superoxide production as another mechanism 
involved in MG-elicited leukocyte recruitment. 
 
 
This chapter has been published as a research paper by Yang Su, Syed M. Qadri, Mokarram 
Hossain, Lingyun Wu and Lixin Liu in Biochemical Pharmacology 2013 Dec 15;86(12):1762-
1774. Contents of this chapter have been adapted / reproduced from the published article with 
permission from the journal Biochemical Pharmacology. In this study, Y.S. conducted all the 
experiments, acquired and analyzed all the data, and also participated in the design of the study 
and manuscript writing.  
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6.1 Abstract 
Elevated levels of the glycolysis metabolite methylglyoxal (MG) have been implicated in impaired 
leukocyte-endothelial interactions and vascular complications in diabetes, putative mechanisms of 
which remain elusive. Uncoupling of endothelial nitric oxide synthase (eNOS) was shown to be 
involved in endothelial dysfunction in diabetes. Whether MG contributes to these effects has not 
been elucidated. By using intravital microscopy in vivo, we demonstrate that MG-triggered 
reduction in leukocyte rolling velocity and increases in rolling flux, adhesion, emigration and 
microvascular permeability were significantly abated by scavenging reactive oxygen species 
(ROS). In murine cremaster muscle, MG treatment reduced tetrahydrobiopterin (BH4)/total 
biopterin ratio, increased arginase expression and stimulated ROS and superoxide production. The 
latter was significantly blunted by ROS scavengers Tempol (300 µM) or MnTBAP (300 µM), by 
BH4 supplementation (100 µM) or by NOS inhibitor NG-nitro-L-arginine methyl ester (L-NAME; 
20 µM). In these tissues and cultured murine and human primary ECs, MG increased eNOS 
monomerization and decreased BH4/total biopterin ratio, effects that were significantly mitigated 
by supplementation of BH4 or its precursor sepiapterin but not by L-NAME or tetrahydroneopterin, 
indicative of MG-triggered eNOS uncoupling. MG treatment further decreased the expression of 
guanosine triphosphate cyclohydrolase I in murine primary ECs. MG-induced leukocyte 
recruitment was significantly attenuated by supplementation of BH4 or sepiapterin or suppression 
of superoxide by L-NAME confirming the role of eNOS uncoupling in MG-elicited leukocyte 
recruitment. Together, our study uncovers eNOS uncoupling as a pivotal mechanism in MG-
induced oxidative stress, microvascular hyperpermeability and leukocyte recruitment in vivo. 
 
6.2 Introduction 
Inflammatory injury afflicting ECs contributes to the pathophysiology of multiple vascular 
diseases [402]. In diabetes, chronic hyperglycemia leads to endothelial dysfunction which fosters 
deranged microcirculation [342, 343]. The underlying mechanisms of impaired endothelial 
functions and innate immunity in diabetes are, however, not completely understood. Chronic 
hyperglycemia results in excessive levels of the cytotoxic metabolite methylglyoxal (MG) [115, 
403] which serves as a precursor to form advanced glycation end-products [404]. MG has been 
implicated in the pathogenesis of diabetes [134], neuronal injury [405] and vascular complications 
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[255, 344, 345]. MG-induced cytotoxicity encompasses both necrotic [346] and apoptotic cell 
death [345] leading to alterations of muti-organ homeostasis. Moreover, MG is a powerful 
modulator of mitochondrial functions, thus altering both cellular energy and redox balance [157].  
 
Inflammatory sequelae of pathological MG concentrations comprise functional modulation of 
various immune cells. MG was shown to stimulate cytokine induction [267], activate macrophages 
[294, 406], suppress T-cell-mediated immune functions [265] and modulate innate immunity by 
enhancing neutrophil apoptosis and Mac-1 expression [255]. Recently, MG was shown to 
stimulate leukocyte-endothelial interactions in an in vivo model of acute inflammation [75]. MG 
treatment up-regulated NF-κB-dependent expression of EC adhesion molecules, mitigated 
intravascular leukocyte rolling velocity, increased rolling flux and leukocyte adhesion and 
accelerated leukocyte emigration in mice [75]. In diabetic mice, deranged leukocyte-endothelial 
interactions were documented [253], but the contribution of the increased metabolite MG alone 
has not been completely characterized. Mechanisms that mediate pro-inflammatory effects of 
elevated MG, however, are largely unidentified. 
 
Nitric oxide (NO) homeostasis is an important determinant of physiological cardiovascular 
functions and its impairment is involved in the pathophysiology of diabetes [350]. Furthermore, 
NO is a powerful modulator of leukocyte-endothelial interactions [407, 408]. The constitutively 
expressed endothelial nitric oxide synthase (eNOS) catalyses the reaction for generation of NO 
and L-citrulline from L-arginine [409] and requires the presence of the essential cofactors 
tetrahydrobiopterin (BH4) and NADPH [347]. Deficiency of either L-arginine or BH4 reduces the 
generation of NO by eNOS which triggers superoxide (O2) production, a process termed eNOS 
uncoupling [351]. Ramifications of eNOS uncoupling include increased eNOS monomerization, 
tyrosine nitration and formation of dihydrobiopterin (BH2) [352, 410]. Guanosine triphosphate 
cyclohydrolase 1 (GTPCH1) is the rate limiting enzyme that regulates de novo BH4 synthesis 
whereas dihydrofolate reductase (DHFR) reduces BH2, thus, salvaging BH4 from BH2 [411]. 
eNOS uncoupling-derived O2 stimulates platelet aggregation [412] and increased monocyte 
adhesion to ECs [413], both effects favouring diabetic vasculopathy. Moreover, reactive oxygen 
species (ROS) are potent regulators of leukocyte-endothelial interactions [414-418]. In fact, redox 
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imbalance is known to participate in a multitude of pathophysiological processes, the mechanisms 
of which may in part be secondary to eNOS uncoupling. 
 
MG influences NO and redox balance and contributes to a myriad of hyperglycemia-induced 
alterations of cellular functions in vivo [115], mechanisms of which still remain elusive. eNOS 
uncoupling was previously shown to be responsible for endothelial dysfunction in diabetic mice 
[358] and essential in both endothelial dysfunction and peripheral neuropathy in Zucker diabetic 
fatty rats [359]. It was only recently shown that MG affects eNOS expression or functions. On the 
one hand, sensitivity of eNOS to MG was increased by the upregulation of eNOS transcription 
[361], while on the other hand, eNOS protein expression was decreased by MG [362, 363]. 
Discordantly, MG was reported to modulate eNOS activity without significantly affecting eNOS 
protein expression but by suppressing phosphorylation of eNOS at serine-1179 [70]. In 
preeclamptic vasculature, increased MG concentrations were shown to affect the expression of 
arginase and arginase-dependent lectin-like oxidized low-density lipoprotein receptor 1 (LOX-1) 
[364], that are associated with enhanced O2 production and uncoupling of eNOS [364, 410, 419]. 
Arginase is further inhibitable by the NOS inhibitor L-NAME [420]. Whether or not MG-sensitive 
eNOS regulation participates in leukocyte-endothelial interactions is not known.  
 
We hypothesized that MG-elicited leukocyte recruitment and microvascular hyperpermeability are 
mediated by modulation of eNOS expression or functions, a mechanism common to other MG-
induced pathologies [362, 364]. To reveal the presence of eNOS uncoupling and its role in MG-
triggered leukocyte recruitment and microvascular hyperpermeability, we quantified BH4 
reduction, eNOS monomerization, L-NAME inhibitable O2 production and used fluorescence 
imaging and real-time intravital microscopic analysis to study microvascular permeability changes 
and leukocyte-endothelial interactions induced by exogenous MG.  
 
6.3 Materials and Methods 
Mice 
Male C57BL/6 mice (Charles River, Saint-Constant, QC, Canada) between 8 and 12 wk-old and 
young C57BL/6 mice at 5 − 7 day-old were used in this study. This study was carried out with the 
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approval of animal protocols from the University Committee on Animal Care and Supply (UCACS; 
protocol permit # 20070028) at the University of Saskatchewan following the standards of the 
Canadian Association of Animal Care. All surgery was performed under ketamine/xylazine 
anesthesia, and all efforts were made to minimize animal suffering.  
 
Intravital microscopy 
Mice were anesthetised using an i.p. injection of 10 mg/kg xyalzine (Bayer, Toronto, ON, Canada) 
and 200 mg/kg ketamine hydrochloride (Rogar, Montreal, QC, Canada). The mouse cremaster 
muscle preparation was used to study dynamic leukocyte-endothelial interactions in 
microvasculature as described previously [114, 280]. The cremaster muscle was superfused with 
37C-warmed bicarbonate-buffered saline (pH 7.4; containing in mM 133.9 NaCl, 4.7 KCl, 1.2 
MgSO4 and 20 NaHCO3, all reagents purchased from Fisher Scientific, Toronto, ON, Canada). A 
BX61WI Olympus upright microscope with a LUCPLFLN 20× objective lens was connected to a 
3CCD color video camera (DXC-990, Sony) for bright-field intravital microscopy. Throughout 
the experiment, leukocyte behaviour and hemodynamic changes in the selected cremasteric 
postcapillary venule (25−40 μm diameter) were visualized, projected on a TV monitor and 
recorded at real time on a DVD recorder. The number of rolling, adherent, and emigrated 
leukocytes during offline playback analysis of the recorded video was determined in the 
cremasteric microvasculature as described previously [75, 114, 280]. MG (25 or 50 mg/kg b.w.; 
Sigma, Oakville, ON, Canada) dissolved in saline, was administered by an intrascrotal injection 
for 4 h before the cremaster muscle was exposed for intravital microscopy. Where indicated, the 
pharmacological agents used to modulate MG-induce leukocyte recruitment were dissolved in the 
bicarbonate-buffered saline and superfused for 2 h on the exposed cremaster muscle. Manganese 
(III) tetrakis (4-benzoic acid) porphyrin (MnTBAP, Santa Cruz, Dallas, TX, USA) or 1-oxyl-
2,2,6,6-tetramethyl-4-hydroxypiperidine (Tempol, Santa Cruz) was used to suppress ROS 
production. NOS inhibitor NG-nitro-L-arginine methyl ester (L-NAME, Sigma), was administered 
to inhibit uncoupled eNOS-derived O2− production [258, 421]. To maintain eNOS dimerization, 
the NOS cofactor 5,6,7,8-tetrahydroboipterin (BH4; Sigma) or the negative control, a pteridine 
analogue, 5,6,7,8-tetrahydroneopterin (NH4; Schircks laboratories, Switzerland) was freshly-
prepared and administered. NH4 has similar antioxidant effects as BH4 but, unlike BH4, is 
ineffective in restoring uncoupled eNOS [366]. BH4 availability may be compromised due to 
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oxidative transformation to 7,8-dihydrobiopterin (BH2) [257, 422]. Thus, BH4- or NH4-
containing superfusion buffer was replaced every 30 min by freshly prepared BH4 to maximize 
BH4 and minimize BH2 availability. Sepiapterin (50 μM; Cayman, Ann Arbor, MI, USA), a 
substrate for BH4 synthesis via the pterin salvage pathway, was used to increase BH4 levels. 
Sepiapterin functions as both a precursor as well as a by-product of BH4 synthesis and is also 
described as a BH4 analog [367].  
 
Measurement of microvascular permeability 
MG-triggered microvascular leakage was studied in postcapillary venules of the cremaster muscle 
as described previously [280, 423, 424]. Briefly, MG (100 µM) was superfused for 1 h over the 
exposed cremaster muscle and where indicated, BH4 (100 µM) or the ROS scavenger Tempol 
(300 µM) or MnTBAP (300 µM) was superfused for 30 min prior to and 1 h during MG 
superfusion.  FITC-labelled bovine serum albumin (BSA; Sigma) at 25 mg/kg b.w. was injected 
to the mice i.v. at the start of the experiment, and FITC-derived fluorescence (excitation at 495 nm, 
and emission at 525 nm) in the venule was detected using a monochrome deep-cooled CCD digital 
camera (Retiga SRV, QImaging, Surrey, BC, Canada) mounted on BX61WI Olympus upright 
microscope. The intensity of FITC-albumin-derived fluorescence within the lumen of the venule 
and in the adjacent perivascular tissue was recorded and analysed using METAMORPH software 
(MetaMorph®, Molecular Devices Inc., PA, USA). The index of vascular albumin leakage, 
permeability index, was determined in the same segment of the venule at different time points as 
shown previously [423, 424].  
 
Harvest of murine primary endothelial cells 
Primary murine ECs were isolated from the lungs or hearts of C57BL/6 mice (aged 57 days) 
according to a previously described protocol [280, 320]. Briefly, ECs were immuno-magnetically 
isolated utilizing anti-ICAM-2 (CD 102) antibody (clone 3C4; BD Pharmingen, Quebec City, QC, 
Canada), seeded in 35-mm laminin-coated petri dishes and cultured in microvascular EC culture 
medium (EBM-2) supplemented with EGM-2 MV bullet kit (Lonza, Mississauga, ON, Canada). 
After the cells reached confluency, they were passaged on laminin-coated 24-well plates and 
treated with MG and other pharmacological agents at the indicated concentrations.  
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Culture of HUVECs 
Human umbilical vein ECs (HUVECs) were obtained from American Type Culture Collection 
(ATCC) and cultured as described previously [70]. Briefly, cells were cultured in Kaighns F12K 
medium (containing 10% FBS, 0.1 mg/ml heparin and 0.03–0.05 mg/ml EC growth supplement; 
Sigma), grown to confluency and treated with MG and other pharmacological agents at the 
indicated concentrations. 
 
Immunoblotting 
For the detection of eNOS dimers and monomers, immunoblotting was performed in the non-
reduced state as described previously [258]. Briefly, after the indicated treatment, cremaster 
muscles were excised and snapped frozen in liquid nitrogen. The tissue was homogenized and 
lysed in lysis buffer (pH 8.0; containing 50 mM Tris-HCl, 150 mM NaCl, 1% NP-40, 0.5% sodium 
deoxycholate, 0.1% SDS and protease and phosphatase inhibitor cocktails purchased from Fisher 
Scientific). The same lysis buffer was used to lyse murine primary ECs. Proteins (50 µg) were 
solubilized in Laemmli sample buffer without β-mercaptoethanol at 37°C for 5 min and resolved 
by 7% SDS-PAGE with the buffer tank placed on ice during electrophoresis. For immunoblotting, 
proteins were transferred onto a nitrocellulose membrane and blocked with 5% non-fat milk in 
TBST at room temperature for 1 h. The blots were then probed by 1:1000 dilution of primary anti-
eNOS antibody (clone M221; Abcam), anti-GTPCH1 (Santa Cruz), anti-DHFR (Santa Cruz), anti-
LOX-1 (Abcam), anti-arginase II (Santa Cruz) or mouse anti-β-actin antibody (Santa Cruz) and 
the secondary horseradish peroxidase-conjugated antibody (Santa Cruz). Antibody binding was 
detected with the ECL detection reagent (GE Healthcare, Baie d’Urfe, QC, Canada). As eNOS 
monomers and dimers were detected in non-reduced conditions, equal volumes of lysates in 
reduced conditions were run in separate gels to quantify β-actin expression. Densitometric 
quantification of the detected bands was performed using Gene Snap Software (Syngene, Frederick, 
MD, USA).  
 
Determination of ROS generation in whole cremaster muscle 
We measured the levels of ROS production in cremaster muscles as previously described [373]. 
Following the indicated treatments, the cremaster muscle was loaded (30 min, 37°C in the dark) 
with a membrane-permeable and non-fluorescent 2',7'-dichlorodihydrofluorescein diacetate 
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(H2DCFDA; 30 μM, Invitrogen, Burlington, ON, Canada) which oxidizes to fluorescent 2',7'-
dichlorofluorescein (DCF) in the presence of ROS. To remove excess probe, the muscle was 
washed with bicarbonate-buffered saline and fluorescence intensity in the excised muscle was 
excited at 495 nm and measured at 527 nm emission wavelengths. Data are collected as 
fluorescence intensity per gram tissue and normalized to the control.  
 
Determination of O2
− production in whole cremaster muscle 
Levels of O2 in excised cremaster muscles after various treatments were determined using a 
commercial superoxide detection kit (Enzo, Brockville, ON, Canada) according to the 
manufacturer’s instructions. After staining with the membrane-permeable and nonfluorescent O2 
detection probe (10 μM; 30 min, 37°C in the dark) and removal of excess probe by washing with 
bicarbonate-buffered saline, the muscle was excised and fluorescence detected using excitation 
and emission wavelengths of 544 nm and 590 nm respectively. Data are collected as fluorescence 
intensity per gram tissue and normalized to the control.  
 
Confocal microscopy 
For estimation of O2 generation in MG-treated HUVECs, dihydroethidium (DHE; Cayman) 
fluorescence staining was used as described previously [425, 426]. After the indicated treatments, 
HUVECs were incubated with DHE (5 µM) for 30 min. The cells were then washed three times 
and images were obtained using a laser scanning confocal microscope (ConfoCor2/LSM510, Zeiss, 
Thornwood, NY, USA) with fluorescence (showing oxidized DHE) detected using excitation and 
emission wavelengths of 517 nm and 610 nm respectively.  
 
Analysis of biopterin levels by HPLC 
Measurement of BH4 and total biopterins was performed by fluorometric HPLC analysis as 
described previously with slight modifications [258, 259]. After indicated treatments, cremaster 
muscles were homogenized in 250 μL lysis buffer (pH 7.4; containing 50 mM Tris-HCl, 1 mM 
DTT and 1 mM EDTA) and 0.1 μM neopterin (Sigma) as an internal recovery standard. The 
samples were deproteinated with 10% 1:1 mixture of 1.5 M HClO4 and 2 M H3PO4 and centrifuged 
(12,000 × g for 10 min).  The supernatant was split into portions and subjected to acid-and alkali-
oxidation respectively. To determine total biopterins (BH4, BH2 and biopterin) by acid-oxidation, 
117 
 
10 μl iodine solution (1% iodine in 2% KI solution) was added into every 90 μl supernatants and 
for BH2 and biopterin estimation by alkali-oxidation, 10 μl 1 M NaOH and 10 μl iodine solution 
were added to 80 μl supernatant. Following incubation (1 h, room temperature in the dark), the 
alkali-oxidation samples were acidified with 1 M H3PO4 and iodine in both acid- and alkali-
oxidation samples was reduced using 5% ascorbic acid (Sigma) and the samples were centrifuged 
(12,000 × g for 10 min). The supernatant was collected for HPLC analysis using a Hitachi D-7000 
HPLC system (Hitachi, Mississauga, ON, Canada) via Symmetry C18 reverse-phase column with 
a methanol-water (1.5:98.5, v/v) mobile phase running at 0.5 mL/min. Fluorescence was detected 
at excitation and emission wavelengths of 348 nm and 444 nm respectively. The level of BH4 was 
calculated by subtracting BH2 and biopterin from total biopterins and expressed as pmol per mg 
protein. The biopterin levels in NH4 treated cells were calculated without adding neopterins. 
 
Statistical analysis 
Data are expressed as arithmetic means ± SEM from at least three independent experiments. 
Statistical analysis was made using Student t test or one way analysis of variance (ANOVA) with 
Tukey’s post-hoc comparison test. n denotes the number of different mice and different batches of 
cremasteric tissues or ECs studied in each group. Values of p < 0.05 were considered statistically 
significant. 
 
6.4 Results 
To address the effects of MG treatment on leukocyte-endothelial interactions we used intravital 
microscopy to analyze real-time dynamics of leukocyte recruitment in post-capillary venules of 
the cremaster muscle. The captured intravital images of cremasteric microcirculation depicted in 
Fig. 6-1A show the number of adherent and emigrated cells was increased after treatment with 
MG (intrascrotal injection of 25 and 50 mg/kg b.w. for 6 h), consistent with previous reports [75]. 
To elucidate the mechanisms underlying MG-induced leukocyte recruitment, we examined the 
effects of ROS scavengers on different parameters of dynamic leukocyte recruitment. As shown 
in Fig. 6-1B, MG (25 and 50 mg/kg b.w. for 6 h) increased rolling flux, an effect that was 
significantly mitigated by superfusion of MG-stimulated cremaster muscle with either Tempol 
(300 µM) or MnTBAP (300 µM). Similarly, Tempol or MnTBAP significantly ameliorated the 
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reduced rolling velocity triggered by MG (25 and 50 mg/kg b.w.; Fig. 6-1C). MG-triggered 
reduction of rolling velocity fosters leukocyte adhesion to vascular endothelium and subsequent 
emigration of leukocytes in the extravascular tissue. As a consequence of pharmacological ROS 
scavenging, either Tempol or MnTBAP significantly attenuated the number of adherent and 
emigrated cells stimulated by MG-induced ROS generation (Fig. 6-1D and 6-1E). These results 
indicate that an increase of MG in local tissue triggers ROS-sensitive leukocyte recruitment.  
 
To unravel the redox mechanisms underlying MG-elicited leukocyte recruitment, we measured 
total ROS and O2 generation in MG-treated muscle tissue. We found that treatment of cremaster 
muscle with MG for 6 h significantly increased both O2 and total ROS levels in a dose-dependent 
manner, an effect reaching statistical significance at 5 mg/kg b.w. dose of MG (Fig. 6-2A). We 
further investigated the effect of ROS scavengers on O2 and total ROS production in MG-treated 
whole cremaster muscle. As depicted in Fig. 6-2B, in the absence of MG, Tempol (300 µ M) or 
MnTBAP (300 µM) did not modify tissue O2 and total ROS levels. However, treatment of the 
cremaster muscle with MG (25 mg/kg b.w. for 6 h) significantly increased O2 and total ROS 
levels, effects that were significantly blunted by either Tempol or MnTBAP superfusion, 
suggesting that pharmacological ROS scavenging ameliorates the oxidative stress triggered by MG 
in the cremaster muscle (Fig. 6-2B). To further explore the mechanism of MG-elicited oxidative 
stress, we tested the effects of NOS essential cofactor BH4 and its control NH4 [366]. Fig. 6-2C 
shows that when perfused at the same concentration for 2 h, NH4 did not significantly reduce MG-
induced O2 production whereas BH4 significantly decreased the O2 amount in MG-treated 
muscle. Because BH4 is an essential cofactor for all NOS and NH4 is not, the different O2-
dependent fluorescence after BH4 and NH4 treatment suggests the involvement of NOS in the 
generation of O2 in MG-treated tissue. Fig. 6-2D, demonstrates that superfusion of cremaster 
muscle with L-NAME (20 µM, 2 h) significantly diminished O2 production elicited by MG (50 
mg/kg b.w.). The reduction of O2 in MG-treated muscle by BH4 supplementation and L-NAME 
treatment indicates that there was an L-NAME-inhibitable O2 production by NOS after MG 
treatment in vivo. Together, these results suggest that, after MG treatment, there was possibly 
uncoupling of NOS in the muscle tissue that was partly responsible for the O2 generation and 
was inhibited by the addition of BH4 or by the NOS inhibitor L-NAME. Additionally, we tested 
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the effects of BH4 supplementation or L-NAME treatment on MG-induced O2 production in 
HUVECs. As shown in Fig. 6-2E, DHE-dependent fluorescence indicating O2 production was 
higher after treatment with MG and was blunted in the presence of either BH4 or L-NAME 
suggesting similar sensitivity of HUVECs to MG.   
 
On the basis of these results and to explore whether there is eNOS uncoupling in tissue after MG 
treatment, we determined whether MG affects tissue levels of BH4 and whether exogenous 
supplementation of BH4 indeed replenishes tissue BH4 in our in vivo model. We found that MG 
significantly and dose-dependently decreased total biopterin content, BH4 content (Fig. 6-3A) and 
more importantly, the ratio of BH4/total biopterin (Fig. 6-3B). Moreover, exogenous 
supplementation of BH4 or its precursor sepiapterin abrogated MG-induced reduction of BH4 
levels (Fig. 6-3C) and BH4/total biopterin ratio (Fig. 6-3D) in tissue; whereas NH4, the BH4 
control, and L-NAME, the NOS inhibitor, did not significantly alter MG-triggered decreased tissue 
BH4/total biopterin ratio (Fig. 6-3D). This suggests that exogenous supplementation of BH4 or its 
precursor sepiapterin efficiently replenishes tissue BH4 levels after MG treatment. To unravel the 
mechanisms of decreased bioavailability of BH4 we tested the expression of the enzymes GTPCH1 
and DHFR in tissue after MG treatment. As depicted in Fig. 6-3E and 6-3F, MG significantly 
decreased GTPCH1 but not DHFR expression in tissue indicating that MG treatment affects de 
novo synthesis of BH4 but may not affect the reduction of BH2 to BH4.  
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Figure 6-1 Methylglyoxal-elicited redox-sensitive leukocyte recruitment 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6-1. Methylglyoxal-elicited redox-sensitive leukocyte recruitment. A. Representative 
images captured from intravital video microscopy showing a postcapillary venule with adherent 
leukocytes and the surrounding cremasteric tissue with emigrated leukocytes in the absence (MG 
0 mg/kg b.w.; left panel) or in the presence of MG (25 mg/kg b.w., middle panel and 50 mg/kg 
b.w., right panel, after 6 h intrascrotal MG injection). The images in the lower panels are amplified 
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areas (with dotted line) from the corresponding images in the upper panels showing the adherent 
(white arrows) and emigrated (black arrows) leukocytes. B – D. The leukocyte rolling flux (B, 
cells/min), leukocyte rolling velocity (C, μm/sec), and the number of adherent (D, cells/100-μm 
venule) and emigrated (E, cells/443×286 μm2 field) leukocytes determined after an intrascrotal 
injection of saline (0 mg/kg b.w. MG) or MG (25 mg/kg b.w. and 50 mg/kg b.w.) for 6 h with the 
last 2-h superfusion with bicarbonate buffered-saline (Control; black bars), MnTBAP (300 µM; 
white bars) or Tempol (300 µM; hatched bars). Data are arithmetic means ± SEM (n = 5). * 
indicates significant difference (p < 0.05) from MG treatment alone (ANOVA). 
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Figure 6-2 Methylglyoxal-triggered oxidative stress 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6-2. Methylglyoxal-triggered oxidative stress. A. The total ROS (white bars) and O2•– 
(back bars) generation determined in whole cremaster muscle at 6-h after intrascrotal injection of 
MG at different doses (0, 1, 5, 25 and 50 mg/kg b.w.) with the last 2-h superfusion with bicarbonate 
buffered-saline. Data are arithmetic means ± SEM (n = 5). * indicates significant difference (p < 
0.05) from the absence of MG (0 mg/kg b.w.; ANOVA). B. The total ROS (white bars) and O2•– 
(back bars) generation determined in whole cremaster muscle after an intrascrotal injection of 
saline or MG (25 mg/kg b.w.) for 6 h with the last 2-h superfusion of the cremaster muscle with 
bicarbonate buffered-saline, MnTBAP (300 µM) or Tempol (300 µM). Data are arithmetic means 
± SEM (n = 5). # indicates significant difference (p < 0.05) from the absence of MG (ANOVA). * 
indicates significant difference (p < 0.05) from MG treatment alone (ANOVA). C and D. The total 
O2•– generation determined in whole cremaster muscle after an intrascrotal injection of saline 
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(Control; white bar) or MG (50 mg/kg b.w.; black bars) for 6 h with the last 2-h superfusion of the 
cremaster muscle with bicarbonate buffered-saline (MG), BH4 (100 µM, C), NH4 (100 µM, C) or 
L-NAME (20 µM, D). Data are arithmetic means ± SEM (n = 5, C and D). * indicates significant 
difference (p < 0.05) from MG treatment alone (ANOVA). # indicates significant difference (p < 
0.05) from Control (ANOVA). E. Representative laser confocal micrographs (from three 
independent experiments) of DHE-stained HUVECs incubated in the absence (Control) or in the 
presence of MG (100 µM) for 6 h with the last 2-h treatment with phosphate-buffered saline (MG), 
L-NAME (20 µM; MG + L-NAME) or BH4 (100 µM; MG + BH4). 
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Figure 6-3. Sensitivity of BH4 metabolism to methylglyoxal. A and B. Effect of an intrascrotal 
injection of MG (0, 25 and 50 mg/kg b.w.) on total cellular biopterin (pmol/mg protein; black bars; 
A) and BH4 (pmol/mg protein; white bars; A) and the respective BH4/total biopterin ratio (B) in 
Figure 6-3 Sensitivity of BH4 metabolism to methylglyoxal 
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whole cremaster muscle determined at 6 h after an intrascrotal injection of saline (Control) or MG 
(25 mg/kg b.w., MG 25 and 50 mg/kg b.w., MG 50) with the last 2-h superfusion with bicarbonate 
buffered-saline. Data are arithmetic means ± SEM (n = 5). * indicates significant difference (p < 
0.05) from the Control (ANOVA). C and D. Effect of addition of BH4, NH4, L-NAME or 
sepiapterin on total cellular biopterin (pmol/mg protein; black bars; C) and BH4 (pmol/mg protein; 
white bars; C) and the respective BH4/total biopterin ratio (D) in whole cremaster muscle 
determined at 6 h after an intrascrotal injection of saline or MG (25 mg/kg b.w., MG 25) with the 
last 2-h superfusion with control saline, BH4 (100 µM), NH4 (100 µM), L-NAME (20 µM) or 
sepiapterin (50 µM). Data are arithmetic means ± SEM (n = 5). * indicates significant difference 
(p < 0.05) from the saline-control (ANOVA). # indicates significant difference (p < 0.05) from 
MG treatment alone (ANOVA). E and F. Original Western blots (E) and the respective 
densitometric analysis (F) of the abundance of GTPCH1 (black bars) and DHFR (white bars) 
relative to β-actin determined in murine primary ECs in the absence (Control) or in the presence 
of MG (100 µM; MG) for 6 h. Data are arithmetic means ± SEM (E, representative of three 
experiments; F, n = 3). * indicates significant difference (p < 0.05) from the Control (ANOVA). 
 
 
Elevated MG levels were previously shown to affect arginase and arginase-dependent LOX-1 
expression which are associated with O2 production [364]. As depicted in Fig. 6-4, expression of 
arginase was significantly enhanced in whole cremaster muscle after an intrascrotal injection with 
MG (50 mg/kg b.w. for 6 h) indicating that MG induces the depletion of the substrate L-arginine 
via increased arginase expression and may thus foster enhanced eNOS uncoupling. MG further 
increased arginase-dependent LOX-1 expression in whole cremaster muscle (data not shown).  
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Figure 6-4. Methylglyoxal-sensitive arginase expression in whole cremaster muscle. Original 
Western blots (A) and the respective densitometric analysis (B) of the relative abundance of 
arginase II (relative to β-actin) in whole cremaster muscle determined at 6 h after an intrascrotal 
injection of saline (Control; white bar) or MG (25 mg/kg b.w., MG; black bar) with the last 2-h 
superfusion with bicarbonate buffered-saline. Data are arithmetic means ± SEM (A, representative 
of four experiments; B, n = 4). * indicates significant difference (p < 0.05) from the Control 
(Student t test). 
 
 
Further, we examined the effect of MG on eNOS monomerization in whole cremaster tissue and 
in isolated primary ECs. As shown in Fig. 6-5A and 6-5B, 6-h treatment of cremaster muscle with 
MG significantly decreased the abundance of eNOS dimers and elevated eNOS monomers and 
increased eNOS monomer/dimer ratio in a dose-dependent manner. To further assess the 
mechanisms regulating eNOS uncoupling by MG, we explored the effects of BH4 supplementation 
and NOS inhibition on eNOS monomerization. As illustrated in Fig. 6-5C and 6-5D, treatment of 
cremaster muscle with MG (25 mg/kg b.w.) for 6 h significantly increased eNOS monomer/dimer 
ratio. Superfusion of BH4 (100 µM, for 2 h) after 4-h MG injection completely reversed the 
increase in eNOS monomer/dimer ratio induced by MG. However, superfusion of the cremaster 
muscle with neither the BH4 control NH4 (100 µM) nor the NOS inhibitor L-NAME (20 µM) 
significantly modified eNOS monomer/dimer ratio, indicating that BH4 addition dissipates the 
increased monomer/dimer ratio induced by MG and suggesting BH4 being the critical NOS 
cofactor during eNOS uncoupling (Fig. 6-5C and 6-5D). To confirm the effects of BH4 
Figure 6-4 Methylglyoxal-sensitive arginase expression in whole cremaster 
muscle 
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supplementation on MG-triggered eNOS uncoupling, we further tested the effects of the BH4 
precursor sepiapterin. Similar to BH4, superfusion with sepiapterin (50 µM, 2 h) significantly 
counteracted the increase in eNOS monomer/dimer ratio elicited by MG (Fig. 6-5E and 6-5F). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6-5 Methylglyoxal-sensitive eNOS monomerization in whole cremaster muscle 
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Figure 6-5. Methylglyoxal-sensitive eNOS monomerization in whole cremaster muscle. A and 
B. Original Western blots (A) and the respective densitometric analysis (B) of the relative 
abundance of eNOS monomers over eNOS dimers (relative to β-actin) in whole cremaster muscle 
determined at 6 h after an intrascrotal injection of saline (Control; white bar) or MG (25 mg/kg 
b.w., MG 25 and 50 mg/kg b.w., MG 50; black bars) with the last 2-h superfusion with bicarbonate 
buffered-saline. Data are arithmetic means ± SEM (A, representative of four experiments; B, n = 
4). * indicates significant difference (p < 0.05) from the Control (ANOVA). C – F. Original 
Western blots (C and E) and the respective densitometric analysis (D and F) of the relative 
abundance of eNOS monomers over eNOS dimers (relative to β-actin) determined in whole 
cremaster muscle after an intrascrotal injection of saline (Control; white bar) or MG (25 mg/kg 
b.w., MG 25; black bars) for 6 h with the last 2-h superfusion with bicarbonate buffered-saline 
(Control or MG 25), BH4 (100 µM; MG 25 + BH4), NH4 (100 µM; MG 25 + NH4), L-NAME 
(20 µM; MG 25 + L-NAME) or sepiapterin (50 µM; MG 25 + sepiapterin; in E and F). Data are 
arithmetic means ± SEM (C and E, representative of four experiments; D and F, n = 4). * indicates 
significant difference (p < 0.05) from Control (ANOVA). # indicates significant difference (p < 
0.05) from MG treatment alone (ANOVA). 
 
 
To characterize the specificity of MG-elicited eNOS uncoupling in primary vascular ECs, we 
cultured and treated HUVECs or murine primary ECs with MG (100 µM) in the presence or 
absence of BH4 (100 µM) or L-NAME (20 µM). L-NAME did not change MG-induced eNOS 
monomerization in either type of ECs (Fig. 6-6). Similar to its effects on whole cremaster muscle, 
BH4 treatment abolished the increase in eNOS monomer/dimer ratio induced by MG (Fig. 6-6) 
indicating that MG-induced eNOS uncoupling is specific to both murine and human ECs and, thus, 
ruling out the possibility of indirect effects of BH4 supplementation in vivo.  
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Figure 6-6. Methylglyoxal-sensitive eNOS monomerization in vascular ECs. Original Western 
blots (A and C) and the respective densitometric analysis (B and D) of the relative abundance of 
eNOS monomers over eNOS dimers (relative to β-actin) in murine primary ECs (A and B) and in 
HUVECs (C and D) determined in the absence (Control; white bar) or in the presence of MG (100 
µM; black bars) for 6 h with the last 2-h treatment with phosphate-buffered saline (MG), BH4 (100 
µM; MG + BH4) or L-NAME (20 µM; MG + L-NAME). Data are arithmetic means ± SEM (A 
and C, representative of three experiments; B and D, n = 3). * indicates significant difference (p < 
0.05) from the Control (ANOVA). # indicates significant difference (p < 0.05) from MG treatment 
alone (ANOVA). 
Figure 6-6 Methylglyoxal-sensitive eNOS monomerization in vascular ECs 
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To determine whether MG-induced redox imbalance via enhanced eNOS uncoupling is relevant 
for increased microvascular permeability during leukocyte recruitment, we measured the changes 
of permeability in cremasteric postcapillary venule after MG treatment. As illustrated in Fig. 6-7A 
and 7B, superfusion of MG (100 µM, 1 h) on the cremaster muscle time-dependently increased 
microvascular permeability, an effect that was significantly inhibited by co-superfusion with the 
ROS scavengers Tempol (300 µM) and MnTBAP (300 µM) 30 min prior to and 1 h following 
superfusion with MG. To detect the involvement of eNOS uncoupling in permeability changes, 
we tested whether or not the NOS cofactor BH4 affects MG-induced hyperpermeability. To this 
end, superfusion of BH4 (100 µM) significantly abated MG-induced increment of microvascular 
permeability (Fig. 6-7A and 6-7B), an effect clearly highlighting the role of eNOS uncoupling as 
an essential regulatory mechanism of endothelial barrier impairment sensitive to MG treatment.  
 
Further experiments sought to elucidate the involvement of eNOS uncoupling-derived O2 in MG-
induced leukocyte recruitment by investigating the effects of L-NAME which modulates O2 
production as shown previously [258, 421] and in Fig. 6-2D in this study. As a result, superfusion 
of cremaster muscle with L-NAME (20 µM, for 2 h) following 4 h of MG treatment (50 mg/kg 
b.w.) tended to decrease enhanced leukocyte rolling flux triggered by MG, an effect, however, not 
reaching statistical significance (Fig. 6-8A). In the absence of MG, L-NAME alone did not 
significantly alter rolling flux (Fig. 6-8A). Analysis of rolling velocity revealed that MG-induced 
reduction in leukocyte rolling velocity was significantly blunted by L-NAME, an effect which 
reached statistical significance at 5.5–6 h after MG treatment, whereas in the absence of MG, L-
NAME alone did not significantly modify rolling velocity (Fig. 6-8B). As is expected and due to 
its effect in suppressing NO production, L-NAME alone slightly but significantly enhanced both 
adhesion and emigration, an effect statistically significant at 5 – 6 h for adhesion and at 5.5 h for 
emigration after normal saline treatment (Fig. 6-8C and 6-8D). Next, we determined the effect of 
L-NAME treatment on the increased number of adherent and emigrated cells elicited by MG. As 
illustrated in Fig. 6-8C and 6-8D, L-NAME significantly mitigated MG-induced leukocyte 
adhesion and emigration, an effect reaching statistical significance at 5 – 6 h after MG injection. 
Because MG-elicited leukocyte recruitment is dependent on ROS production (Fig. 6-1) and 
inhibitable by L-NAME (Fig. 6-8), our results suggest that eNOS uncoupling is important in MG-
induced leukocyte recruitment.  
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Figure 6-7. Methylglyoxal-induced redox-sensitive and BH4-inhibitable microvascular 
hyperpermeability. A. Representative fluorescence intravital microscopy images of cremasteric 
postcapillary venules after i.v. infusion of FITC-labelled BSA (25 mg/kg b.w.) showing leakage 
of fluorescent BSA before (0 min; upper panels) and 60 min after superfusion (lower panels) with 
buffered-saline (Control) or MG (100 µM) without (MG) or with Tempol (300 µM; MG + Tempol), 
MnTBAP (300 µM; MG + MnTBAP) or BH4 (100 µM; MG + BH4). Arrow indicates the venule 
observed for permeability index measurements. B. The permeability index in the cremasteric 
postcapillary venules following 1-h superfusion of bicarbonate-buffered saline (Control; white 
circles) or 100 µM MG in the absence (black cricles) or presence of Tempol (300 µM; white 
squares), MnTBAP (300 µM; black squares) or BH4 (100 µM; white triangles) 30 min prior to 
and during 1-h MG superfusion. Data are arithmetic means ± SEM (n = 4).  * indicates significant 
difference (p < 0.05) from MG alone (ANOVA). 
Figure 6-7 Methylglyoxal-induced redox-sensitive and BH4-inhibitable microvascular hyperpermeability 
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Figure 6-8. Effect of L-NAME on methylglyoxal-induced leukocyte recruitment. The 
leukocyte rolling flux (A, cells/min), leukocyte rolling velocity (B, μm/sec), the number of 
adherent (C, cells/100-μm venule) and emigrated (D, cells/443×286 μm2 field) leukocytes 
determined in cremasteric venules after intrascrotal injection of saline for 6 h with the last 2-h 
superfusion with control saline (Control; white circles) or L-NAME (20 μM; black squares), or 
after an intrascrotal injection of MG (50 mg/kg b.w.) for 6 h with the last 2-h superfusion with 
bicarbonate buffered-saline (MG; black diamonds) or L-NAME (MG + L-NAME; 20 μM; white 
triangles). Data are arithmetic means ± SEM (n = 5). * indicates significant difference (p < 0.05) 
from MG treatment alone (ANOVA). # indicates significant difference (p < 0.05) from control 
saline (ANOVA). 
Figure 6-8 Effect of L-NAME on methylglyoxal-induced leukocyte recruitment 
133 
 
To confirm the role of eNOS uncoupling on MG-induced leukocyte-endothelial interactions, 
additional series of experiments were performed to examine the effect of supplementation of NOS 
cofactor BH4. As a result, superfusion of BH4 (100 µM), but not the analog NH4 (100 µM), 
significantly blunted MG-stimulated increases in leukocyte rolling flux (Fig. 6-9A). MG-induced 
reduction in leukocyte rolling velocity was significantly increased in the presence of BH4 but not 
NH4 (Fig. 6-9B). Moreover, analysis of MG-triggered leukocyte adhesion and emigration revealed 
that BH4, but not NH4, significantly reduced the number of adherent and emigrated leukocytes 
elicited by MG, effects statistically significant after 4.5 h (adhesion) and 5 h (emigration) 
following MG treatment respectively (Fig. 6-9C and 6-9D). To further elucidate the robust effects 
of BH4 on leukocyte adhesion and emigration, we tested the effects of addition of sepiapterin, a 
precursor of BH4 synthesis. As shown in Fig. 6-9E and 6-9F, either BH4 (100 µM) or sepiapterin 
(50 µM) superfusion for 2 h significantly attenuated adhesion and emigration after 4-h MG (25 
mg/kg b.w.) administration. Remarkably, the inhibitory potency of both BH4 and sepiapterin on 
MG-induced leukocyte recruitment is similar, suggesting that BH4 depletion fosters leukocyte 
recruitment as a result of enhanced eNOS uncoupling following MG treatment.  
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Figure 6-9. Effect of exogenous biopterins on methylglyoxal-induced leukocyte recruitment. 
A – D. Leukocyte rolling flux (A, cells/min), rolling velocity (B, μm/sec), the number of adherent 
(C, cells/100-μm venule) and emigrated (D, cells/443×286 μm2 field) leukocytes determined in 
cremaster venules after an intrascrotal injection of saline for 6 h with the last 2-h superfusion with 
control saline (Control; white squares), or after an intrascrotal injection of MG (50 mg/kg b.w.) 
with the last 2-h superfusion with bicarbonate buffered-saline (MG; black diamonds), BH4 (MG 
+ BH4; 100 μM; black triangles) or NH4 (MG + NH4; 100 μM; white triangles). Data are 
arithmetic means ± SEM (n = 5). * indicates significant difference (p < 0.05) from MG treatment 
alone (ANOVA). E and F. The number of adherent (E, cells/100-μm venule) and emigrated (F, 
cells/443×286 μm2 field) leukocytes determined in cremasteric venules at 6 h after an intrascrotal 
injection of MG (25 mg/kg b.w.) with the last 2-h superfusion with bicarbonate buffered-saline 
(MG 25), BH4 (MG 25 + BH4; 100 μM) or sepiapterin (MG 25 + sepiapterin; 50 μM). Data are 
arithmetic means ± SEM (n = 4). * indicates significant difference (p < 0.05) from MG treatment 
alone (ANOVA). 
Figure 6-9 Effect of exogenous biopterins on methylglyoxal-induced leukocyte recruitment 
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6.5 Discussion 
The present study reveals that oxidative stress plays a key role in MG-induced leukocyte 
recruitment, eNOS uncoupling is important for MG-triggered ROS production in vivo and the O2 
produced by uncoupled eNOS contributes to redox-sensitive leukocyte recruitment elicited by MG. 
MG stimulates dose-dependent monomerization of eNOS, depletion of the NOS cofactor BH4 and 
generation of ROS and L-NAME-inhibitable O2, effects that indicate eNOS uncoupling 
contributing to the increased leukocyte-endothelial interactions and microvascular 
hyperpermeability. We provide biological evidence that pharmacologically scavenging ROS, 
inhibition of NOS, replenishment of the NOS cofactor BH4 or addition of BH4 precursor 
sepiapterin ameliorates MG-induced leukocyte recruitment (Figure 6-10). Although the 
concentrations of MG used in this study are higher than those detected in diabetic plasma [427] 
and tissue [136], they currently serve as an optimal model to elucidate mechanisms involved in 
pathological changes in animal models of diabetes [187], and in acute MG-induced leukocyte-
endothelial interactions in vivo [75]. To our knowledge, the role of eNOS uncoupling in MG-
induced leukocyte trafficking has never been studied in vivo. 
 
 
 
 
 
 
 
 
Figure 6-10. Schematic diagram of MG-induced eNOS uncoupling in ECs. 
 
The consequence of the unequivocal link between enhanced ROS generation and MG metabolism 
is reflected by impaired cellular functions in diabetes. We observed that 16 – 18% of MG-triggered 
O2 production was inhibitable by either BH4 or L-NAME suggesting that previously identified 
sources such as NADPH oxidase and mitochondrial enzymes are pivotal in MG-elicited O2 
production in addition to uncoupled eNOS [115]. MG has been shown to impair redox balance 
Figure 6-10 Schematic diagram of MG-induced eNOS uncoupling in ECs 
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[428] by not only stimulating ROS production but also by modulating the availability and/or 
functions of cytoprotective molecules such as glutathione [371], superoxide dismutase [174], 
glyoxalase [372] and H2S [373]. Whether the increased ROS generation is required for MG-
elicited leukocyte-endothelial interactions has not been elucidated. Upregulation of endothelial 
adhesion molecules such as P-selectin, VCAM-1 and ICAM-1 is associated with ROS generation 
[429] and the expression of superoxide dismutase [430] and Nox2 [431]. Furthermore, both O2 
[432] and peroxynitrite (ONOO) [433] activate endothelial NF-κB signalling. MG was recently 
shown to induce NF-κB-dependent upregulation of the expression of P- and E-selectins and 
ICAM-1 on ECs which fosters leukocyte recruitment [75]. MG-induced leukocyte-endothelial 
interactions could also be elicited by neutrophil-derived ROS [434]. At least in theory, 
counteracting enhanced ROS production is pivotal to anti-inflammatory therapeutics in diabetes.  
 
An important feature for non-physiological O2 induction in endothelium is the uncoupling of 
eNOS [351]. The activity of eNOS was shown to be substantially affected by MG [70]. Increased 
NADPH oxidase-derived O2 reacts with eNOS-derived NO to generate ONOO which oxidizes 
BH4 [351]. In our study, MG treatment affected de novo BH4 synthesis, thereby decreasing its 
bioavailability. Mounting evidence suggests that the NOS essential cofactor BH4 is critical for the 
maintenance of eNOS dimers and is functionally related to S-glutathionylation, a powerful 
regulator of eNOS uncoupling [382]. Exogenous administration of BH4 or overexpression of 
GTPCH1 gene can increase endothelial BH4 [435] and maintain eNOS dimerization in murine 
[358] and human [259] diabetic endothelium. Besides increasing NO availability, BH4 treatment 
blunted Ca2+-independent NOS activation and tissue nitrotyrosine levels essential for 
inflammation but without appreciable changes in eNOS phosphorylation [436]. Interestingly, BH4 
treatment was shown to protect against experimental arthritis [437] and ischemia-reperfusion- and 
CCl4-triggered hepatic injury [438-440]. In a cardiac model of ischemia-reperfusion, BH4 was 
shown to mitigate both leukocyte adhesion and emigration [441]. Supported by the ineffectiveness 
of NH4 in MG-induced O2 generation and leukocyte recruitment, it is tempting to speculate that 
BH4-elicited inhibitory responses in microvasculature in vivo are attributed to maintenance of 
functional eNOS dimers than BH4 antioxidant effects per se.  
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The robust effects of BH4 reconstitution or administration of its analog sepiapterin on O2 and 
BH4 availability can be translated into its effects on reducing MG-elicited leukocyte recruitment 
and microvascular hyperpermeability. To corroborate those findings, we used selective NOS 
inhibitor L-NAME to inhibit O2  production by the uncoupled eNOS [442, 443]. L-NAME 
dissipated MG-induced leukocyte adhesion and emigration. L-NAME alone increased leukocyte 
recruitment in our model and as was shown elsewhere [407, 408] through the suppression of NO 
production by NOS. Paradoxically, L-NAME counteracted the effects of MG for O2 production 
and leukocyte recruitment, which underscores its effect on suppressing eNOS for O2 production, 
suggesting eNOS uncoupling following MG increases.  
 
Several studies have shown that compromised endothelial barrier function is an essential 
phenomenon of the diabetic milieu that contributes to microangiopathy [444, 445]. Hyperglycemia 
and advanced glycation end-products have been reported to increase microvascular permeability 
by activation of PKC [446, 447], HIF-1α [448], RhoA/ROCK [449] and AMPK [450] signalling 
in endothelium. In diabetic rats, retinal VEGF expression and vascular hyperpermeability were 
shown to be associated with enhanced tyrosine nitration [451]. However, the implication of the 
increased MG and the mechanism by which it triggers microvascular leakage remains ill-defined. 
We observed that administration of ROS scavengers or BH4 abated MG-induced microvascular 
hyperpermeability and by the same token attenuated leukocyte recruitment. In fact, increases in 
microvascular permeability is associated with both leukocyte-EC interactions [423, 424] and 
oxidative imbalance [452, 453]. In the blood-retinal barrier, MG was shown to induce 
hyperpermeability via stimulation of matrix metalloproteinases and subsequent proteolytic 
degradation of occludin [454]. Clearly, our data highlight that MG-induced O2− derived from 
uncoupled eNOS contributes to, but may not totally account for, the diminished vascular barrier 
function in diabetes.  
 
In summary, eNOS uncoupling is critical for the regulation of leukocyte-endothelial interactions 
in MG-triggered inflammation that is associated with diabetes. In the present work, this role was 
specifically demonstrated in vivo for the metabolite MG. Our findings of pharmacological 
targeting eNOS uncoupling-derived O2 may be relevant for the management of inflammation in 
diabetes.   
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7.1 General discussion  
Many studies have proposed that elevated MG level in diabetic state could promote endothelial 
dysfunction that leads to diabetic vascular damage. The studies presented in this thesis suggest 
leukocyte recruitment can be a contributory factor in this phenomenon. To examine the effect of 
MG in inducing leukocyte recruitment, the present study used an acute local MG administration 
to mimic the effect of increased MG on local microvasculature, and showed that there was a clear 
dose-response relationship between local MG dose and the degree of leukocyte recruitment in the 
tissue. Based on the intravital microscopy results, we established an acute inflammation model by 
using 25 mg/kg and 50 mg/kg MG injection to investigate the mechanisms of MG-induced 
leucocyte recruitment. It is known that plasma MG level in healthy human is about 1 µmol/L or 
less, but it is increased by 2―6 fold in diabetes patients [112, 131]. Using HPLC, we detected the 
levels of MG in plasma and cremaster muscle. The results showed that at 50 mg/kg MG local 
injection, with the significant increase of leukocyte recruitment in cremasteric microvasculature, 
the plasma MG level was increased only by 1.7 fold. This suggests that the effect of MG may be 
localised. Under pathological conditions, the vascular complications of diabetes usually occur 
years after the initial illness. However, the overexpression of adhesion molecules is important in 
the early stages of diabetic vascular complications [256], which is consistent with what we 
observed following acute MG treatment (50 mg/kg injection for 4 h). In the present study, the role 
of each of the three MG-upregulated EC adhesion molecules was characterised by functional 
blocking studies using specific antibodies. Our data indicate that acute MG treatment increases 
leukocyte rolling flux by upregulating P-selectin expression, reduces leukocyte rolling velocity by 
upregulating E-selectin expression, and increases cell adhesion by upregulating ICAM-1 
expression. All these contribute to the increased leukocyte-EC interactions that result in leukocyte 
emigration. 
 
In exploring the mechanisms of MG-induced adhesion molecule expression, we observed that MG-
induced expression of endothelial adhesion molecules is NF-κB-dependent. Additionally, gene 
ablation or pharmacological inhibition of either GSK3 or SGK1 blunted MG-induced NF-κB 
activity, suggesting the regulatory role of GSK3 and SGK1 in NF-κB activation. The glycogen 
synthase kinase, GSK3, is a pleiotropic serine/threonine kinase. It is a critical downstream effector 
of PI3K signalling [307]. GSK3 regulates glucose homeostasis and is inhibited by stimulation of 
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insulin receptors, thus playing a crucial role in energy metabolism. Remarkably, GSK3 is critical 
in inflammatory processes by playing either a positive or negative regulatory role [310]. 
Endothelial GSK3 was reported to regulate E-selectin expression [313] and vascular permeability 
[314], thus highlighting the importance of GSK3 signalling in ECs. Similarly, SGK1 is activated 
by PI3K and phosphoinositide-dependent kinase-1 (PDK1). It is regulated by a wide array of 
stimuli [316] including hyperglycemia [317]. Previous studies have shown SGK1 to be a 
promising therapeutic target in diabetes [318]. SGK1 was shown to foster the activation of NF-κB 
[241] and CREB [242], two transcription factors that are important in inflammatory responses. 
However, the function of SGK1 expressed in ECs is not completely understood. In our study, we 
showed that NF-κB activity was sequentially regulated by GSK3 and SGK1 in MG-treated ECs. 
MG induced Akt-regulated transient GSK3 activation in ECs, which was responsible for NF-κB 
activation at early time-points (< 1 h). After 1 h, the GSK3 activity was decreased due to the up-
regulation of SGK1 which sustained the NF-κB activity at later time-points. The activation of 
SGK1 was also responsible for CREB activity which was partially involved in ICAM-1 expression. 
In accordance with our results, SGK1 was previously reported to mediate NF-κB-dependent 
ICAM-1 expression in mesangial cells [336], while the knockdown of SGK1 gene was previously 
shown to attenuate NF-κB activation in cells isolated from renal collecting ducts [337]. Taken 
together, our study is the first to demonstrate the modulatory role of GSK3 and SGK1 in leukocyte 
recruitment in vivo by regulating the expression of endothelial adhesion molecules, thus revealing 
the role of SGK1- and GSK3-dependent signalling in MG-induced inflammation. 
 
Besides its role in activating signalling pathways and upregulating adhesion molecule expression, 
MG has its damaging effects by promoting ROS generation. In this study, we identified uncoupled 
eNOS as a new source of superoxide in MG-treated ECs. In hyperglycemia [455], hypertension 
[456], and aging [457], the eNOS protein expression was increased, yet its function was impaired. 
It was reported that eNOS uncoupling can be triggered by an oxidative environment, by BH4 
depletion, or by decreased BH4/BH2 ratio in cells, leading to the insufficient binding of BH4 to 
eNOS [257, 458, 459]. Under these circumstances, the electron transport from the C-terminal-
bound NADPH to N-terminal heme center is changed, and the oxygen molecule instead of L-
arginine is the terminal electron acceptor, leading to the formation of superoxide. For the last a 
few years, eNOS uncoupling has been related to atherosclerosis, diabetes, hypertension, smoking 
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and ischemia and reperfusion injury [356]. In ECs and VSMCs, MG decreases eNOS activity and 
NO production, whereas superoxide and peroxynitrite formation is increased [31, 70]. These 
findings indicate that eNOS uncoupling might be one of the mechanisms underlying MG-induced 
vessel damage. However, to our knowledge, the effect of MG on eNOS uncoupling has not been 
reported previously. In this part of the study, we found that MG-triggered eNOS uncoupling and 
hypophosphorylation were associated with superoxide generation and biopterin depletion in 
EA.hy926 ECs and in the endothelium of cremasteric microvasculature. In these tissues and cells, 
MG increased eNOS monomerization and decreased BH4/total biopterin ratio, effects that were 
significantly mitigated by supplementation of BH4 or its precursor sepiapterin but not by L-NAME 
or tetrahydroneopterin, indicative of MG-triggered eNOS uncoupling. We also found that MG-
induced leukocyte recruitment was significantly attenuated by supplementation of BH4 or 
sepiapterin or suppression of superoxide by L-NAME confirming the role of eNOS uncoupling in 
MG-elicited leukocyte recruitment. Our study further showed that MG treatment decreased the 
expression of guanosine triphosphate cyclohydrolase 1 and increased the expression of 3-
nitrotyrosine (3NT), suggesting that impaired BH4 biosynthesis and increased peroxynitrite 
formation are responsible for MG-induced eNOS uncoupling. Our results are consistent with 
previous reports that MG increases peroxynitrite formation [31] and peroxynitrite uncouples eNOS 
by causing BH4 oxidation in bovine aortic ECs [460]. However, given the multiple effects of MG, 
other mechanisms may also be involved. Other studies show that PKC activity is elevated under 
hyperglycemic condition, and eNOS uncoupling seems to be the consequence of PKC activity 
since PKC inhibitors reverse eNOS uncoupling [442, 461]. It was also shown that MG-induced 
AGE activates PKC in cultured ECs [462]. Thus, it is reasonable that the activation of PKC may 
also be involved. However, more evidence is needed to prove the link between AGE formation 
and PKC activation, and their role in MG-induced eNOS uncoupling.  
 
Taken together, our study reveals two distinct molecular mechanisms of MG-induced leukocyte 
recruitment which support the role of inflammation in the early stage of diabetic vascular 
complications. Our findings may unveil the mystery of vascular complications and immune 
dysfunction in diabetes and may provide a new clue for possible therapeutic strategies. 
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7.2 Conclusions  
The present study explores the mechanism of MG-induced leukocyte recruitment in mouse 
cremasteric microvasculature. Using biochemical and intravital microscopy techniques, this study 
shows that administration of MG (25 and 50 mg/kg) dose-dependently induced leukocyte 
recruitment in cremasteric vasculature, with 84-92% recruited cells being neutrophils. Such MG 
treatment up-regulated the expression of EC adhesion molecules P-selectin, E-selectin, and ICAM-
1 via the activation of NF-κB signalling pathway in ECs, which contributed to the increased 
leukocyte rolling flux, reduced leukocyte rolling velocity, and increased leukocyte adhesion, 
respectively. Further study of MG-related signalling pathways revealed that NF-κB activity is 
sequentially regulated by GSK3 and SGK1 in ECs. Our data suggest that MG induces Akt-
regulated transient GSK3 activation in ECs, which was responsible for NF-κB activation at early 
time-points (< 1 h). After MG activation for 1 h, GSK3 activity was decreased due to the up-
regulation of SGK1 which sustained the NF-κB activity at later time-points. Silencing or inhibiting 
GSK3 or SGK1 attenuated P-selectin, E-selectin and ICAM-1 expression in ECs and abated MG-
induced leukocyte recruitment by supressing NF-κB activity. SGK1 also promoted CREB activity 
which was partially involved in ICAM-1 expression. Silencing CREB blunted ICAM-1 expression 
with no changes in the expression of P-selectin and E-selectin levels. Additionally, this study 
reveals MG-triggered eNOS uncoupling as an important source of MG-induced superoxide in ECs. 
MG increased eNOS monomerization and decreased BH4/total biopterin ratio, effects that were 
significantly mitigated by supplementation of BH4 or its precursor sepiapterin but not by L-NAME 
or tetrahydroneopterin. MG-induced leukocyte recruitment was significantly attenuated by 
supplementation of BH4 or sepiapterin or suppression of superoxide by L-NAME confirming the 
role of eNOS uncoupling in MG-elicited leukocyte recruitment. MG treatment also decreased the 
expression of guanosine triphosphate cyclohydrolase I in murine primary ECs, suggesting the 
impaired BH4 biosynthesis being one of the mechanisms underlying MG-induced eNOS 
uncoupling.  
 
7.3 Significance of the study 
Leukocyte recruitment from the blood stream into the extravascular space is essential for 
developing an appropriate inflammatory response to injury and infection. However, the interaction 
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between neutrophils and ECs induced by hyperglycemia brings more damage than cure to the 
microvasculature. Increased MG levels and increased leukocyte transmigration are both believed 
to play an important role in the pathogenesis of diabetic vascular complications, but the correlation 
between these two phenomena has never been studied, neither has the mechanisms underlying 
MG-induced leukocyte recruitment. In this study, we show, for the first time, that administration 
of MG to the tissue dose-dependently induced leukocyte recruitment, with 84-92% recruited cells 
being neutrophils. We also demonstrate two distinct mechanisms that are involved in MG-induced 
leukocyte recruitment. Firstly, MG sequentially induces the activation of GSK3 and SGK1, which 
subsequently activates downstream transcriptional factors NF-κB and CREB. NF-κB- and CREB-
mediated expression of endothelial adhesion molecules fosters leukocyte adhesion and is also 
crucial for leukocyte recruitment. Secondly, we show for the first time that MG-induced eNOS 
uncoupling in ECs, which shifts the functions of eNOS from producing NO to producing 
superoxide, is at least partially responsible for MG-induced leukocyte recruitment. The change in 
eNOS function is possibly due to the inhibition of guanosine triphosphate cyclohydrolase I and the 
reduction of BH4. These novel findings not only uncover the mechanisms of MG-induced 
leukocyte recruitment, but also suggest the potential therapeutic targets for MG-sensitive 
endothelial dysfunction in diabetes. 
 
7.4 Limitations of the study 
In the study of MG-induced pathological changes, the dose of exogenous MG administered to the 
animal, the tissue and the cells has been debated. One tends to compare the doses used in the in 
vivo or in vitro studies to MG concentrations in the plasma of diabetes patients, and usually the 
MG doses used in these studies are much higher than the MG concentrations measured in patients. 
As reviewed in Chapter 1, the progression of diabetes lasts for years, and under hyperglycemic 
condition, MG is not the only agent that contributes to the damage to the cells and local tissues. 
Thus, in the study that uses only exogenous MG, it should be reasonable and acceptable to use 
high MG doses (sometimes even higher than pathological condition) to establish the in vitro or in 
vivo model, especially in a short term study [134]. In Sprague-Dawley rats, using MG as the only 
stimulus, Dhar et al. found that it requires 60 mg/kg/day and 28 days of chronic MG infusion by 
minipump to induce impaired glucose tolerance, apoptosis in pancreatic islets and reduced 
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pancreatic insulin content in rats [134]. This suggests that large doses of exogenous MG are 
required to establish a diabetic animal model and reach the similar plasma MG level as in diabetic 
patients. Besides, in diabetic patients, the data of MG level in the tissue is still missing. Thus it is 
not known whether the MG level in the local tissue is higher or lower than its level in the plasma. 
As we mentioned, MG formation is due to glucose or fructose overload and the activation of polyol 
pathway. Therefore, under pathological condition, cells that are exposed to high glucose or 
fructose have the potential to produce MG and to have the damaging effects locally. However, 
exogenous MG is firstly absorbed through the peritoneum into the blood, and then distributed to 
the whole body. Thus, it is not surprising that it requires large doses of MG to simulate pathological 
changes in local tissue encountered in diabetic states. The progression of diabetes is a complicated 
process that involves many active agents with the potential to damage tissues and cells. Without a 
specific MG inhibitor, it is impossible to study the role of MG alone in the progression of diabetes. 
Therefore, this leaves the exogenous administration of MG to be the only approach to perform the 
study, and a higher MG dose is usually required in short term in vivo and in vitro studies. Diabetes 
is a complicated disease that requires years to develop, and a large amount of data o MG from the 
patients is not available. Regardless, the mechanistic studies using animal models and cell models 
are useful to reveal the molecular mechanisms of MG-induced pathological changes, and to 
indicate potential therapeutic targets for diabetic patients.  
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